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A b s t r a c t
Two of the most frequent causes of excessive menstrual blood loss are dysfunctional 
uterine bleeding (DUB) and fibroids. Both can be cured by hysterectomy, but no non- 
surgical treatment for either is entirely satisfactory. This thesis looks at the potential 
of minimally invasive, low power laser techniques for treating these conditions: 
photodynamic therapy (PDT) for endometrial ablation for DUB and interstitial laser 
photocoagulation (ILP) for fibroids.
PDT is the local destruction of tissue with light after prior administration of a 
photosensitising drug. No heat is involved. In pharmacokinetic studies, I instilled the 
photosensitiser aluminium disulphonated phthalocyanine (AlS2Pc) into the homs of 
normal rabbit uteri, using fluorescence microscopy of uterine sections to document 
the drug distribution. The most appropriate drug levels in endometrium and 
myometrium were seen at 3 hours, at which time a diffuser fibre delivered laser light 
(670nm) to the endometrium.. Histological examination 3-28 days later showed that 
under optimal conditions, there was close to complete endometrial ablation with 
minimal myometrial damage. Studies on human hysterectomy specimens compared a 
range of light delivery devices for PDT. The bifurcator gave the most uniform light 
distribution.
ILP involves inserting one or more thin needles into fibroids at laparoscopy. Laser 
fibres are passed through the needles to gently heat the target lesion (typically 3W for 
10 minutes per fibre site). 21 symptomatic patients with 32 fibroids were treated. At 6 
weeks, most lesions were oedematous, but there was a mean shrinkage of 25% at 6 
months and 50% at 12 months, with corresponding symptomatic relief.
These studies have shown that in the rabbit, PDT with AlS2Pc can produce 
endometrial ablation safely. The technique is ready for consideration for pilot clinical 
studies. ILP has been shown to be a safe and relatively simple treatment for moderate 
sized fibroids, which could be incorporated into gynaecological practice now.
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SECTION 1 - BACKGROUND AND 
INTRODUCTION
Chapter 1 Medical management of heavy periods
Chapter 2 Surgical alternatives to hysterectomy for heavy periods
Chapter 3 Low power laser treatments for heavy periods
Chapter 4 Aims of the thesis
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[1] Medical 
management of 
heavy periods
1.1 Introduction
Excessive menstrual bleeding is a significant health care problem worldwide. In the 
United Kingdom alone 1 in 20 women aged 30-49 years consult their general 
practitioner each year with this problem (Vessey et al. 402-07). In 1995, the 
estimated cost o f primary care prescriptions was around £7 million (Coulter, Kelland, 
and Long). It remains one o f the commonest causes o f primary care referral to a 
gynaecologist. Sixty per cent o f women seen by a gynaecologist will have a 
hysterectomy within 5 years (Coulter et al. 789-96). In 1997-1998 there were 63,345 
hysterectomies carried out in England (National Health Service Executive). Two 
thirds o f these were performed for menorrhagia (Coulter et al. 218-26). o f which the 
two most common causes are Dysfunctional Uterine Bleeding (DUB) (46%) and 
uterine fibroids (17% causal; 35% associated) (Maresh et al. 302-12).
The treatment options for DUB and uterine fibroids include medical management, 
conservative surgical management and hysterectomy. Although hysterectomy is an 
effective treatment it is associated with significant morbidity and even mortality. This
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has led to the development o f medical and conservative surgical techniques to avoid 
hysterectomy.
Medical treatment o f menorrhagia relies on the manipulation o f the endocrine and 
paracrine changes that occur in the menstrual cycle. Conservative surgical therapy for 
DUB relies on the destruction o f the endometrial lining to a sufficient depth to prevent 
regeneration. Removal o f the fibroids is a good alternative to hysterectomy but is 
associated with significant recurrence rates. Interference with the blood flow to the 
uterus, to the uterine fibroid and damage to the collagen within the uterine fibroid are 
being investigated to an attempt to reduce the size o f the fibroid thereby causing 
symptomatic relief. This thesis investigates two procedures, photodynamic therapy o f 
the endometrium for DUB and interstitial laser photocoagulation o f uterine fibroids, 
which utilises lower power laser energy for its therapeutic effect. Development o f 
both procedures will provide an exciting alternative to hysterectomy.
This chapter aims to review our understanding of the menstrual cycle and how this 
can be exploited for the medical treatment o f women with DUB and uterine fibroids. 
Chapter 2 will review the existing methods o f conservative surgical management o f 
DUB and uterine fibroids. Chapter 3 will review the rationale for the use o f low 
power lasers in the treatment o f both these conditions.
1.2 The normal menstrual cycle
1.2.1 The endometrial cycle
The endometrium undergoes a cycle o f endometrial growth and regression, which is 
repeated some 300-400 times during reproductive life. Endometrial changes involve 
both the endometrial glands and the stroma. For descriptive purposes these changes 
will be described in the following phases; proliferative, early secretory, pre 
implantation, endometrial breakdown and menstrual endometrium.
1.2.1.1 The proliferative phase
The ovarian follicle grows and increases the production o f oestrogen. In response to 
this there is reconstruction and growth o f glands, which show increased mitotic 
activity and pseudostratification. The ends o f the glands link up together forming a 
continuous layer o f glandular epithelium that faces the endometrial cavity. The 
number o f ciliated and microvillous cells keep increasing and this is thought to be
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important in the mobilisation o f secretions in the secretory phase. The stroma 
“inflates” from the dense cellular layer at the end o f menstruation to a loose syncitium 
through which the spiral vessels travel to the epithelium where they end in a dense 
capillary network. Macrophages and lymphocytes derived from the bone marrow are 
diffusely distributed in the stroma. During the proliferative phase the thickness o f the 
endometrium increases from 0.5 mm to 3.5 -  5.0 mm.
1.2.1.2 The secretory phase
Both oestrogen and progesterone are secreted in increasing amounts after ovulation. 
Further increase in endometrial thickness is not seen despite the high levels o f 
oestrogen as progesterone inhibits its action. Growth continues in a fixed thickness 
and hence the endometrial glands become progressively tortuous and the spiral vessels 
in the stroma become intensely coiled. The first sign o f ovulation is the formation o f 
sub nuclear intracytoplasmic vacuoles in the epithelium which migrates around the 
nucleus and then discharges into the endometrial cavity leaving a saw toothed 
appearance on the surface o f the cells. The glands actively secrete glycoproteins and 
peptides into the endometrial cavity. There is also a transudation o f plasma with 
carrier-mediated transport o f important immunoglobulins into the endometrial cavity. 
This activity reaches a peak 7 days after the mid cycle gonadotrophin surge. This 
corresponds to the time at which a blastocyst implants if  fertilisation has occurred in 
that cycle.
1.2.1.3 The implantation (late secretory) phase
There is differentiation o f the endometrium into 3 zones. The lower zone comprises 
o f the stratum basalis with is mainly unchanged and is fed by straight vessels running 
through a spindle shaped stroma. In this layer the glands are tubular. The 
intermediate zone is called the stratum spongiosum and has the loose oedematous 
stroma with tightly coiled spiral vessels and dilated glandular ribbons. The upper 
zone is called the stratum compactum, which contains large polyhedral stromal cells 
abutting one another forming a compact sturdy layer. Here the spiral vessels form a 
rich engorged capillary plexus. The upper 2 layers are also referred to as the 
functional layer as it prepares for the implantation o f the blastocyst and goes through 
the changes o f proliferation, secretion and regeneration. The function o f the stratum
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basale is to provide the regenerative endometrium following the menstrual loss o f the 
functional layer.
1.2.1.4 The phase of endometrial breakdown
In the absence o f fertilisation, the corpus luteum in the ovary ceases to function and 
the oestrogen and progesterone levels start to decline. This causes three endometrial 
events namely vasomotor reactions, tissue loss and menstruation. There is shrinkage 
o f the height o f the endometrium and marked coiling and spasm o f the spiral vessels. 
This occurs in waves o f rhythmic contractions and relaxation, which progressively 
increase in duration causing endometrial blanching and finally ischaemic necrosis. 
The increased vascular permeability and stasis as a result o f the ischaemia causes 
diapedesis o f the white cells and movement o f the red cells into the interstitial spaces. 
Cellular necrosis and liberation o f the lysosymal enzymes causes digestion o f the cells 
and collapse o f the tissue. Once the plane o f cleavage between the stratum basalis and 
the functional layer is breached the functional layer desquamates. Menstrual fluid is 
therefore composed o f the autolysed functional layer, inflammatory exudates, red 
blood cells and proteolytic enzymes.
1.2.1.5 Menstrual endometrium
This is composed o f the stratum basalis and a small and variable component o f the 
stratum spongiosum. The epithelium over the tubal ostia and the isthmus o f the cervix 
are not lost during menstruation. Following desquamation o f the functional layer, the 
stroma forms a compact mass over which the epithelium from the stumps o f the 
endometrial glands in the basalis and from the region o f the tubal ostia and cervical 
isthmus can grow. This epithelium covers the entire uterine cavity usually by day 5-6 
o f the menstrual cycle.
1.2.2 Local biochemical changes
Prostaglandin F2a and the prostaglandin E2 reach their highest concentrations in 
secretory endometrium during the time o f menstruation and are thought to be the 
mediators o f vasoconstriction and myometrial contractility. The late secretory and 
menstrual endometrium has a high concentration o f fibrinolytic agents. Bleeding is 
limited by the formation o f thrombin - platelet plugs both at the stumps o f the
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denuded blood vessels and upstream. The slowly rising levels o f oestrogen enhance 
this effect.
1.2.3 Regulation of the menstrual cycle
Regulation o f the menstrual cycle is by the integration o f hormonal signals, autocrine 
and paracrine factors and target cell receptor function in the uterus, ovary, pituitary, 
hypothalamus and other central nervous system sources. Gonadotrophic releasing 
hormones (GnRH) are produced in the basal hypothalamus and are carried in the 
blood via the hypothalamo- hypopohyseal portal to the anterior pituitary gland. The 
GnRH is released in pulses -  the amplitude and frequency o f which should be within a 
critical range for normal gonadotrophin production. In response to the release o f 
GnRH, the gonadotrophins -  Follicle Stimulating Hormone (FSH) and Luteinising 
Hormone (LH) are secreted in a pulsatile manner from the gonadotrophes, which are 
situated in the lateral aspect o f the anterior pituitary. GnRH also primes the 
gonadotrophes so that at a later stage o f the cycle there is a much bigger response and 
this self priming action is thought to be important for the induction o f ovulation.
FSH is mainly responsible for the early development o f the Graafian follicle with the 
production o f oestrogen. LH may contribute to follicular growth and oestrogen 
production but its principal action is to induce ovulation and to convert the ruptured 
Graafian follicle into a corpus luteum which occurs through 4 feed back cycles.
1.2.4 Cycle length and ovulation
The studies o f Vollman (Vollman 1-193) o f more than 30,000 cycles recorded by 650 
women and the study o f Treloar (Treloar et al. 77-126) o f more than 25,000 woman- 
years in a little over 2,700 women provide us with information on the normal 
variation in menstrual cycles.
Menstrual cycle length ranges from 21 days to 35 days (0.5% women have shorter 
cycles and 0.9% of women have longer cycles). The longest cycles are seen 5 years 
after the menarche and again after the age o f 40 years. This coincides with the highest 
incidence o f anovulatory cycles. The perfect 28 day cycle is indeed the most common 
length but occurs in only 12.4% of the cycles studies by Vollmans. Overall, 
approximately 15% o f reproductive age cycles are 28 days in length with 20% of 
women experiencing irregular cycles.
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1.2.5 Normal MBL
The most reproducible menstrual pattern in terms o f quantity and duration occurs with 
the post ovular oestrogen and progesterone withdrawal MBL. In normal menstrual 
periods 79% of the blood is lost during the first two days and at least 92% in the first 
three days (Rybo Suppl-45). In a study by Hallberg in 1966 o f 476 randomly selected 
Swedish women who considered their periods to be normal and who were not 
anaemic, the average blood loss measured quantitatively was 43ml. The 95th centile 
was 76.4 mis. The upper range o f normal MBL was considered to be 60-80 mis and 
this occurred in 10-25% o f women (Hallberg et al. 320-51).
1.2.6 Significance of an increased MBL
The haemoglobin and serum iron concentrations were decreased among women 
having an MBL exceeding 60ml per cycle and their incidence o f iron deficiency 
anaemia was up to five times increased when compared to women with lighter MBL. 
Women losing 80 ml o f blood per cycle without dietary iron supplementation had a 
67% incidence o f anaemia (Hallberg et al. 320-51).
Consequently a MBL o f 80 mis or more in a woman with regular periods is generally 
regarded as the definition o f menorrhagia. This is reflected initially by a reduced 
serum ferritin followed by iron deficiency anaemia.
1.3 Excessive menstrual bleeding -  Definitions and terminology
1.3.1 Menorrhagia
It can be appreciated that in clinical practice measurement o f 80 mis o f MBL is not 
practical. The Royal College o f Obstetricians and Gynaecologists suggested that 
menorrhagia be defined as a complaint o f “heavy cyclical menstrual bleeding over 
several consecutive cycles without any intermenstrual or postcoital bleeding”(The 
Royal College o f Obstetrics and Gynaecology). If it is certain that the MBL is greater 
than 80 mis then the term “objective menorrhagia” is used. If  the woman perceives 
her MBL to be heavy but it is not found to be so then the term subjective menorrhagia 
is used. This is a clinically difficult problem as up to 50% o f women presenting with 
heavy MBL have subjective menorrhagia.
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1.3.2 Dysfunctional uterine bleeding (DUB)
DUB is the term given to menorrhagia in the absence o f any organic pathology.
Factors that affect MBL
1.3.3 Non organic causes
1.3.3.1 Stress and anxiety
The complex interrelationships that are required for regulation o f the menstrual cycle 
have been described (see section 1.2.3). It has been shown that norepinephrine 
stimulates GnRH production while Dopamine inhibits it. Endogenous opiate 
production causes a reduction in the pulse frequency o f GnRH, which may explain the 
basis by which stress interferes with menstrual function as Corticotropin Releasing 
Hormone (CRH) is increased and the resulting increase in serum cortisol augments 
endogenous opiate production.
1.3.3.2 Disorders of the thyroid gland
Goldsmith et al showed that 70 % of menstrual cycles in women with clinical and 
laboratory evidence o f hypothyroidism were anovular resulting in menorrhagia. 
Thyroid replacement therapy restores ovulation. A return to normal menstrual
function is presumed though none o f the studies in the past documented MBL
(Goldsmith et al. 846-55). A recent case report (Higham and Shaw 695-96) used the 
pictorial blood assessment chart (PBAC) to document a MBL of almost 500 ml in a 
woman with hypothyroidism which reduced to less than 80 mis with thyroxine.
There is however a lack o f evidence that some women who present with menorrhagia 
may have subclinical hypothyroidism, which may be corrected by thyroxine 
replacement. Consequently, the routine screening o f asymptomatic women who 
present with menorrhagia is not recommended (The Royal College o f Obstetrics and 
Gynaecology).
1.3.3.3 Clotting abnormalities
Menorrhagia is known to be associated with platelet abnormalities, afibrinogenaemia, 
Von W illebrand’s disease, and macroglobulinaemia, factors II, V, VII X and XI 
deficiency. Inherited bleeding disorders would tend to present in adolescence and
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were found in 29% o f adolescents who were admitted with acute menorrhagia with no 
genital tract pathology (Claessens and Cowell 369-78). Menorrhagia in the older 
woman can result from the use o f anticoagulants as shown by a small study o f women 
using oral anticoagulants where 50% of women had a measured blood loss o f greater 
than 80 mis o f blood (Van Eijkeren et al. 1261-63). Universal screening for 
coagulation defects however is not sensitive and hence not cost effective.
1.3.4 Organic causes of excessive MBL
Conditions that are known to cause excessive MBL include adenomyosis, uterine 
fibroids, endometrial polyps and the use o f the intra uterine contraceptive device.
1.3.4.1 Uterine Fibroids
Uterine fibroids are benign monoclonal tumours that arise from the smooth muscle 
cells o f the uterus and are peculiar to humans. They are clinically detected in 20% of 
women under the age o f 50 years (Graves WP). With increasing sensitivity and 
expertise with imaging techniques fibroids are found more frequently. Careful 
pathological examination o f uterine specimens have revealed a prevalence in the order 
o f 77% (Cramer and Patel 435-38). The incidence o f fibroids is related to 
uninterrupted menstruation and age. With more women choosing to postpone the age 
o f conception, an increase in the incidence o f fibroids is expected.
In most instances, uterine fibroids do not cause symptoms but when they do they can 
impair the quality o f life. Symptoms that are attributed to fibroids include 
menorrhagia, pressure effects and occasionally pelvic pain and infertility. Symptoms 
are usually dependent on the position, location and the size o f the fibroids. Due to 
their high prevalence, fibroids may not be the cause o f symptoms and women must be 
counselled accordingly. While most women with fibroids can be managed 
expectantly, some require treatment.
Uterine fibroids are the commonest pathology associated with menorrhagia (see 
section 1.1). Submucous fibroids and to some extent intramural fibroids are known to 
cause increased MBL. It is uncertain as to whether subserous fibroids have similar 
effects.
27
1.3.4.2 Adenomyosis
Adenomyosis is a condition where endometrial glands with stroma are found 
surrounded by smooth muscle cells in the myometrium o f the uterus. It is thought that 
the endometrial glands penetrate the myometrium by lymphatic and vascular 
channels. This is possibly due to the breakdown o f the endometrial-myometrial 
border after trauma although the aetiology still remains unclear.
Adenomyosis is identified in 20 -  30% of all uteri and is much less common in uteri 
weighing greater than 280 g and above 12 weeks gestation size (Bird, McElin, and 
Manalo-Estrella 583-93; Molitor 275-84). This may be due to pressure atrophy caused 
by co existing uterine fibroids or that extensive adenomyosis causes such severe 
symptoms that a hysterectomy is performed before they reach a large size.
Due to its high prevalence there is considerable debate regarding the minimum 
distance o f penetration o f the myometrium to make a diagnosis o f significant 
adenomyosis. Suggestions include a) a minimum distance o f penetration ranging 
from 2-4 mm from one to two low-power fields and b) the involvement o f at least 
25% o f the myometrial thickness with adenomyotic foci (Hendrickson MR and 
Kempson RL 452-67). Histopathological features used to assess the degree o f the 
severity o f the disease are depth and number o f foci, number o f glands, and number of 
glands per adenomyotic focus and the ratio o f the depth o f foci to muscle thickness.
Symptoms that have been attributed to adenomyosis are menorrhagia (40-50%) and 
dysmenorrhoea (15-30%). One third o f women are asymptomatic (BENSON an d - 
SNEEDEN 1044-57). The depth o f adenomyotic foci have been shown to be related 
to the severity o f menorrhagia. There is no correlation shown with the number o f foci 
and the number o f glands per focus although all these factors correlate well with the 
severity o f dysmenorrhoea (Nishida 229-31; Nishida 229-31). Diagnosis w ith - 
hysteroscopy and ultrasonography are disappointing but the adenomyotic foci may be 
visualised by Magnetic Resonance Imaging (MRI), which because o f its cost 
precludes its use in routine practice. More commonly adenomyosis is discovered in 
extirpated uteri from women with what was presumed to be DUB where all medical 
treatments and endometrial ablative treatments have failed.
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1.4 Medical treatment of DUB
The medical treatment o f menorrhagia depends on whether the woman is trying to 
conceive or not. In the woman who is trying to conceive, a non hormonal preparation 
taken during menstruation will help reduce MBL without interfering with ovulation 
and conception. In the woman who does not wish to conceive, hormonal 
manipulation is usually given during the cycle. Although in most cases ovulation is 
inhibited, it is important to counsel women that alternative methods o f contraception 
would be required unless the method used is also contraceptive.
1.4.1 Drugs used in the treatment of menorrhagia that does not interfere with 
fertility
1.4.1.1 Antifibrinolytic agents
Epsilon aminocaproic acid was discovered in 1959 and 5 years later tranexamic acid 
and para amino methyl benzoic acid were synthesized. These substances were found 
to inhibit the activation o f plasmin from its precursor plasminogen in the fibrinolytic 
pathway. In women with DUB there appears to be an increase in the normal 
fibrinolytic activity seen in the late proliferative and menstrual endometrium as 
described in section 1.2.2
In a meta analysis o f seven trials where women with both objective and subjective 
menorrhagia were treated by tranexamic acid, Coulter et al (Coulter et al. 456-71) 
found a reduction in pre treatment MBL by an average o f 46.7% (range = 35-56%). 
The dose varied from 0.5g -  3g a day during menstruation. Therapy lasted from two 
to six months. Limitations o f the studies were that a placebo effect could not be 
excluded as some o f the trials did not have a placebo arm.
In other studies that have compared tranexamic acid to placebo and NSAIDs, 
tranexamic acid was shown to cause the biggest reduction in MBL and improvement 
o f QOL. It does not however appear to have any effect on the duration o f MBL or 
menstrual pain.
Side effects that have been reported in up to 60% of women taking tranexamic acid 
include nausea, vomiting, diarrhoea, headache, dizziness, weight gain and leg cramps. 
A report o f intra cranial thrombosis as a rare but serious side effect (Rydin and 
Lundberg 49) delayed the introduction o f this drug in the United Kingdom until large
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scale studies in Scandinavia showed that the incidence o f thromboemblism with the 
use o f tranexamic acid was no higher than the background incidence. However a 
history o f thromboembolism is a contraindication to treatment. Another rare adverse 
effect is transient colour vision disturbance, which requires the withdrawal o f the 
drug.
The RCOG recommend Tranexamic acid at a dose o f 1 g three times a day. 
Treatment should be started on the first day o f the period for the days o f the heavy 
flow. This is now the recommended first line o f treatment in women who do not 
require contraception or who prefer non hormonal contraception (The Royal College 
o f Obstetrics and Gynaecology).
1.4.1.2 Prostaglandin inhibitors
In 1971, Vane demonstrated that a wide range o f substances that were non steroidal, 
anti inflammatory and acidic in nature were potent inhibitors o f prostaglandin 
synthetase, which promoted the conversion o f unsaturated fatty acids into 
prostaglandins (Vane 232-35). This group o f substances are referred to as Non 
Steroidal Anti Inflammatory Drugs (NSAIDS). The fenamates were also found to 
inhibit the action o f prostaglandin on the uterine smooth muscle. DUB especially 
associated with dysmenorrhoea appears to be due in part to the high concentrations o f 
prostaglandins that are normally found in the implantation and menstrual 
endometrium as described in section 1.2.2
In the meta analysis already referred to , Coulter examined ten studies which showed 
that mefenamic acid reduced the pre treatment MBL by a mean o f 29% (range = 1 9 -  
47%). Dosage was 1.5 g each day and was given during menstruation for two 
months. Mefenamic is effective in controlling symptoms o f dysmenorrhoea, 
menstrual migraine and diarrhoea. No effect on the duration o f the menstrual period 
is seen.
Side effects occur in 50 -  80 % o f women and include nausea, indigestion, abdominal 
discomfort, depression, tiredness, light-headedness, headaches and skin irritation. 
Skin rashes are only occasionally seen but require withdrawal o f treatment. There are 
more contraindications to treatment than tranexamic acid. These are a history o f 
gastro intestinal ulceration or bleeding, inflammatory bowel disease, a history o f
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hypersensitivity (e.g. asthma, angioedema, urticaria or rhinitis) precipitated by aspirin 
or other NSAIDs and hepatic or renal impairment.
The RCOG guidelines recommend mefenamic acid as an alternative to tranexamic 
acid as a first line treatment for menorrhagia. Even though mefenamic acid is not as 
efficacious as tranexamic acid, its anti prostaglandin properties makes it desirable in 
women with additional menstrual symptoms like dysmenorrhoea, menstrual migraine 
and menstrual diarrhoea.
Mefenamic acid and Tranexamic acid are now the recommended first line therapeutic 
agents in the treatment o f menorrhagia. Knowledge o f their mechanisms o f action 
suggests that when used in combination their actions should be synergistic. However 
there is no evidence from clinical trials to support this.
1.4.2 Drugs used in the treatment of menorrhagia that affect fertility
1.4.2.1 Combined oral contraceptive pills (COCP)
COCP’s are useful in regulating MBL probably by inducing an element o f 
endometrial atrophy. The proliferation o f the endometrium and the final height o f the 
endometrium are reduced and as a result so is the blood loss when menstrual 
endometrial shedding occurs.
Effect o f the COCP on objective menorrhagia
Nilsson and Rybo studied 164 women with objective menorrhagia who were given the 
COCP in the usual 21 day cycles for a total of 284 cycles (Nilsson and Rybo 713-20). 
The COCP preparations used were: 5mg lynestrenol and 0.15mg mestranol in 131 
cycles; 3 or 4 mg norethisterone acetate and 0.05 mg of ethinylestradiol in 86 cycles; 
1 mg norgestrel and 0.05 mg o f ethinylestradiol in 54 cycles and another COCP in 12 
cycles. There was a 52% reduction in MBL in the whole series: Eighty eight percent 
o f women with a pre treatment MBL o f 80 -  100 ml; 69% of women with a pre 
treatment MBL o f 100 -  200 ml and 44.5% of women with a MBL o f greater than 200 
ml benefited from therapy. There was no significant difference in the reduction in 
MBL between the treatments.
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Effect o f the COCP on subjective menorrhagia
Nilsson and Slovell studied the effect o f the COCP in women with subjectively 
normal MBL with no detectable pelvic pathology (Nilsson and Solvell Suppl-31). 
COCP preparations that were used contained either 50 pg o f ethinylestradiol or 0.075 
-  0.1 mg o f mestranol. Pre and post treatment MBL were compared in 19 women 
over a total o f 187 periods. A 54% reduction in MBL was seen with there being no 
statistically significant differences between the preparations used.
Effect o f COCP on the development o f iron deficiency anaemia
A large prospective observational study in 1969 published through the auspices o f the 
Royal College o f General Practitioners (Royal College o f General Practitioners) 
compared the prevalence o f iron deficiency anaemia between COCP users and non 
users. 23,611 COCP users were compared with 22,766 non users who were matched 
for age and social class. COCP users were found to be less likely to develop 
menorrhagia (relative risk o f 0.52) and iron deficiency anaemia than non users.
It appears that the COCP improves both subjective and objective menorrhagia and 
thereby iron deficiency anaemia. However, the trials quoted used the 50-pg 
ethinylestradiol preparations, which are seldom used today because o f risks o f 
thromboembolispi. Furthermore it is not known whether the nature o f the progestagen 
used influences the amount o f MBL. Whilst tranexamic acid does not seem to 
increase the therapeutic effect o f the COCP, it is not known whether mefenamic acid 
would affect it. Further research is required to answer these questions. The 
justification for using the current COCP preparations (30 pg ethinylestradiol) is from 
the extrapolation o f the data from the high dose formulations.
1.4.2.2 Progestogens
Low dose luteal phase treatment
Low dose luteal phase administration o f progestogens has been used for the treatment 
o f menorrhagia in the belief that menorrhagia is due to lack o f progesterone support in 
the luteal phase o f the menstrual cycle. It was hypothesised that treatment with 
progestogens would rectify this and result in normal endometrial shedding and 
therefore normal MBL. Luteal phase norethisterone acetate (NET) was the 
commonest drug prescribed by general practitioners for menorrhagia.
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There are four randomised controlled trials that compared the effect o f luteal phase 
progestogens with other drugs used in the treatment o f menorrhagia(Cameron et al.
99-110; Cameron et al. 85-88;Higham and Shaw 1134-39; Preston et al. 401-06). Two 
studies which recruited women with objective measurements o f MBL > 80 mis 
showed an increase in the MBL o f 12% and 20%. The other two studies which also 
entered women with objective menorrhagia (MBL >80 mis & MBL > 50mls) showed 
a reduction in MBL o f 20% and 4% respectively.
A meta analysis o f these studies showed that NET actually caused an increase in MBL 
by 3.6% (Coulter et al. 456-71). The RCOG publication states that “in the dosages and 
timings currently recommended in data sheets and in the British National Formulary 
norethisterone cannot by recommended as an effective treatment for menorrhagia” .
Increased dose and long course progestogens treatment
NET at a dose o f 5mg tds from day 5 to day 26 o f the menstrual cycle to 22 women 
with objective menorrhagia caused a significant reduction in median MBL o f 85% at 
1 month and 94% at 3 months (Irvine et al. 592-98). Nearly half the women “liked 
the treatment well or very well” with about a quarter indicating that they would “wish 
to continue with the treatment”.
Long acting depot preparations of progestogens
Depot preparations o f progestogens may be administered either by a depot injection or 
as a subdermal implant. Medroxyprogesterone acetate is used for contraception at a 
dose o f 150mg every 3 months. One o f the common side effects is unpredictable 
irregular spotting that may last up to 6 months. However with repeated use 
endometrial gland atrophy and stromal decidualisation occur and after 1 year 40 -  
50% o f women have amenorrhea. Subdermal implants that release levonorgestrel 
have similar effects.
Consequently depot preparations o f progestogens may be used to treat women with 
menorrhagia. However it has not been investigated in this context. The unpredictable 
and sometimes very heavy irregular bleeding that it can induce together with recent 
concerns o f osteoporosis does not make it a desirable alternative to other medications 
in current use.
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Levonorgestrel loaded intra uterine system (LNG-IUS)
The LNG-IUS (Mirena intrauterine system -  Schering Health Care Ltd, Burgess Hill) 
is a medicated intra uterine system that was developed in Finland in the mid 1970’s to 
release 20 pg o f levonorgestrel every 24 hours directly into the endometrium. This is 
taken up mainly by the basal layer o f the endometrium with only slight increases in 
plasma progestagen levels when compared to other hormonal contraceptives. The 
hormone causes suppression o f endometrial growth and within three months o f 
insertion the endometrial glands are inactive with stromal decidualisation. There are 
also changes in the cervical mucus but the concentration o f the progestagen in the 
blood is too low for inhibition o f ovulation. These changes reverse to normal with 
removal o f the device.
The LNG-IUS was initially developed in order to reduce the heavy periods associated 
with the use o f the copper IUCDs that resulted in women discontinuing it. Review o f 
results after five years o f use showed that the incidence o f pregnancies was very low, 
expulsion rates were no different from other IUCDs and the incidence o f ectopic 
pregnancies was very low. It was also noted that there was a significant reduction in 
MBL with a high incidence o f oligo - amenorrhea. The LNG-IUS was initially 
licensed in 1995 for contraceptive use for a period o f 3 years. The period o f use was 
extended to 5 years in 1998.
The initial findings o f its effect on MBL prompted some studies that investigated its 
effect on women with menorrhagia. A systematic review o f 5 case studies and 5 case 
controlled studies was done by Stewart et al in 2001 (Stewart et al. 74-86).
C ase studies
These were observational studies on women with menorrhagia who were prescribed 
the LNG-IUS system. One study used the system in menorrhagia associated with 
adenomyosis while others used it in women with presumed DUB (n=91). Mean MBL 
reduction at 3 months (75-87%) and 12 months of use (79-97%) were found to be 
significant. This was associated with an increase in haemoglobin (8-19%) and serum 
ferritin (36-47%) with relatively few side effects (0-15%). Barrington and Bowen- 
Simpkins recruited 50 women who had menorrhagia that had failed medical treatment 
and were on the waiting list for a TCRE or a hysterectomy(Barrington and Bowen-
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Simpkins 614-16). Following insertion o f the LNG-IUS, 41 women (85%) were 
removed from the waiting list because o f a reduction in the mean MBL score.
Case C on tro lled  studies (Com parison o f  the LN G-IU S w ith other m anagem ents)
Comparison o f LNG-IUS with Norethisterone acetate (NET)
In 1998, Irvine et al (Irvine et al. 592-98) randomised 44 women with DUB into either 
taking NET 5mg three times daily for 21 days (n=22) or the LNG-IUS (n=22). 
Reduction in median MBL was significantly greater in the LNG-IUS group when 
compared to the NET group (85% vs. 62% at 1 month; 94% vs. 83% at 3 months). 
More women “liked treatment well” or “very well” in the LNG-IUS group (64% vs. 
44%) and were prepared to continue with the treatment when compared to the NET 
group (77% vs. 22%).
Comparison o f LNG-IUS with NSAIDs and Antifibrinolytic drugs
Milsom et al (Milsom et al. 879-83) compared the LNG-IUS with the NSAID 
Flurbiprofen (lOOmg twice daily for 5 days) and the anti fibrinolytic Tranexamic acid 
(1.5g three times daily for days 1-3 and lg  bd for days 4-5 o f the menstrual cycle) in 
women with DUB. The first 20 women were given the LNG-IUS and the next 15 
women were randomised to the drugs in a cross over design. Reduction in mean 
MBL was significantly higher in the LNG-IUS group (96% at 1 year) when compared 
with the Flurbiprofen group (22%) and the Tranexamic acid group (44%). However 
side effects were most significant in the LNG-IUS group with a 20% discontinuation 
rate. None o f the women in the other two groups discontinued treatment.
Comparison o f LNG-IUS with TransCervical Resection o f the Endometrium (TCRE)
Crosignani et al (Crosignani et al. 257-63) compared the effects o f the LNG-IUS with 
TCRE in women with DUB in a randomised trial. MBL was measured by the PBAC 
and the effect o f treatments on the QOL o f these women by using Short Form 36 (SF 
36) questionnaires. The mean reduction in MBL was higher in the women who 
underwent TCRE (89% at 12 months) compared with the LNG-IUS group (78% at 12 
months). Side effects were more commonly reported in the LNG-IUS group (15) and 
the discontinuation rate was 15%. There was no significant difference in the SF 36 
scores between the two groups.
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Comparison o f LNG-IUS with Hysterectomy
Hurskainen (Hurskainen et al. 273-77) compared the effect o f the LNG-IUS with 
hysterectomy on the QOL o f women with menorrhagia and the cost effectiveness o f 
each procedure. 236 women with menorrhagia were randomised to treatment with the 
LNG-IUS (n=119) or hysterectomy (n=117). The amount o f MBL was objectively 
measured and a QOL assessment was repeated at 12 months follow up. In the group 
assigned to LNG-IUS, 24 (20%) women had a hysterectomy and 81 (68%) continued 
to use the system at 12 months. O f the women assigned to the hysterectomy group, 
107 underwent the operation. Health-related QOL improved significantly in both the 
IUS and hysterectomy groups, as did other indices of psychological well being. There 
were no significant differences between the treatment groups except that women with 
hysterectomy suffered less pain. Overall costs for hysterectomy group were three 
times higher compared to the IUS group.
The LNG-IUS has been studied mainly in the context of contraception. The studies 
reported above are the ones that investigated the use o f the LNG-IUS in women with 
DUB. These are few with small numbers o f women recruited, and the maximum 
follow up has been only up to one year in a device that has been licensed for 5 years. 
Nevertheless all studies report a substantial reduction in MBL and a reduction in the 
request for a surgical procedure. It has also been shown to improve the QOL of 
women with DUB and be a cost effective alternative to a hysterectomy. The data on 
the comparison of the efficacy o f the LNG-IUS with other medical treatments are 
sparse. This medical treatment is however being increasingly utilised in women with 
DUB and it has now been licensed for use in menorrhagia. Problems that remain are a 
discontinuation rate o f up to 25%. Furthermore, the side effect o f unscheduled 
vaginal bleeding that may last up to 6 months may not be acceptable to certain women 
because o f religious or other reasons.
1.4.2.3 Danazol
Danazol is a derivative of testosterone. It acts centrally by inhibiting the mid cycle 
surge and pulsatile secretions o f gonadotrophins. It also directly inhibits ovarian 
steroidogenesis and competitively blocks androgen, progesterone and oestrogen 
receptors in the endometrium. Free testosterone is increased by the inhibition o f 
hepatic synthesis o f sex hormone binding globulin.
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Danazol has been extensively studied for the treatment o f menorrhagia. Dosages that 
have been used vary from 50 -  400mg daily for variable time periods. A 200mg dose 
reduces MBL by 85% after 3 months (Chimbira et al. 1152-58). The main 
disadvantages o f this treatment however are the side effects, which were reported by 
up to 75% o f women who were on the medication with up to 40% o f women finding 
them unacceptable leading to discontinuation o f therapy.
The commonest complaint was the anabolic side effect o f the drug causing an average 
weight gain o f 2-4 Kg within 3 months o f use. Other side effects are related to the 
androgenic nature o f the drug and include acne, seborrhoea, hirsuitism and voice 
changes. Hypo-oestrogenic side effects are rare and include hot flushes and breast 
atrophy. Voice changes in some women are irreversible and hence a matter o f 
concern. Treatment with Danazol is not contraceptive and carries the risk o f 
virilisation o f a female fetus if  a woman became pregnant while on treatment. Hence 
barrier contraception is required throughout therapy.
Danazol is currently licensed in the treatment o f menorrhagia. The RCOG guidelines 
state the “while Danazol is effective in reducing menstrual blood flow, its daily 
regime and its side effects mean that it is not a suitable or acceptable treatment for all 
women and should not be used as a first line o f treatment.”
1.4.2.4 Gestrinone
Gestrinone is a derivative o f testosterone and has an action similar to Danazol. It has 
been shown to cause a significant reduction in MBL. Following cessation of 
treatment MBL returns to pre treatment levels in 3 months. The commonest side 
effect is weight gain (average 2 Kg) (Turnbull and Rees 713-15). Other side effects 
are acne, seborrhoea, hirsuitism and muscle cramps, which are reversible on stopping 
treatment.
Gestrinone does appear to be an effective short term medical treatment for the 
treatment o f menorrhagia. It however has an undesirable side effect profile, which 
may be unacceptable to some women. It is currently not licensed for menorrhagia and 
requires larger studies to confirm its efficacy and safety.
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1.4.2.5 Gonadotrophin Releasing Hormone analogues (GnRHa)
Modifying the native gonadotrophin releasing hormone molecule with substitutions o f 
amino acids in position 6 and 10 causes a prolongation o f its therapeutic half life. 
Continued occupation o f receptors leads to pituitary down-regulation with a state o f 
hypogonadotrophic hypogonadism resulting in endometrial atrophy. Even though it is 
unlikely for pregnancies to occur while on treatment, contraception is not guaranteed 
and as such barrier contraception is required.
GnRHa are not licensed for the management o f menorrhagia. The evidence for its 
effect on DUB comes from 3 studies. In a study on women with objectively proven 
MBL o f > 80mls, intranasal buserelin reduced MBL from 95-198 mis to 4-30mls after 
3 months o f treatment in the four women studied (Shaw and Fraser 913-16). 
Goserelin by a subcutaneous injection monthly for 3 months had similar effects. Five 
out o f six women studied had amenorrhea and the remaining woman had a MBL of 2 
mis (Gardner RL and Shaw 149-59). The effect o f Goserelin was also studied in 22 
women with anovular DUB causing an iron deficiency anaemia o f <9 g% (Vercellini 
et al. 127-29). All the women became amenorrhoeic with a significant increase in 
serum ferritin, serum iron, Hb and haematocrit. Stopping treatment with GnRHa 
caused the MBL to return to pre treatment levels in 16-27 days when intranasal 
buserelin was used and 7-10 weeks when Goserelin was used.
The most troublesome side effect was hot flushes as a consequence o f the hypo 
oestrogenic state and this was experienced by up to 91% of women. Over a six month 
period there was a 3-5% loss in vertebral trabecular bone density o f the lumbar spine. 
This has not been shown to be associated with an increase in fracture risk and said to 
be equivalent to the osteoporotic effect o f 6 months o f breast feeding. Because o f the 
risk o f irreversible osteoporosis with long term use, GnRHa have been licensed only 
for 6 months use. Add back therapy with hormone replacement therapy to counteract 
the vasomotor symptoms and decrease osteoporosis has been used and appears not to 
reduce the therapeutic effect (Homstein et al. 16-24).
The RCOG guidelines state that “GnRH analogue treatment is effective in reducing 
MBL but can only be considered as a temporary treatment, perhaps while awaiting 
surgery or the natural menopause”.
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1.5 Medical management of uterine fibroids
1.5.1 Antifibrinolytic drugs and NSAIDs
There is no conclusive evidence that shows the effect o f Antifibrinolytics and 
NSAIDs on the treatment o f menorrhagia secondary to uterine fibroids.
1.5.2 Combined Oral Contraceptive Pills
A reduction in MBL o f 25% was seen in women with menorrhagia and uterine 
fibroids (Nilsson and Rybo 713-20). However, details o f the fibroids were not 
included and high dose formulations were used making it difficult to interpret the 
significance o f these results.
1.5.3 Danazol and Gestrinone
Danazol can be used to induce amenorrhea and thereby correct iron deficiency 
anaemia in women with fibroid induced menorrhagia. Reduction in uterine volumes 
in 100 women who had uterine fibroids were seen when Gestrinone was administered 
in 3 regimes: 2.5 mg oral capsules three times weekly; 5.0 mg oral capsules twice 
weekly; 5 mg vaginal tablets three times weekly (Coutinho and Goncalves 939-46). 
Volume reduction was greatest in the vaginal route group. Interestingly 89% o f 
treated women maintained the reduction 18 months after stopping treatment.
1.5.4 Gonadotrophin Releasing Hormone analogues (GnRHa)
Studies have shown that GnRHa reduce uterine size from 35% to 65% with a large 
number o f women having amenorrhea (Shaw 859-64;Stovall et al. 65-71 ;Friedman et 
al. 251-56;Schlaff et al. 856-62). However with cessation o f treatment rapid 
regrowth occurs with a return to pre treatment size in 3 to 6 months.
GnRh agonist therapy before surgery causes a reduction in the uterine volume, 
improved pre operative packed cell volume, decreases in the intraoperative estimated 
blood loss and vertical incisions at surgery. The significance o f this is not known as 
the incidence o f blood transfusion is not reduced and there are claims that 
myomectomy is more difficult due to a loss o f a plane o f cleavage between the fibroid 
and normal myometrium.
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There have been attempts to extend the use of GnRha with additional medications that 
would reduce its side effects. The earliest medication that was introduced was 
medroxyprogesterone acetate. This was chosen in the belief that it would not interfere 
with the degree o f hypooestrogenism induced by GnRHa. Results however showed a 
reduction in the effect when compared to using GnRHa alone. (Carr et al. 1217-23) 
However, if  GnRHa are used alone for the first three months before a progestagen add 
back regime is commenced, some o f the reduction in uterine volume and symptoms 
are maintained.
Since then, oestrogen and progestogens add back therapy has also been studied. Fifty 
one women with uterine fibroids were given GnRHa for 3 months. A 40% reduction 
in uterine volume and 2.6% reduction in bone mineral density were noted. They were 
then randomised into 2 groups o f add back therapy for 2 years -  oestrogen and 
progestogens add back and progestogens only add back (Carr et al. 1217-23; 
Friedman et al. 1618-25). Women who received the combined add back maintained 
the uterine volume reduction with no further reduction in bone density. In the 
progestogens add back group, the uterine size returned to pre treatment size by month 
24.
1.6 Summary and conclusions
An increasing understanding o f the menstrual cycle has enabled the development o f 
many medical interventions to reduce MBL as shown in Table 1. Until recently, this 
has been used in a non systematic way with the most ineffective treatment (low dose 
luteal phase progestogens) being the most common prescription used in primary care. 
Consequently, the RCOG has published national guidelines for managing women 
with menorrhagia. It is presumed that if  these were to be fully supplemented it would 
significantly reduce the need for surgery. The limitations with medical therapy are 
the resumption o f symptoms once treatment is stopped. In addition, side effects can 
further reduce the QOL in these women. Comparisons o f the mode o f action, dosage, 
side effects, efficacy and recommendations for use of each o f the group o f 
medications discussed in this chapter are shown in Table 1. The LNG-IUS was 
thought to revolutionise treatment but is limited by the almost constant blood stained 
vaginal discharge for 6 months which precludes it from use from certain religious 
minorities and causes discontinuation o f treatment in up to 25% of women.
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Drug Mode of action Dose Main side 
effects
MBL
reducn
Contraceptive
effect
Use
Tranexamic
Acid
Antifibrinolytic lg  tds Mainly
thrombosis
50% None 1 st line -  
retain 
fertility
Mefenamic
Acid
Prostaglandin
inhibitor
500m g tds GI effects 30% None 2nd line -  
retain 
fertility
COCP Endometrial
atrophy
Depends on 
preparation
Thrombosis 50% Contraceptive Effective
method
Luteal phase 
Progestogens 
Day 16-25
Endometrial
atrophy
NET 5mg tds
MPA lOmg 
tds
Acne weight 
gain
-4% Barrier method 
required
Not to be 
used
Long cycle  
Progestogens 
Day 5 - 25
Pseudo decidual 
change
NET 5mg tds
MPA lOmg 
tds
Acne weight 
gain
90% Barrier method 
required
Effective
method
Danazol Anti Gn, Anti E2 
Anti P; 
Androgenic
200 mg daily Weight gain 
androgenic
85% Barrier method 
required
Side
effects
prohibit
use
Gestrinone Similar to 
Danazol
2.5 mg twice 
weekly
Weight gain 
androgenic
85% Barrier method 
required
Evidence 
too scanty
GnRh
analogues
Pituitary
downregulation
3 .7 5 /3 .6 0  
mg SCT
Vasomotor
osteoporosis
100% Barrier method 
required
Short term 
use
LNG-IUS 
MI REN A
Endometrial
atrophy
20pg daily 
release
Nuisance
bleeding
85% Contraceptive Must be 
offered 
before 
surgery
Table 1 Table comparing the dosage, mode o f  action, side effects, efficacy, contraceptive effect and 
recommendations for use o f  medications available for treatment o f  heavy periods
GnRHa are limited to short term therapy because o f the side effects o f vasomotor 
symptoms and loss o f vertebral mineral bone density.
Evidence for the medical treatment o f uterine fibroids is surprisingly scarce in what is 
a very common condition. The evidence reviewed shows that there is no long term 
effective medical treatment for uterine fibroids.
If  hysterectomy for the treatment o f women with DUB and symptomatic fibroids is to 
be reduced by medical treatment alone, further research and development is required.
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[2] Surgical 
alternatives to 
hysterectomy for 
heavy periods
Hysterectomy is associated with a 100% primary success rate and high patient 
satisfaction scores but it is a major surgical procedure with significant physical and 
emotional complications, social and economic costs (see section 2.1.1). As 
dysfunctional uterine bleeding and uterine fibroids contribute to 63% of 
hysterectomies that are performed for the complaint o f menorrhagia, the last twenty 
years have seen a rapid increase in the development o f alternative surgical techniques 
to treat these conditions in an attempt to reduce the need for hysterectomy.
The aim o f this chapter is to discuss the need, history o f development and current 
alternative techniques used for the treatment o f DUB and uterine fibroids.
2.1 Hysterectomy
Hysterectomy used to be considered the treatment o f choice for menorrhagia in 
women who had completed their family. It is associated with a high patient 
satisfaction rate and sense o f mental well being after surgery(Carlson, Miller, and
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Fowler, Jr. 556-65; Kjerulff et al. 1440-47). It is also the only modality o f treatment 
which guarantees a 100% cure for both heavy MBL and uterine fibroids.
2.1.1 Problems with hysterectomy
Hysterectomy is a major operation with attendant morbidity and mortality (1:2000 
under the age o f 50). The average hospital stay is five days with a further four to 
eight weeks required to return to normal activity (Dicker et al. 841-48).
The complications associated with hysterectomy are shown in Table 2.
Complication Frequency of occurrence
Haemorrhage 1-3%
Infection Up to 9%*
Injury to bladder, bowel and ureter 1-2%, 0.4% and 0.2%
Thromboembolic disease Low risk 0.25, high risk 2.4%
Wound dehiscence 0.3 -  0.7%
Return to the operating theatre 4%
Preponement o f  the menopause Not known
Table 2 Table showing the frequency o f  intraoperative and postoperative complications o f  a 
hysterectomy. Long term sequels are also shown. *Infection rates are currently lower as prophylactic 
antibiotics at the time o f  surgery have becom e routine practice.
2.1.2 History of uterine conserving surgery
In 1949, vigorous curettage o f the uterus in the puerperium or after a miscarriage was 
observed to be associated with obliteration o f the uterine cavity from fibrosis resulting 
in reduced or absent menstrual periods.(Ashermann JG 892-96) This has led 
gynaecologists to find a way o f inducing this situation as a treatment for DUB. The 
first report o f destruction of the endometrial lining by the thermal energy from a laser 
for the treatment o f DUB as an alternative to a hysterectomy was in 1981(Goldrath, 
Fuller, and Segal 14-19).
The first uterine conserving procedure for uterine fibroids was performed by Amussat 
in 1840 when he did a myomectomy under the misconception that it was an ovarian 
tumour because it was on a pedicle. Atlee was the next surgeon to perform it. In 
1889, Alexander o f Liverpool reported a technique by which he was able to remove
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25 such tumours from a single uterus. It was however only 24 years later that Victor 
Bonney developed this technique as an alternative to a hysterectomy(0'Dowd MJ and 
Phillip EE 411-12). The ethos for doing so can be summarised by his following 
remark;
“A part from  its ph ysica l value, the wom b  
has fo r  m ost women a  sentim ental value 
which how ever illogical cannot be 
discounted.  ”
Figure 1 Victor Bonney
This may have been from his personal observations on the change in his wife Annie 
who had to undergo an emergency hysterectomy at the Middlesex Hospital for severe 
anaemia from menorrhagia. It is said that after the hysterectomy, she retired from 
active life and lived away from children.
Alternative routes to myomectomy have been developed to avoid laparotomy. 
Recently techniques that reduce the blood supply to the fibroid and damage the 
collagen within the fibroid are being investigated.
2.2 Alternative surgical treatment of DUB
2.2.1 First generation endometrial ablation techniques
2.2.1.1 Laser ablation
Transcervical endometrial ablation was first described by Goldrath in 1981. 
(Goldrath, Fuller, and Segal 14-19) The procedure involves destroying the 
endometrium including the basal layer by coagulation or charring using an Nd:YAG
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laser. This is done via an optical fibre that is passed through a channel in the operating 
hysteroscope.
The procedure is done under general anaesthesia. The resectoscope sheath has a 
diameter o f 9 mm and as a result the cervix needs to be dilated to Hegar 10. The 
hysteroscope is inserted, the optical fibre introduced and the fibre is then drawn along 
the fundus and the walls o f the uterus till the whole uterus is treated. The power used 
is usually 50 Watts at continuous wave.
The procedure is not very popular due to the expense o f the laser and the availability 
o f cheaper alternatives. In addition, personnel are required to have been specifically 
trained in operating the laser. Health and safety regulations today also need the 
appointment o f a laser safety officer to ensure that all precautions are taken to reduce 
the risk o f inadvertent laser injury to the patient, operator and other staff. Another 
disadvantage o f this procedure is that there is no tissue available for histopathological 
examination. Adequate biopsies o f the endometrium must therefore be taken prior to 
the procedure.
2.2.1.2 Loop resection
The technique used for loop resection o f the endometrium was borrowed from the 
urologists from the procedure transurethral resection o f the prostate. The procedure 
was developed in North America in 1987 by Alan DeChemey (DeChemey et al. 668- 
70). Adam Magos’s group published the first case series (Magos, Baumann, and 
Turnbull 1209-12). This is the commonest method (80%) practised in the United 
Kingdom (Overton, Hargreaves, and Maresh 1351-59).
Transcervical resection o f the endometrium is carried out usually under a general 
anaesthetic. The cervix is dilated as described in section 2.2.1.1. The procedure is 
started at the fundus and then the sidewalls o f the uterus before proceeding to the 
anterior and posterior walls. The uterus is distended with a non electrolyte solution 
(commonly 1.5% glycine) which is continuously irrigated through the double lumen 
sheath enabling the clearing o f blood and debris and the maintenance o f an optimal 
view. The operating hysteroscope is attached to a monitor so that the operation is 
performed visualising the monitor. The hysteroscope is a 4mm diameter scope with a 
30 degree or 12 degree angle. The loop electrode is 24 F through which is delivered a
100-150 W cutting or blended current.
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Figure 2 Picture showing the loop resectoscope being used. At the bottom o f  the picture two sections 
o f  the uterine endometrium have been resected with the loop. The distension medium is 1.5% glycine
The activated loop is moved towards the operator under vision taking 3-4 mm depth 
o f endometrium as a chip exposing the muscle fibres of the underlying myometrium. 
The chips are then sent for histopathological evaluation. Rollerball diathermy may be 
used after the procedure to control bleeding points.
2.2.1.3 Roller ball ablation
This was first described by Vancaille in 1989 (Vancaillie 425-27). It is a simpler 
technique than loop resection and may be employed by an operator who is in the early 
learning curve o f operative hysteroscopic surgery. The rollerball electrode has a 
larger contact with the endometrium (a 3 mm ball is usually used though a 5 mm ball 
is also available but tends to obscure the operators view). It is easier to maintain as it 
rotates around its own axis, thereby distributing the electrical energy over a larger 
surface area reducing the likelihood o f damage to the deeper layers o f the 
myometrium and serosa. It also fits better into the cornua o f the uterus making it 
easier to treat this area, which is difficult to resect with the loop electrode. However, 
there are no strips o f endometrium produced, which not only obscure the operators 
view but also increase the procedure time. As the procedure time is reduced and the 
depth o f penetration is controlled the chances of fluid overload with dilutional 
hyponatraemia is reduced. After introduction of the resectoscope the ball is placed 
firmly onto the endometrium and current is then applied to check the extent o f 
surrounding blanching in order to gauge the amount o f current needed.
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Figure 3 Diagrammatic representation o f  roller ball ablation o f  the endometrium. The thermal burns to 
the endometrium are illustrated. This procedure does not produce any tissue for histological evaluation
The usual recommendation is 40 -  60 W on a coagulation setting moving the ball 
through a distance of 1 cm per second. Under direct vision, the entire endometrium 
can be ablated. Adequate biopsies must be obtained prior to treatment as there is no 
histological specimen.
2.2A .4 Combined loop resection and roller ball ablation
Many surgeons today use a combination o f both techniques. The roller ball is used to 
thermally destroy the endometrium in the cornua and the fundus. The loop 
resectoscope is then used to finish the treatment. This is following a national audit 
that showed lower risk of perforation with roller ball treatment o f the ostia (Overton, 
Hargreaves, and Maresh 1351-59).
2.2.1.5 Outcome of hysteroscopic surgery
The success rate at one year for TCRE and ELA is approximately 75% (amenorrhea 
rates o f 42% and oligomenorrhea of 33%) with 9% requiring repeat treatment, and 
16% needing a hysterectomy. (A Scottish audit of hysteroscopic surgery for 
menorrhagia: complications and follow up. Scottish Hysteroscopy Audit Group 249- 
54;Dwyer, Hutton, and Stirrat 237-43) Patient satisfaction is about 84% with median 
hospital stay being one day. There is no significant difference in these outcome 
measures between TCRE and ELA. 5 year follow up studies have shown that 76% - 
80% of women would avoid a hysterectomy. (O’Connor and Magos 151-56) Failure 
was found to be more common in women under the age of 40 years, if  the surgeon
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had performed less than 10 procedures, if  intramural fibroids were present or if  the 
operation was done in the luteal phase o f the menstrual cycle. Endometrial thinning 
was thought to be a significant factor but this was shown to make no difference to the 
outcome in the MISTLETOE study (Overton, Hargreaves, and Maresh 1351-59).
2.2.2 Second generation endometrial ablation techniques
2.2.2.7 Cryotherapy
In this procedure, the cervix is dilated with a cryoprobe (similar to a Hegar dilator) as 
shown in Figure 4, which enables its introduction to the uterine cavity. 3-5ml o f saline 
is introduced into the device via a syringe. Using nitrous oxide or carbon dioxide, the 
probe is cooled by the rapid gas expansion to -45°C. Two freeze thaw cycles, each 
taking about 5 minutes are required to complete treatment. Initial results from this 
procedure were disappointing. In a more recent study 279 women with menstrual 
bleeding due to benign causes were prospectively randomised to undergoing 
endometrial cryoablation or roller ball electroablation. MBL reduction was similar in 
both groups (92% vs. 94%), as was improvements in pain, mood and QOL. (Duleba 
et al. 17-26)
Figure 4 Figure showing the cryoprobe with gas delivery unit
2.2.2 2 Radio frequency
This method consists o f thermal ablation o f the endometrium induced by the rapid 
oscillation o f charged particles in the tissue directly around an intrauterine 
radiofrequency probe. 550 watts o f power is applied for 20 minutes to raise the
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temperature o f the stratum basalis to approximately 50 -  55 ° C whilst the rest o f the 
pelvic contents remain at normal body temperature.
Figure 5 Diagrammatic representation o f  the activated radiofrequency tip probe
Early experience included complications o f anterior vaginal wall fistulae in 2 women 
(Phipps et al. 374-76). Since then the probe has been considerably modified. A more 
recent study involving thirty two women with DUB reported a success rate o f 84% 
with 31% o f women becoming amenorrhoeic and 53% showing significant reduction 
in MBL (Prior et al. 213-20).
2.2.2 3 Microwave endometrial ablation (MEA)
This surgical device was developed in 1992 at the University o f Bath in conjunction 
with the Royal University Hospital. (Microsulis pic, Waterlooville, Hampshire, UK) 
It consists o f a microwave “waveguide” (a metal tube along which microwave energy 
propagates and is then released at the tip or distal opening) filled with dielectric 
material (that focuses the beam as it passes through so that a smaller diameter o f 
waveguide may be used). The dielectric propagates microwaves at a frequency o f 
9.2GHz which was shown in experiments (both in vitro and in vivo) to produce tissue 
destruction to a depth o f 6 mm. The diameter o f the waveguide is 8 mm requiring the 
cervix to be dilated to 9 mm. The microwaves that are released from the tip are 
distributed in a spherical fashion which helps the heating effect to be evenly 
distributed. The waveguide is coated with a fluoroplastic sheath, which allows for 
chemical and autoclave cleaning. It is graduated in cms.
Figure 6 Figure showing the waveguide with the sheath (graduated in cm s) which is used for
microwave endometrial ablation
The device is attached to a system that generates the microwaves (magnetron) and 
monitors temperature. This is viewed by the surgeon as a computer display with an 
allocated treatment band. A hard copy can be obtained at the end o f the procedure. 
Under a general anaesthetic (more recently MEA is being performed under a local 
anaesthetic) the cervix is dilated to Hegar 9. The uterus is sounded and the applicator 
is inserted to that depth. The power is switched on with a foot switch and heating 
occurs rapidly and temperatures enter the treatment band within a few seconds. The 
applicator is then moved from side to side until the whole fundal area is treated. The 
applicator is withdrawn with the same side to side movements for treatment o f the 
walls o f the uterus. As the applicator approaches the internal os a safety zone 
becomes visible at the internal os as indicated on the applicator. This has been set at 4 
cms from the tip.
The initial study included a 6 month follow up o f 23 women with a total o f 26 
treatments (Sharp et al. 1003-04). The average procedure time was 2 minutes and 12 
seconds. The success rate o f the procedure was 83% with 13 (57%) patients 
becoming amenorrhoeic, and six (26%) experiencing light menstruation. Three initial 
failures were successfully retreated.
In a  randomised controlled trial comparing MEA (n=129) with TCRE (n=134) 
(Hodgson et al. 684-94), participants were asked to complete a baseline clinical and 
SF-36 questionnaire, to grade severity o f bleeding and pain and to document bladder 
and bowel symptoms. This was repeated at 4 and 12 months. MEA achieved a 77% 
satisfaction rate and TCRE a 75% satisfaction rate. Both techniques were highly 
acceptable and improved QOL after 1 year. There was one case o f uterine perforation
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reported in each treatment group, the woman undergoing the TCRE requiring an 
urgent hysterectomy.
MEA appears to be as effective as TCRE but most o f the outcomes measured were not 
significantly different between the two procedures. The odds o f haemorrhage were 
higher in the TCRE group but the odds o f equipment failure were higher in the 
microwave group. In both studies, MEA was mainly performed under a general 
anaesthetic even though one o f the advantages cited are its use in the outpatient 
setting. There are scarce data in this setting and it would be interesting to see if  the 
patient satisfaction results are the same.
2.2.2.4 Fluid Balloon
Cavaterm endometrial ablation system
The system consists o f a disposable catheter and a battery operated central unit. The 
central unit has a self-regulating electrical element that generates heat at 80 °C. The 
oscillatory pump maintains a continuous flow o f heated fluid around the system. The 
balloon is made o f silicone and its length can be adjusted to fit the uterine cavity. The 
end o f the catheter at the lower end o f the balloon is insulated to prevent thermal 
injury to the cervix. The outer diameter o f the catheter is 8 mm requiring cervical 
dilatation to 9 mm for insertion.
Figure 7 The Cavaterm balloon
The catheter is inserted till the fundus is reached and the balloon is inflated with 
glycine until a target pressure o f 180 mm is reached. The pressure is maintained at 
140-200 mm of Hg (20 mm above systolic blood pressure). The thermal unit is 
activated and balloon surface temperature rapidly reaches 75 C, which is maintained 
for a total treatment time o f 15 minutes.
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Published case studies have reported amenorrhoea rates o f 22-68%, combined 
amenorrhoea and hypomenorrhoea rates o f 56-82% and overall success rates o f 92- 
98% (Hawe et al. 1143-48; Friberg et al. 330-35).
In a randomised controlled trial comparing the Cavaterm endometrial ablation system 
(n=37) and endometrial laser ablation (n=35) there was no significant difference in the 
amenorrhoea rates (29% vs. 39%) or combined amenorrhoea and hypomenorrhoea 
rates (73% vs. 69%) (Hawe et al. 350-57). There was a high patient satisfaction rate 
and improvement in QOL with both procedures.
The Cavaterm endometrial ablation system has been shown to be as effective and 
acceptable as laser ablation o f the endometrium. However long term follow up will 
be required to assess long term outcome with this method.
Thermachoice endometrial thermal balloon therapy
This device consists o f a plastic catheter o f 16cm length and 5 mm width with a latex 
balloon that when inflated is designed to conform to the uterine cavity. The catheter 
is inserted into the uterine cavity and the balloon is inflated with a non electrolyte 
sterile aqueous liquid. An intraluminal pressure o f 160-170 mm Hg is required for the 
balloon to be dilated by 10 mis. The distal end o f the catheter contains a heating 
element and a temperature recording device (thermistor) which is connected to the 
central control unit that monitors, displays and adjusts the preset intrauterine balloon 
pressure, temperature and duration o f treatment. The temperature is programmed to 
rise to 87 °C with a cut off when the temperature exceeds 92 °C. The pressure feature 
is set so that when the pressure is outside the range o f 45-165 mm Hg the heating unit 
shuts down. When the temperature falls below 90 °C and the pressure stabilises in the 
preset range the heating coil switches on. Treatment time is scheduled for 8 minutes 
and starts when the temperature monitored is 85 °C. After treatment another 4-5 
minutes is added for the system to cool down before the balloon is deflated and 
withdrawn. This treatment aims to cause a uniform coagulation o f 3-5 mm of 
endometrium by the transfer o f heat through the balloon.
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Figure 8 Figure showing the diagrammatic representation o f  the placing o f  the inflated Thermachoice 
balloon in the uterine cavity. The optical fibre is placed in the centre o f  the balloon
In a prospective observational study involving 296 women with DUB, Thermachoice 
balloon ablation was shown to have a success rate o f 88-91% at 1 year. Pre treatment 
with GnRHa (5% o f women in trial) increased the amenorrhea rates (Amso et al. 517- 
23).
In a long term multicentre follow up study o f 188 women who replied to a 
questionnaire, (72% response rate) 47% had amenorrhoea, 30% had hypomenorrhoea 
and 86% o f women had avoided a hysterectomy four to six years after the procedure 
(Amso et al. 1082-87).
2.2.2.5 VestaBlate electrode balloon
The VestaBlate consists o f a disposable single use multi electrode balloon. It contains 
six foil electrodes each o f which has a thermistor on each side o f the balloon 
connected to a controller. The balloon is placed in the uterine cavity through an 8 mm 
diameter inserter. When inflated by 10 mis o f room air, the balloon distends to fit the 
uterine cavity and compresses the endometrium. The electrodes are then in contact 
with the endometrium and are connected through the controller to a standard 
electrosurgical generator. The thermistor is preset to a temperature between 65 °C 
and 75 °C. When one electrode is warmed up to that level the energy to that electrode 
is blocked and diverted to another electrode where the temperature is below the range. 
After an initial warm up period o f 1-3 minutes the treatment phase starts and lasts for 
4 minutes after which the system shuts off and the device may be removed. The aim
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is to provide a uniform depth o f desiccation by the uniform distribution o f heat on the 
surface o f the balloon.
In a multicentre randomised study (n=276) comparing the VestaBlate to endometrial 
resection and rollerball it was found that the duration o f the procedure was 
significantly shorter and was more likely to be performed under a local anaesthetic 
than the first generation methods (Corson et al. 45-49). There were no significant 
differences in the amenorrhoea rate, complication rate, PBAC score after 12 months, 
additional surgery and success rates.
2.2.2.6 Interstitial lasers
The ELITT (endometrial laser interstitial thermotherapy) consists o f a disposable 
handset containing three optical light diffusers (which can be manipulated 
individually on each side) and a compact tabletop diode laser (20W, 830 nm). The 
cross section o f the folded handset is 6 mm requiring the cervix to be dilated to Hegar 
7-8 for insertion. The portion o f the handset that is inserted into the uterus is coated 
with Teflon, which does not adhere to the tissue while still transmitting light. The aim 
o f the treatment is that the 830 nm laser light penetrates the endometrium and is 
absorbed by haemoglobin, warming the endometrium and causing coagulation.
Figure 9 Diagrammatic representation o f  the activated ELLITT device inside the uterus. This shows
optimal placement o f  the device
The endocervical canal is dilated to Hegar 7 and the light diffuser handpiece is 
inserted into the uterus. The distal end o f the handpiece is advanced and the side
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diffusers are adjusted forming a butterfly wing contour that conforms to the uterine 
cavity. The laser is then activated for a 7 minute program (20W for the first 90 
seconds; 18W during the next 90 seconds and 16 W during the final 240 seconds), 
which automatically shuts down allowing folding o f the side diffusers and removal o f 
the handpiece.
Donnez group pioneered this method and in a recent update it has now been 
performed on 100 women with DUB (Donnez et al. 791-96). At 12 months the rate o f 
amenorrhoea was 71% and the combined rate o f amenorrhoea and hypomenorrhoea 
(defined as less than 1 pad a day) was 91%. 87% of women said that they were most 
satisfied while another 12% were satisfied with the procedure. One woman was not 
satisfied, despite having a Higham score that was 88 % lower than her pre-treatment 
score. Sixty percent o f the procedures were carried out under a general anaesthetic, 
21% under paracervical block and epidural analgesia and 2% under conscious 
sedation only. There were no cases o f perforation o f the uterus or intraoperative 
complications reported. In a study by a British group the results were reproduced 
(n=40) with an amenorrhoea rate o f 70% and a satisfaction rate o f  88%. However the 
rate o f hysterectomy in this series was 12.5%, four operations being the result o f 
recurrent menorrhagia and one due to pelvic pain.
There is no randomised trial comparing this method to any o f the first generation 
endometrial ablation techniques.
2.2.2.7 Hydrothermal ablation
This consists o f a double lumen insulating sheath that fits over the hysteroscope. 
Heated saline at 80-90 C is recirculated though the sheath distending the uterine 
cavity and causing destruction to all the layers o f the endometrium and about 1-3 mm 
of the myometrium. The HTA system is designed as a closed circuit system, which 
will automatically shut down if  more that 10 ml leakage is detected in the system. 
The intra uterine pressure achieved during the HTA procedure is 50 mm o f Hg and 
this is achieved by the saline chamber being kept at a designed pole height above the 
procedure table. This is less than the opening pressure o f the tubal ostia (70 mm o f 
Hg) thereby minimising the passage o f heated saline into the fallopian tubes.
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Figure 10 Diagrammatic representation o f  the double lumen sheath hysteroscope circulating heated
saline in the uterine cavity.
The leakage o f up to 10 ml o f heated saline into the fallopian tube has been shown not 
to be harmful as the fallopian tubes are very vascular and act as a heat sink with 
temperatures at the corneal ends during HTA ablation been measured to be 42 °C and 
further rapid cooling occurs once the fluid enters the peritoneal cavity due to the large 
peritoneal surface area.
The cervix is dilated to 8.5 mm. This allows for a tight fit o f the insulating sheath at 
the level o f the cervix so that no leakage o f fluid occurs. The ablation phase includes 
heating saline up to 90 C and then recirculating it for 10 minutes. This can be done 
under continuous visualisation. After the ablation phase is over the uterus is cooled 
with saline at room temperature before the instruments are removed from the uterus.
In 1995, Goldrath (Goldrath, Barrionuevo, and Husain 235-40) performed animal 
studies to show that instillation o f hot saline into the endometrial cavity can cause 
ablation o f the endometrium. This idea has been developed into the only second 
generation technique that is performed under hysteroscopic vision.
In a multicentre study 276 women with DUB were randomised into having HTA 
ablation or balloon ablation. There was no significant difference in the success o f 
treatment, amenorrhoea rate, need for further surgery or operative adverse events. 
Women in the HTA group however were more likely to experience nausea, vomiting 
and abdominal pain after surgery. Women in the balloon ablation group were more
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likely to have haematometra after the procedure. There were seven women in the 
HTA group who could not proceed with treatment because o f equipment failure.
2.3 Alternative surgical treatment of uterine fibroids
Surgical alternatives to hysterectomy for uterine fibroids are possible because uterine 
fibroids are benign tumours and the frequency o f sarcomatous change is low (2-3 per 
thousand) (Parker, Fu, and Berek 414-18). Conservative surgery involves 
myomectomy or fibroid shrinkage either by embolisation, clipping o f both uterine 
arteries and myolysis.
2.3.1 Removal of fibroids
2.3.1.1 Myomectomy by laparotomy
Myomectomy by laparotomy was described as far back as 1840 when Amussat 
removed a tumour thought to be an ovary because it had a pedicle (O’Dowd, Michael 
J, and Phillip Elliot 411). In a recent technology assessment and evidence report on 
the management o f uterine fibroids (File Inventory and AHRQ Publication No.01- 
E052) where selected published series were analysed, there was an 80 -100 % relief 
o f menorrhagia and a 50 -90%  relief o f pressure and pain symptoms after 
myomectomy. Fifty per cent o f women with fibroids and otherwise unexplained 
infertility conceived after a myomectomy and the risk o f uterine rupture in a 
subsequent pregnancy was low (0.002%) compared with that after a previous 
caesarean section (0.1%). Intraoperative blood transfusion rates o f up to 18% and an 
increased febrile morbidity compared to hysterectomy were reported. Clinically 
significant recurrence rates were quoted as 10% at 5 years with post operative 
adhesions (often involving bowel) being long term complications.
There were significant difficulties encountered in the synthesis of the data. There 
were variations in patient selection, inadequate reporting correlating the number and 
location o f the fibroids to the presenting symptoms and outcome, differences in 
practice in terms o f measures taken to reduce intra operative blood loss, surgical 
techniques, indications for blood transfusion and the methods used to measure 
symptom improvement. The effect o f myomectomy on infertility was also 
compounded by not accounting for the effect of assisted reproductive techniques after 
surgery. Furthermore, groups which performed large numbers o f myomectomies have
57
reported no increase in short term complications like blood transfusion rates and 
febrile morbidity when compared to hysterectomy. This may reflect an evaluation o f 
the practice o f the particular group rather than the procedure itself in general use.
2.3.1.2 Laparoscopic Myomectomy
Laparoscopic myomectomy (LM) was first performed in 1977 (Semm and Mettler 
121-27). Since this report it has been developed for subserous and intramural fibroids 
because o f the possibilities o f reduced postoperative pain, shorter hospitalisation, and 
earlier return to normal activity and reduced adhesions. Initially the procedure was 
associated with prolonged operating times, significant blood loss and a high risk of 
conversion to a laparotomy. Two specific issues were tissue retrieval from the 
peritoneal cavity and the repair o f the uterine wall defect especially after the removal 
o f a deep intramural fibroid. Case reports o f spontaneous rupture o f the uterus at 33 -  
36 weeks o f a subsequent pregnancy have been reported between 1992 and 1997 
making the technique questionable in women desiring future pregnancies. (Dubuisson 
et al. 1475-77; Harris 545-46)
Figure 11 Figures showing a uterus with an 8 cm intramural fibroid with subserosal extension before
and after laparoscopic m yomectomy
With improving patient selection, laparoscopic skills in suturing, the adoption o f 
microsurgical techniques and the development o f more efficient electric morcellators 
considerable advances have been made in the efficacy o f the procedure. Recent 
studies have shown comparable operating times and pregnancy rates to open 
myomectomy with reduced febrile morbidity, haemoglobin drop postoperatively,
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transfusion rates and hospital stay. There is also a suggestion o f reduced 
postoperative adhesions including periadnexal adhesions but the evidence is not 
conclusive. Rates for conversion to laparotomy range from 0 -  2.9% but this is not 
taking into account mini laparotomy to complete uterine closure.
There is still considerable debate as to whether the integrity o f endoscopic sutures is 
equivalent to that at laparotomy. It is difficult to calculate an incidence o f uterine 
rupture from isolated case reports as the total number of pregnancies following LM is 
not known. Recurrence o f fibroids after LM is significantly higher and occurs earlier 
than after open myomectomy. The cumulative risk is 50% at 5 years (Tavmergan E, 
Tavmergan EN, and Turker S 68;Stringer, Walker, and Meyer 457-64). This is due to 
the lack o f tactile sensation at laparoscopy resulting in an inability to detect small 
fibroids at the time o f surgery. Meticulous preoperative investigation and careful 
patient selection reduces this risk.
LM is therefore recommended in women with a maximum o f 3 fibroids, the largest 
not being greater than 8 cms in size and the overall uterine size being not greater than 
16 weeks gestation. It should be performed by surgeons with sufficient skill 
especially in laparoscopic suturing to allow for proper closure o f the uterine defect 
after deep intramural fibroids are removed thereby minimising the risks o f uterine 
rupture in a subsequent pregnancy.
2.3.1.3 Laparoscopic Assisted Myomectomy (LAM)
LAM was first reported in 1994 (Nezhat et al. 39-44). The procedure involved the use 
o f a 5 cm suprapubic minilaparotomy, which aided in morcellation and removal o f the 
fibroid and repair o f the uterus in layers. Convalescence and symptom relief is similar 
to that o f LM. The technique was proposed to reduce operating time and improve 
uterine closure thereby reducing the risk o f uterine dehiscence in a subsequent 
pregnancy. Recommended indications are fibroids which are deep intramural in type, 
are greater than 5 cms in diameter and require uterine closure in layers with the 
indication being primarily for infertility. However a recent case report on uterine 
rupture after LAM (Friedmann et al. 683-84) does not help in the creation o f clear 
guidelines on the indications o f this procedure in women undergoing LM.
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2.3.1.4 Vaginal Myomectomy
The first report o f a vaginal approach to myomectomy was in 1988 and was used for 
the removal o f prolapsed submucosal fibroids. (Ben Baruch et al. 858-61) 
Subsequently an anterior hysterotomy was described for the removal o f large 
submucous fibroids. More recently vaginal myomectomy has been described as an 
alternative approach to myomectomy by laparotomy (Davies, Hart, and Magos 961 - 
64). In this procedure, an anterior or posterior colpotomy is made depending on the 
position o f the bulk o f the fibroids. The uterus is manipulated till the fibroid is 
presented to the colpotomy and a vertical incision is made over the fibroid and the 
fibroid removed intact or piece meal by morcellation. As many fibroids as possible 
are removed in this manner and when the uterus is sufficiently debulked it is delivered 
into the colpotomy enabling closure o f the uterine defect as at laparotomy.
Anterior colpotomy
Posterior colpotomy
Figure 12 Diagrammatic representation o f  the technique described in removing anterior and posterior
wall fibroids through a vaginal route
Removal o f the fibroid has been found to be associated with minimal blood loss and 
this has been thought to be due to the tourniquet effect on uterine blood supply that is 
achieved by anteflexing or retroflexing the uterus to deliver it to the colpotomy. 
Other advantages quoted are the low morbidity associated with the avoidance o f  an 
abdominal incision. Advantages over LM are that vaginal myomectomy can be used 
for women with more than 3 fibroids, the operating time is far less, closure o f the 
uterine defect is similar to that at laparotomy and the recurrence risk o f fibroids 
should be less due to presence o f tactile sensation.
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However vaginal myomectomy is not suitable for all fibroids especially when situated 
in the fundal and lateral walls o f the uterus. The risk o f conversion to laparotomy is 
about 9 % and it is associated with an 11.4% risk o f vault haematoma. To date there 
are no studies on long term complications. This procedure requires a high degree o f 
specialised skill in vaginal surgery and therefore precludes it from widespread use.
2.3.1.5 Hysteroscopic resection of a fibroid
Transcervical hysteroscopic resection o f submucous fibroid (TCRF) was first 
described for the treatment o f submucous fibroids in 1976 (Neuwirth and Amin 95- 
99). Submucous fibroids are classified into three types. Type 0 is when the fibroid is 
entirely submucous, Type I is when < 50% is intramural and Type II is when > 50% is 
intramural. TCRF has been shown to be effective in reducing menstrual blood loss 
(63-90%) caused by a submucosal fibroid (Cravello et al. 374-80; Hallez 703-08;Hart, 
Molnar, and Magos 700-05; Phillips et al. 147-53). It is particularly attractive as it 
can be performed as a day case surgical procedure and 80% o f women who undergo 
this procedure avoid further surgery including a hysterectomy (Hart, Molnar, and 
Magos 700-05). TCRF is associated with a pregnancy rate o f up to 73% in women 
with infertility (Phillips et al. 147-53). However the evidence on infertility does not 
include any randomised trials and hence the debate is not conclusive. Long term 
complications include intra uterine adhesions in 10% of women (Hallez 703-08) The 
most significant factors that influence outcome are the type o f the fibroid (Type 0 
giving the best results) and the overall size o f the uterus (less than a six week 
gestation size). Factors such as the age o f the woman and the number and size o f the 
individual fibroids are only secondary to these in affecting outcome. TCRF is 
however associated with short term complications which include haemorrhage 
requiring transfusions (1-4%), (Derman, Rehnstrom, and Neuwirth 591-94) uterine 
perforation (1-4%), (Cravello et al. 374-80; Emanuel et al. 743-48; Hallez 703-08) 
emergency hysterectomy (up to 1%) and pulmonary oedema (0.3%) (Emanuel et al. 
743-48) from dilutional hyponatraemia. Long term complications include an 
Ashermanns syndrome o f up to 10%, (Hallez 703-08) and a 11% uterine rupture rate 
in a subsequent pregnancy (Hart, Molnar, and Magos 700-05).
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Figure 13 showing a uterus with a Type 0 large submucous fibroid almost filling the uterine cavity  
before and after removal with transcervical resection. The best results are obtained with Type 0
fibroids
Developments with instrumentation have enabled the use o f miniature bipolar 
resectoscopes, which can be passed into the uterus without dilating the cervix. It can 
be used in the outpatient setting and employs physiological saline as a distending 
medium thereby reducing the risks o f electrolyte disturbances with fluid overload. 
Because o f the high energy intensity a vaporising effect is produced at the electrode 
tip and therefore there are no resection chips produced making the procedure easier 
and hence promises to be o f more widespread use. After initial concerns with reports 
o f non fatal air embolism for which the product was taken out o f the market it has 
been reinstated without any modifications as investigators found that the complication 
was associated with any electro surgical procedure and not with the instrument itself. 
Results using this system seem to be comparable to the conventional operative 
hysteroscopes with an improvement in bleeding being reported by 78% o f women at 6 
months and a patient satisfaction rate o f 92% (Clark et al. 237-42).
2.3.2 Reduction in the size of fibroids
2.3.2.1 Uterine artery embolisation (UAE)
In 1995, Ravina’s group performed prophylactic UAE on women prior to 
myomectomy and hysterectomy with the aim o f reducing complications o f 
intraoperative bleeding, blood transfusion and the conversion o f a myomectomy to a 
hysterectomy (Ravina et al. 671-72). Surprisingly 14 out o f 16 women in this series
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had resolution o f symptoms with a 20-60% reduction in uterine volume at 20 months 
and therefore did not require surgery. Since Ravina’s work, other groups have 
evaluated UAE as a primary treatment for uterine fibroids.
The procedure is performed under fluoroscopic guidance under conscious sedation 
and involves a single femoral artery puncture through which the uterine artery is 
cannulated and an embolic agent introduced. The catheter is withdrawn across the 
internal iliac artery guided into the contralateral uterine artery and the procedure 
repeated. Embolic agents reported have been polyvinyl alcohol beads ranging in 
diameter size from 355-500 to 500-700 micrometers. Other agents used are gelatin 
sponge and trisacryl plastic spheres o f 500-900 micrometer diameter.
Embolic agent
Catheter
Uterine artery
Figure 14 Diagrammatic representation o f  uterine artery embolisation. The catheter is in the uterine 
artery and polyvinyl particles have been injected to cause obstruction to the distal branches o f  the
uterine artery
The use o f platinum coils in addition to PVA particles to prolong the duration o f 
fibroid ischaemia has also been used. The procedure takes between 35 -  135 minutes 
to perform and in most series the women are admitted overnight for analgesia though 
the procedure can be done on a day case basis. Women receive a radiation dose o f 
approximately 20cGy which is about ten times that o f a CT o f the pelvis or equivalent 
to a Barium enema examination. Revascularisation o f the myometrium and 
endometrium occurs by an effective collateral circulation developing which does not 
seem to extend to the fibroids. Fibroid necrosis and regression in size are therefore 
maintained.
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In the hands of an experienced interventional radiologist, UAE is technically feasible 
in 96-100% of cases (Ravina et al. 272-75; Walker and Pelage 1262-72). Its efficacy 
is similar to that of the use of GnRH analogues. Fibroid volume shrinkage of 30-50% 
at 6 months in 85% of treated women have been reported (Goodwin et al. 1159-65; 
Spies et al. 1149-57; Brunereau et al. 1267-72). It is associated with a smaller 
reduction in the uterine volume of 29-48% (Spies et al. 1149-57; Walker and Pelage 
1262-72). The shrinkage is however maintained at 6 months post treatment. UAE is 
associated with improvements in menstrual blood loss (80-96%),(Ravina et al. 233- 
43; Bradley et al. 235-40; Worthington-Kirsch, Popky, and Hutchins, Jr. 625-29; 
Hutchins, Jr., Worthington-Kirsch, and Berkowitz 279-84) pressure effects (84%), 
and dysmenorrhoea (77%) (Walker and Pelage 1262-72). Complications while 
performing the procedure are rare. Early post procedural complications include pain, 
post embolisation syndrome and sepsis. Pain is the commonest problem requiring 
narcotic analgesia, non-steroidal anti-inflammatory agents, anti emetics and patient 
controlled intravenous analgesia requiring admission. Unfortunately there is 
difficulty in predicting which women will develop severe pain with there being no 
relationship to the initial size, number and location of the fibroids. Attempts at 
reducing ischaemic complications by performing a more selective embolisation has 
been recently reported with reduced post procedural pain and a return to normal 
activity in 2.3 days^Zupi et al. 107-1 l),This technique however is applicable only to 
women with single large fibroids.
Late complications include vaginal fibroid expulsion. This occurs in 10% and is 
often associated with a persistent vaginal discharge (Goodwin et al. 1159-65; Spies et 
al. 1149-57; Bradley et al. 235-40; Berkowitz, Hutchins, Jr., and Worthington-Kirsch 
373-76). Amenorrhea with or without ovarian compromise can occur. This has been 
reported in 3% in women less that 40 years of age and 47% in women over the age of 
45 (Goodwin et al. 1159-65; Spies et al. 1149-57; Bradley et al. 235-40). 
Transcervical resection of the fibroid for the incomplete vaginal expulsion of a fibroid 
or a hysterectomy for uterine sepsis may be required. Laparotomy and bowel 
resection for sepsis from a subserous fibroid is an occasional complication. There 
have been 3 reported cases of mortality from UAE, 2 from sepsis and 1 from a 
pulmonary embolism (Vashisht et al. 307-08; Lancoita R et al.; McLucas et al. 1730).
64
All series report pregnancies following the procedure but there are no detailed reports 
of outcome.
From the evidence available it does appear that UAE is a useful modality of treatment 
for women with symptomatic uterine fibroids. Further investigation is required to the 
applicability of the procedure to women desiring fertility, adapting methodology to 
reduce the dose of radiation, determining the ideal embolic agent, assessing whether 
the treatment can be repeated and more long term follow up data of the procedure. 
The Royal College of Radiologists and the Royal College of Obstetricians and 
Gynaecologists had a joint working party that issued clinical recommendations on the 
use of UAE in the management of uterine fibroids in November 2000. This 
recommends that all cases of UAE must be part of a primary research programme and 
be registered with the Safety and Efficacy Register for New Interventional Procedures 
(SERNIP), Class C procedure and that all cases be subject to prospective audit. It is 
not recommended in women wanting fertility (RCOG/RCR Report).
2.3.2.2 Laparoscopic bipolar coagulation of the uterine blood vessels
This procedure has recently been reported as an alternative to bilateral uterine artery 
embolisation (UAE). The uterine artery is isolated from the ureter and the internal 
iliac artery and desiccated using bipolar electrosurgery. Bipolar coagulation of the 
anastomotic sites of the uterine and ovarian arteries, after isolation of the ovary to 
prevent thermal damage, is also performed.
Liu et al (Liu et al. 417-22), reported this procedure and found that it was feasible in 
98% of women with no intra operative complications. Postoperative pain occurring 
immediately postoperatively and lasting for 2 weeks was seen in 28% of women with 
one woman having an infection, which resolved with antibiotics for 7 days. Symptom 
relief was obtained for menorrhagia in 93% of women and pelvic pressure in 87%. 
Three women (3%) aged 46, 48 and 53 years became menopausal following surgery. 
Mean fibroid volume reduction was 76% (range = 38 -  100%).
This report is encouraging as the benefits are equivalent to that obtained at UAE and 
postoperative sepsis seems to be markedly reduced. However the study is a 
preliminary one and a high degree of laparoscopic skill is required to isolate the 
uterine artery without causing ureteric or vascular injury.
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2.3.2.3 Laparoscopic Myolysis
Myolysis consists of causing coagulation necrosis in the substance of the fibroid 
resulting in denaturation of collagen and vascular damage thereby causing shrinkage 
of the fibroid and reducing the chances of regrowth. Sources of energy that have been 
employed have been lasers, electrosurgery and cryotherapy.
The initial report (Nisolle, Smets M, and Gillerot S et al 95-99), laparoscopic 
myolysis used a laser at a power of 80 watts. The laser fibre was introduced in to the 
centre of the fibroid, activated and then withdrawn to the serosal surface. This was 
repeated at distances of 5-7 mm. In the 48 women who underwent the procedure 
there were no intraoperative complications or conversions to laparotomy with all 
patients being discharged home after an overnight stay in hospital. There was no 
significant postoperative pain or sepsis. A 41% mean decrease in fibroid diameter 
was seen after 6 months that persisted to one year. The main disadvantage however 
of this procedure was the operating time and a 10-50% incidence of postoperative 
adhesions to the serosal scars many of them being dense and involving bowel. Electro 
surgical bipolar needles have also been developed for myolysis with similar results 
(Goldfarb 636-38). This has the advantage of reducing the procedure time however 2 
out of the 150 women (1.5%) developed postoperative sepsis.
2.3.2.4 Cryomyolysis
Cryomyolysis consists of inserting a cryoprobe into the substance of the fibroid and 
freezing it to -180 °C creating an ice ball in the substance of the fibroid. Several 
freeze/thaw cycles were repeated. Results were disappointing with reduction in 
fibroid volume being only 6% but it has been shown to maintain the reduction of size 
achieved by pituitary downregulation in 14 women who underwent the procedure 
(Zreik et al. 33-38). Postoperative adhesions were a significant long-term 
complication.
2.4 Summary and conclusions
2.4.1 Uterine conserving surgery for DUB
The results of the first generation endometrial ablative techniques suggest that 80% of 
women would avoid a hysterectomy for DUB. It is associated with a reduced post 
operative morbidity (overall complication rate of 0.6%) with an earlier return to
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normal activity. Ovarian function was not affected at 2 years when compared to 
hysterectomy. Patient satisfaction rates were only slightly less than that with 
hysterectomy. Hysteroscopic surgery is also proved to be more cost effective.
The efficacy of the three techniques is similar. Significant differences are illustrated 
in Table 3. The drawbacks of the first generation techniques are that a considerable 
skill is required on the part of the operator. There is a slow learning curve for 
proficiency in the procedure and the complications include perforation, visceral 
damage, fluid overload and haemorrhage. Furthermore a general anaesthetic is 
required in most cases
Procedure Equipment Advantages Disadvantages
ELA Complex View not obscured No histology, Cost
TCRE Standard Histology available Higher risk o f perforation
RBAE Standard View not obscured No histology
Table 3 Table comparing the first generation endometrial ablative techniques. Specific differences 
between the techniques have been illustrated. ELA=Endometrial laser ablation, TCRE = transcervical 
resection of the endometrium and RBAE= roller ball ablation of the endometrium
The second generation endometrial ablative techniques have been developed to 
address these issues. They are non hysteroscopic techniques (other than for HTA) 
requiring minimal operator skill with a steep learning curve. These techniques were 
thought to eliminate the risks associated with hysteroscopic surgery and could be 
performed more commonly under a local anaesthetic.
They do not require any special skills or a distension medium. Due to financial 
considerations owing to the scope of the problem, industry has invested in a number 
of techniques of second generation endometrial ablation. These have been described 
in section 2.2.2. The main differences between these techniques and the evidence 
quoted in the section have been summarised in Table 4.
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Device Reduction 
in MBL
Anaesthetic used Complications Quality of studies
Cryotherapy 92% 50% GA None reported Observational
Radiofrequency 84% Mostly GA Vaginal fistula Observational
Microwave 83% Mostly GA Uterine perforation RCT vs TCRE
Interstitial laser 91% Mostly GA None reported Observational
Fluid balloon 73 -88% 70-75% GA Cramping pain; 
Haematometron
RCT vs ELA
Electrode balloon 84% 10% GA Haematometron RCT vs TCRE
Hydrothermal 75% 55% GA Nausea vomiting 
abdominal pain
RCT vs roller ball 
ablation
Table 4 Table comparing the efficacy, ease o f use, complications, cost and quality o f evidence 
available for the second generation endometrial techniques described in section 2.2.2.
Most of the evidence for the efficacy of second generation ablative techniques comes 
from small case studies and a single randomised controlled trial comparing them to 
another first generation method. Overall it does appear that the efficacy of these 
methods are only slightly less than that of the first generation methods. However they 
are not free from complications and most procedures are still being performed under a 
general anaesthetic. A significant factor is the incidence of equipment failure 
reported.
2.4.2 Uterine conserving surgery for uterine fibroids
The different routes that have been employed for removing fibroids have been 
described in section 2.3.1 These have been developed in an attempt to reduce hospital 
stay and enable an earlier return to normal activity. The clinical situation in which 
these techniques are best used have been summarised in Table 5. With increasing 
skill in laparoscopic suturing methods this technique is increasingly being employed 
in women requiring fertility.
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Route of 
myomectomy
Suitable 
type of 
fibroid
Suitable 
location of 
fibroid
Unsuitable 
type/location 
of fibroid
Suitable 
for women 
requiring 
fertility
Advantages Uses
Laparotomy All types All locations Type 0 SM 
fibroid
Yes Technically 
feasible in 
almost all 
cases
Large 
fibroids, 
difficult 
access to 
fibroid
Laparoscopy SS and IM 
fibroids
Fundal and 
upper 
posterior 
wall
Very large 
fibroids and 
difficult 
access
Anterior 
and fundal
Earlier 
return to 
normal 
activity
Ideally 
women not 
requiring 
fertility
Laparoscopic
assisted
SS and IM 
fibroids
Fundal and 
upper 
posterior 
wall
Very large 
fibroids and 
difficult 
access
Anterior 
and fundal
Earlier 
return to 
normal 
activity
Ideally 
women not 
requiring 
fertility
Vaginal Small SS 
fibroids
Anterior and 
posterior 
wall
Fundal and 
large fibroids
Yes Earlier 
return to 
normal 
activity
Limited to 
specialist 
centres only
Hysteroscopic Type 0 
and some 
Type 1
Any location Cervical
fibroids
Yes Day care 
surgery
First line 
treatment 
for SM 
Type 0
Table 5 Table comparing the efficacy, ease of use, complications, cost and quality o f  evidence 
available for the different routes used for fibroid removal as described in section 2.3.1.
Myomectomy (by whatever route) is seen to be associated with a high degree of 
recurrence and post operative adhesions. The perioperative complications of 
haemorrhage and pyrexia are now much less with improvements in surgical 
techniques and pre operative pituitary down regulation.
Comparison of the treatments used to reduce the size of fibroids have been 
summarised in Table 6. UAE is a promising technique but is associated with 
significant morbidity. It requires a multidisciplinary team comprising both 
interventional radiologists and gynaecologists as most of the complications would 
require treatment by gynaecologists. Laparoscopic myolysis (using high power 
lasers) has largely been abandoned due to the high incidence of post operative bowel 
adhesions. Cryomyolysis requires further investigation. In conclusion, the gold
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standard second generation technique for the treatment of DUB has not yet been 
found.
Device Fibroid
Shrinkage
Effect on 
Symptoms
Complications Uses Quality of 
studies
UAE 30-50% 
at 5 years
Reduction in 
MBL (80- 
96%) pressure 
effects (84%), 
dysmenorrhoea 
(77%)
Pain, post embolisation 
syndrome, sepsis, 
fibroid expulsion, early 
menopause, bowel 
perforation, 
hysterectomy, mortality
Specialist 
interventional 
radiology 
centres , not 
in infertility
Case
reports
Laparoscopic 
UA clipping
76% Reduction in 
MBL (93%) 
pelvic pressure 
(87%)
Pain, sepsis, early 
menopause
Highly
specialist
surgery
Case
reports
Laparoscopic
Myolysis
41% Not known Post operative 
adhesions, sepsis
Relatively 
easy to 
perform
Case
reports
Cryomyolysis 6% Not known Dense post op 
adhesions, sepsis
Specialist
centres
Case
reports
Table 6 Table comparing the efficacy, ease o f use, complications, cost and quality o f evidence 
available for the uterine conserving surgical treatments for uterine fibroids as described in section
2.3.2.
In conclusion, there is still a need for a second generation endometrial ablative 
technique that does not require complex equipment, can be used in an outpatient 
setting with minimal anaesthetic while still having a steep learning curve. Uterine 
conserving surgery for uterine fibroids is far from ideal. There is a need for the 
development of a treatment which can be applied to general clinical use without the 
complications that are associated with the current methods.
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[3] Low power laser 
treatments for heavy 
periods
The two conservative surgical techniques that utilise lasers for the treatment of DUB 
and uterine fibroids are the ELLITT procedure and laser myolysis as described in 
Chapter 2. These treatments however utilise lasers at high power settings. Both 
procedures rely on a thermal effect for treatment. The aim of this chapter is to review 
our understanding of tissue effects of lasers and how low power lasers may be 
exploited for photodynamic therapy of the endometrium and interstitial laser 
photocoagulation of uterine fibroids. The lack of success of PDT of the endometrium 
in current clinical practice and the lack of data for ILP of uterine fibroids will also be 
presented and discussed.
3.1 LA SER - Tissue interaction
A LASER (Light Amplification by the Simulated Emission of Radiation) is a device 
that produces a coherent monochromatic and highly collimated beam of light. This 
beam can be transmitted by thin flexible optical fibres, which can be delivered into 
body cavities with the aid of endoscopes or through needles to produce a precise 
controlled effect at a desired target area. The tissue effect of lasers depends on the 
properties of the incident laser beam, (wavelength, power, exposure time and beam
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dimensions), the optical properties of the target tissue (reflection, transmission, 
scattering and absorption) and the biological response of the target tissue to the energy 
absorbed.
3.1.1 Effect of wave length of the laser beam on tissue effects
Tissue penetration depends on the wavelength of the laser beam used. Ultraviolet 
light (193-400nm) is very strongly absorbed by the pigment in tissue and by water 
(wavelength less than 300nm). Visible light (400-700nm) becomes more weakly 
absorbed as its colour changes from blue to red. Tissue becomes relatively 
transparent in the infrared range (700-1000nm) with absorption increasing again as 
the wavelength increases above 1300 nm as absorption in water increases.
3.1.2 Effect of the optical properties of the target tissue on the tissue effect
When laser light strikes a living tissue surface, it can be reflected, transmitted, 
scattered or absorbed depending on the optical properties of the target tissue. It is 
only the absorbed light energy that produces the biological effect, but reflection, 
transmission and scattering determine where the light goes and as a result the volume 
of the tissue which finally absorbs the light. In addition the thermal property of the 
target tissue will affect the final biological effect and this includes the water content, 
concentration of chromophores (haemoglobin, oxyhaemoglobin and melanin,) and the 
blood supply to the tissue.
3.1.3 Terminology with light delivery
The fluence rate is the amount of photons per second that passes through a particular 
area (mW.cm'2). The optical dose is a product of the incident fluence rate and the 
exposure time. The effective penetration depth of light is the distance (in mm) 
corresponding to a decrease in the fluence rate by a constant factor (1/e). The average 
light penetration depth is about l-3mm at 630nm and 2-6mm at 700-850nm of light.
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3.1.4 Biological response of the target tissue to the energy density of the 
incident laser beam
3.1.4.1 Non-linear effects
3.1.4.1.1 Photodisruption
This principle is used in the laser fragmentation of renal calculi which is usually done 
with flash pumped dye lasers. This is possible with Q switched Nd:YAG pulses. 
Effective fragmentation is possible with microsecond pulses which work under water. 
In addition to the shock wave created by the short laser pulse, boiling of a tiny drop of 
water at the tip of the fibre where is makes contact with the stone creates a mini 
explosion leading to the disruption of the calculus.
3.1.4.1.2 Photoablation
Photoablation occurs when using light of very short wave length (ultraviolet) because 
the photon energy may be great enough to directly disrupt bonds within tissue. The 
excimer laser is said to exert its effect by means of photoablation and is used in 
ophthalmology for reshaping the cornea to correct refraction errors.
3.1.4.2 Linear - thermal effects
3.1.4.2.1 Tissue Hyperthermia
At a low energy density, lasers can cause an increase in tissue temperature to 41-45 
°C. This tissue warming causes localised oedema and inflammation only which is 
reversible. If this relatively small temperature rise is maintained for a long time (e.g. 
1 hour @ 44°C, 30 minutes at 45°C and 15 minutes at 46°C) cell death occurs over the 
remaining cell cycle over several days. This principle is utilised for the treatment of 
superficial cancers.
3.1.4.2.2 Tissue coagulation
When the increase in the tissue temperature is between 45 -  99 °C, there is 
irreversible denaturation of proteins and coagulation occurs. This is dependent on the 
length of time that a particular temperature is maintained. Tissue necrosis occurs and 
healing is by scarring or regeneration depending on the tissue being treated.
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Figure 15 Biological response of the target tissue to the energy density absorbed
3.1.4.2.3 Tissue vaporisation
At temperatures that are greater than 100 °C tissue water boils. The conversion of 
water to steam causes a one thousand fold rapid rise in the cellular volume, which 
causes the cell wall to burst releasing steam and cellular debris. Once the water 
around the laser tip has vaporised the temperatures rapidly increase to 300-400 °C. 
Tissue blackens due to carbonisation and there is smoke production. With 
vaporisation there is total tissue destruction with underlying necrosis and later 
sloughing. If the energy applied is continued then the laser will bore a hole in the 
tissue.
3.1.4.3 Linear- non thermal (photochemical)
These tissue interactions produce biological effects at power and energy levels that do 
not cause significant tissue heating. The most promising technique employs tissue 
sensitising agents and forms the basis of photodynamic therapy.
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3.1.5 Biomodulation
It has been shown that small doses of ruby laser radiation (e.g. 1 J / cm2) can stimulate 
cell division that can accelerate wound healing. However the effect is sensitive to the 
total energy and after 10 such doses of energy, inhibition occurs, with suppression of 
cell growth. This principle has been used with some beneficial effect in the healing of 
long standing ulcers but has not found widespread acceptance in clinical practice.
3.2 Lasers in clinical use
3.2.1 Conventional lasers
The common lasers that are used in clinical practice are shown in Table 7 and Table 8. 
The wavelengths at which soft tissue absorb light energy vary enormously. The CO2 
laser which has a wavelength in the far infra red range is absorbed mainly by cellular 
water. The Nd: YAG laser (wavelength in the near infra red range) and the Argon ion 
laser (wavelength in the blue-green range) is absorbed mainly by pigments such as 
haemoglobin, oxyhaemoglobin and melanin.
3.2.1.1 Type of laser vs. depth of damage
The depth of tissue damage varies with the laser used. For example at a power of 40- 
50 watts for a few seconds the CO2 laser produces tissue damage to a depth of 0.1mm, 
the Argon ion laser produces damage to 1mm whereas the Nd: YAG laser produces 
damage to a depth of 5 mm.
3.2.1.2 Volume of tissue treated
The volume of tissue treated depends on the dissipation of energy. With the CO2  
laser, the volume of tissue heated outside the vaporised tissue is minimal and hence it 
may only cause coagulation of capillary oozing. The Nd: YAG laser (at 50-80 W) 
causes a thermal effect of a greater volume of tissue and can seal vessels up to 1mm in 
diameter in suitably supporting tissue by thermal contraction of the surrounding 
tissue.
3.2.2 Semiconductor Diode lasers
The conventional lasers described have many disadvantages that have resulted in them 
not being widely used in clinical practice. An important consideration is the cost. In
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addition to being expensive they are cumbersome to move and sensitive to 
misalignment with the minimum of trauma.
Laser Wavelength (nm) Power (W) Fibre transmission
C02 10,600 5-50 No
Nd:YAG 1,064 5-100 Yes
Argon 488; 514 1-10 Yes
Dye Tunable (visible region) 0.05-5 Yes
Semiconductor 
Diode laser
Selected wavelengths (mainly in the 
red and near infra red region)
1-25 Yes
Table 7 Continuous wave (CW) lasers in clinical use
Laser Wavelength (nm) Pulse duration Pulse energy (Joules) Fibre transmission
Nd.YAG Q 
switched
1,064 nanoseconds 0 . 1-1 Yes
Nd:YAG 1,064 microseconds 0 . 1-1 Yes
Dye Tunable visible 
region
nanoseconds 0.01-0.1 Yes
Excimer Ultraviolet nanoseconds 0.01-0.1 No
Table 8 Pulsed lasers in clinical use
The diode lasers rely on the activation of n-p junctions in semiconductor materials to 
produce a laser effect. They may be tuned over a very short range by altering the 
temperature of the semiconductor used. The early diode lasers emitted in the infra red 
part of the spectrum (e.g. GaAlAs -805 nm) but they are now being adapted to emit in 
the visible red regions of the spectra as well. They are much cheaper, portable, and 
are highly robust and may be plugged into a standard plug socket. They are more 
reliable than conventional lasers and as the cost reduces with the increase in demand, 
they may be more readily used in clinical practice in all hospitals and not be confined 
to specialist centres.
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3.2.2.1 Low power laser therapy
Conventionally, most clinical applications of laser therapy utilise a thermal effect 
requiring a power of 50 -100 watts which causes damage to surrounding tissue in 
addition to the tissue being treated. The optimal aim however of laser therapy is to 
harness the properties of lasers to match the tissue damage produced with the disease 
being treated. This minimises alteration to the structure and function of the tissue.
Consequently there is a growing interest in using low power thermal treatments like 
interstitial laser photocoagulation and non thermal treatments like photodynamic 
therapy. There is the potential to treat the disease with minimal disruption to the 
structural and functional integrity of the organ being treated. Characteristics of these 
two modalities of treatment are summarised in the table shown below.
Interstitial laser 
photocoagulation
Photodynamic therapy
Laser wavelength Near infrared (805-1064nm) Red (630-730nm)
Laser type Nd;YAG, Diode Dye, Diode
Nature of biological damage Thermal Photochemical
Effect on collagen and elastin Destroyed Largely unaffected
Inherent selectivity o f necrosis 
between tumour and surrounding 
healthy tissue
None Minimal (some selectivity 
between different layers of normal 
tissue)
Healing Resorption and scarring Regeneration, sometimes with 
scarring
Cumulative toxicity None None
Table 9 Characteristics of interstitial laser photocoagulation and photodynamic therapy
3.3 Photodynamic therapy (POT)
This is a low power laser treatment that is not associated with a rise in tissue 
temperature. PDT treated connective tissues like elastin and collagen are largely 
unaffected. There is therefore much less risk of altering the mechanical integrity of a 
hollow organ. Healing takes place more by regeneration than scarring. These 
properties are in contrast to thermal damage and are therefore particularly appealing. 
Like ILP there is no cumulative toxicity and the treatment may be repeated.
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3.3.1 Terminology
3.3.17 Phototherapy
Phototherapy refers to the use of light in the treatment of disease. The light involved 
is in the 250-900 nm regions. The processes involved being photochemical ones.
3.3.1.2 Photochemotherapy
Photochemotherapy is a subdivision of phototherapy where the treatment involves the 
administration of a drug and the administration of light.
3.3.1.3 Photodynamic therapy
Photodynamic therapy is a part of photochemical therapy. In addition to light and the 
administered drug, oxygen is also required.
3.3.2 History of PDT
In 1900 a German medical student called Oscar Raab studied the behaviour of 
paramecia in the presence of minute concentrations of acridine (Bonnett R 1-17). His 
findings were erratic until he realised that daylight was affecting his results. 
Controlling for light he showed that acridine killed the paramecia in the presence of 
light but not in the dark. He also demonstrated that light alone did not kill the 
paramecia.
The first clinical report in modem literature of PDT describes the treatment of a 
woman with a large ulcerating breast tumour (Lipson, Gray MJ, and Baldes 393). She 
received multiple injections of Haematoporphyrin Derivative (HpD) injections 
followed by exposure to filtered light from a Xenon arc lamp. It was observed that 
the tumour responded to this treatment. Interest was rekindled only in the early 1970’s 
when two American groups further investigated PDT.
In 1972, Diamond and colleagues transplanted gliomas into the subcutaneous tissue of 
rats (Diamond et al. 1175-77). Haematoporphyrin was administered which was found 
to localise in these tumours. The application of light caused massive destruction of 
these porphyrin containing tumours. This report brought the term “photodynamic 
therapy” in to general use. In 1974, Dougherty demonstrated the eradication of a
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transplanted mouse mammary tumour using HpD activated by red light from a filtered 
xenon arc lamp (Diamond et al. 1175-77;Dougherty 1333-36).
3.3.3 Principle of PDT
The three fundamental elements of PDT are oxygen, a photosensitiser and visible 
light. The photosensitiser is activated by light and interacts with molecular oxygen to 
produce a reactive singlet oxygen moiety which has a short lifetime and a short radius 
of action. It is possible that other highly reactive intermediaries like free radicals are 
also produced. The result is an irreversible oxidation of essential cellular components 
leading to the destruction of crucial cell membranes, organelles and vasculature and 
ultimately cell death.
3.3.4 Photosensitisers
3.3.4.1 First generation photosensitisers
The original photosensitiser was a preparation obtained from haematoporphyrin (Hp). 
Since its structure was not known it was termed haematoporphyrin Derivative (HpD). 
It is a mixture of products based on the porphyrin structure -  monomers, 
protoporphyrin and intermediate products. The commercial product is Photofrin 
where the concentrations of the monomers and unstable products have been greatly 
reduced. Many institutions involved in PDT need to prepare their own product, each 
having different PDT efficacy. This made comparison of clinical results difficult. 
The wavelength of light required to activate HpD (628-630 nm) penetrates tissue to a 
maximum depth of only 1 cm limiting treatment to superficial lesions. Furthermore 
HpD causes severe skin photosensitivity lasting several weeks which has limited its 
acceptance.
In order to avoid the side effects of Photofrin -  newer photosensitisers have been 
synthesised as shown in Table 10.
3.3.4.2 Choosing a photosensitiser for PD T
The choice of the photosensitiser depends on the nature of the lesion treated. PDT 
was first used for the treatment of malignant conditions. Today however it is also 
being investigated for the treatment of benign disease. Selectivity for hyper 
proliferating tissues varies between photosensitisers. Some such as Photofrin are
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distributed to connective tissue and blood vessels whereas others such as ALA have a 
mucosal predilection.
Structure Photosensitisers
Chlorins and chlorin-type 
Sensitisers
NPe6
Meta-tetrahydroxyphenyl chlorin MTHPc
Purpurins Tin etiopurpurin (SnET2)
Benzoporphyrins Benzoporphyrin Derivative (BpD)
Phthalocyanines Disulphonated zinc Phthalocyanine (ZnPcS2) 
Disulphonated aluminium Phthalocyanine (AlS2Pc)
Texaphyrins Lutetium texaphyrin
5-Aminolaevulinic acid Amino laevulinic acid (ALA)
Table 10 Second generation photosensitisers
It is important to choose a route of delivery of the photosensitiser that would reduce 
skin photosensitivity. This can be achieved by topical application or administering 
the photosensitiser directly into the tumour. It must be ensured that adequate target 
tissue levels of the photosensitiser are achieved so that the optimum PDT effect is 
achieved.
The wavelength of light at which the photosensitiser is activated is also important as 
discussed in section 3.3.5
3.3.5 Light delivery for PDT
3.3.5.1 Effect of wavelength on PDT
Each photosensitiser has its own absorption spectrum. Light of the appropriate 
wavelength must be applied for maximum absorption. For clinically used 
photosensitisers this ranges from 420 nm (blue light) to 780 nm (near infra red light). 
As the wavelength increases the depth of tissue penetration increases. Blue light 
penetrates about 0.3 mm while red light about 5 mm. As the wavelength shortens 
more light gets absorbed by chromophores like melanin and haemoglobin (see section 
3.1.1). The haemoglobin absorption spectrum falls off rapidly above a wavelength of 
600 nm in the red spectrum. Longer wavelengths are therefore chosen for PDT even 
though some photosensitisers absorb less well at these levels.
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3.3.5.2 Light sources and delivery
Initially only large complex laser systems were capable of delivering the power at 
appropriate wavelengths for effective treatment. The development of semi conductor 
diode lasers has however changed this (see section 3.2.2). Non laser light sources 
have also been investigated for PDT. However at present these cannot be directed into 
suitable optical fibres. The major attraction with lasers is that the light fibres can be 
passed though endoscopes, needles or customised light delivery devices allowing 
effective light delivery to the target area.
3.3.5.3 Effect of light fractionation on PDT
During PDT the treated tissue is rendered ischaemic and oxygen concentrations begin 
to fall reducing the efficacy of the treatment. With some photosensitisers switching 
off the light temporarily during treatment allows the tissue to revascularise increasing 
oxygen concentrations. Studies fractionating the light delivery have shown an 
enhanced PDT effect. This however increases the treatment time and is inconvenient 
for the patient (Messmann et al. 589-94).
3.3.5.4 Drug light interval
This is the time period from the administration of the drug until the delivery of light. 
It is important that sufficient data are available on the time at which the concentration 
of the photosensitiser is the highest in the tissue that is to be treated. It is convenient 
if the drug light interval is short so that both the administration and the delivery of 
light would occur on the same time. Long drug-light intervals (several days) are 
inconvenient to the patient and may not be acceptable.
3.3.6 Limitations of PDT
PDT has many limitations. It is an ablative treatment that yields no biopsy material so 
a histological diagnosis must be made before treatment is carried out. It is more 
complex that other modalities of treatment as it involves a multi-disciplinary team 
comprising scientists (photo chemists and physicists) and clinicians.
3.3.7 Clinical applications of PDT
Most of the clinical applications of PDT are for malignant or premalignant conditions. 
There was much optimism as it was initially thought that photosensitisers were
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selectively taken up by tumour tissue with the possibility of subsequent selective 
tumour destruction with PDT. This is not the case. There does however appear some 
selectivity between the endothelium and other tissue layers and this may be exploited 
for PDT.
3.3.7.1 PDT for the treatment of malignancy
PDT has a limited depth of destruction of 5 mm or more. It is therefore best suited for 
the treatment of early invasive cancers in which the patient is not suitable for 
conventional surgery. PDT has been extensively investigated for the treatment of oral 
cancers. It has been shown to produce a depth of necrosis of 5 mm or more and heals 
with a very good cosmetic and functional result. Encouraging results have also been 
reported for cancers of the oesophagus, stomach and colon but it cannot treat tumours 
that have spread beyond the wall of the organ of origin (Sibille et al. 337-44).
PDT with the use of the photosensitiser 5-amino laevulinic acid shows some affinity 
for the epithelium or mucosa of hollow organs compared to the underlying 
submucos^and muscle. As mentioned before, this can be exploited for the treatment 
of dysplasias of the oesophagus (Barrett’s disease), major bronchi and the vulva. PDT 
in this situation carries the advantage of causing epithelial destruction with minimal 
damage to the underlying muscle thereby maintaining the structural integrity of these 
organs.
More recently PDT has been investigated for the treatment of solid tumours of the 
pancreas, prostate, and lung. Here the light is delivered by fibres inserted 
percutaneously under radiological surveillance like that described for ILP. Interstitial 
PDT has been used to treat inoperable cancers of the pancreas. Results showing large 
areas of tumour necrosis which resolve spontaneously have been encouraging. (Bown 
et al. 549-57) Similarly in the studies done in patients with localised recurrence of 
prostatic cancer after radiotherapy, interstitial PDT has been shown to cause necrosis 
of these tumours with marked lowering of PSA levels (Nathan et al. 1427-32). 
Interstitial PDT has a place where the situation of the tumour causes technical 
difficulties with surgical resection like in the lungs and also where complete resection 
is not possible. PDT has been used as an adjuvant therapy to treat residual disease 
after surgical resection as in tumours of the brain (Muller and Wilson 346-54).
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3.31.2 PDT for the treatment of skin conditions
One of the original indications for PDT was for the treatment of skin conditions like 
basal cell carcinoma. This has been further investigated for the treatment of actinic 
keratosis, refractory acne vulgaris and psoriasis with varying results (Coulter 149- 
50;Itoh et al. 575-79). The advantage is healing with minimal fibrosis and scar 
formation resulting in remarkably good cosmetic results.
3.3.7.3 PDT for the treatment of vascular disease
PDT with ALA has been shown to inhibit smooth muscle proliferation from the tunica 
media of blood vessel walls. This proliferation is one of the main reasons why 
restenosis occurs following balloon angioplasty or the insertion of vascular stents in 
patients with obstructive vascular disease. PDT to the procedure site to suppress this 
proliferation is being investigated as an alternative to brachytherapy and coated stents 
to reduce the incidence of restenosis. Minimal damage to the elastin and collagen of 
the blood vessel walls appears to minimise complications such as aneurysms (Jenkins 
et al. 1258-63).
One of the success stories of PDT is the treatment of patients with age related 
macular degeneration which is a leading causes of blindness in the UK (Bressler 
1425-27). Conventional therapy which consists of laser photocoagulation of the 
neovasculature causes adjacent thermal damage to the retina. PDT with BpD can be 
done under local anaesthetic with the light delivered by a slit lamp for duration of less 
that one minute. Unlike laser treatment, selectivity is possible because at the time of 
the treatment the photosensitiser is still in the neovasculature.
3.31.4 PDT for the treatment of infections
PDT was coined by the serendipitous discovery of the effect of acridine on paramecia 
(see section 3.3.2) in the presence of light and oxygen. Many bacteria and fungi like 
Candida take up photosensitisers which can be activated by light thereby destroying 
the organisms. Clinical applications would include the treatment of superficial ulcers 
on the skin and the mouth which are easily accessible to the administration of both the 
photosensitiser and light. This would be useful especially in Methicillin Resistant 
Staphylococcus aureus (MRSA) infection. Another potential application would be the 
treatment of helicobacter pylori. PDT has also been used in the treatment of viral
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infections particularly with Human Papilloma Virus when it forms condylomata 
accuminata of the vulva with two thirds of women showing a complete response 
(Frank and Bos 70-71). The attraction is that scarring is minimal with a good 
cosmetic result. As this condition tends to recur PDT is an ideal treatment as it can be 
repeated without any toxicity. The drawback is the pain during illumination.
3.3.8 PDT for the treatment of DUB
There are a number of methods currently in use to destroy the endometrium in an 
attempt to reduce menstrual blood loss in the absence of any pathology (see section 
2.2). None of these methods guarantee complete global destruction of the 
endometrium. Furthermore the methods use a thermal effect for tissue destruction 
which carries with it a risk of uterine perforation and transmission of heat to the 
serosal surface of the uterus with subsequent damage to intraperitoneal organs. Post 
treatment intra uterine adhesions occurs which makes future biopsy to exclude 
endometrial cancer, where indicated, difficult.
3.3.8.1 Characteristics of the ideal minimal access technique for endometrial 
ablation in women with DUB
The ideal characteristics of a minimal access technique is summarised in Table 11
Ideal characteristic 
Requires no endometrial preparation 
Requires only a local anaesthetic or no anaesthetic 
No risk of uterine perforation 
No risk of damage to other intraperitoneal organs 
Does not cause intra uterine adhesions 
Easy to perform 
Acceptable to women 
100 % success rates
Table 11 Box showing the characteristics of the ideal minimal access technique
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3.3.8.2 Suitability of PDT as an alternative minimal access technique for 
endometrial ablation in women with DUB
PDT is a non thermal technique of endometrial ablation and hence does not carry the 
risk of thermal damage to intra peritoneal organs. It has a maximum depth of 
destruction of 5-7 mm and hence the possibility of uterine perforation is minimal. As 
there is minimal PDT destruction of the myometrium it is thought that intrauterine 
adhesions and synechiae would be minimal! PDT could be performed as an out 
patient procedure but would preferably need conscious sedation. It is non operator 
dependant on its effect and hence would have a very sharp learning curve and would 
therefore be easy to perform. With these advantages it is not difficult to see that 
women would have no difficulty in making this their choice of treatment. The 
problems however with PDT is to obtain total or global destruction of the 
endometrium. As described in section 1.2.1.5, even if a small area of endometrium is 
left that is viable -  complete endometrial regeneration would occur resulting in a 
treatment failure.
3.3.8.3 Results of PDT of the endometrium
Our understanding of the pharmacokinetics of photosensitisers investigated for PDT 
of the endometrium comes from animal studies. This enables refinements to be made 
before clinical trials are commenced.
3.3.8.3.1 Route of administration
Rats were randomised to receive intravenous, intraperitoneal and intrauterine 
Photofrin II (Chapman et al. 685-92). Intra uterine administration provided the best 
uptake and distribution within the uterus with the lowest drug dosage. When 
clinically applied this would be the ideal route of administration as skin 
photosensitivity would be minimised.
3.3.8.3.2 Endometrial selectivity of photosensitiser
Wyss et al (Wyss et al. 409-14), conducted a study on the intrauterine instillation of 
BpD in female rabbits. They showed that there was a much higher concentration of 
BpD in the endometrium compared to the myometrium and the stroma. PDT at 1 and 
4 weeks showed destruction of the endometrium and not the myometrium.
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Intrauterine instillation of PHP (similar to BpD) in volunteers prior to hysterectomy 
showed similar results.
Yang et al (Yang et al. 995-1001) studied ALA in rats. Exposure of the sensitised 
uteri to light produced endometrial ablation. There was however some preservation of 
glandular elements but no regrowth at 10 days. Pregnancy implantation in the treated 
uterine horn was significantly less than that of the untreated horn indicating a 
functional effect. ALA PDT in the rabbit uterus did not show such consistent results 
with patchy areas of regrowth of the endometrium at 10 days. This was attributed to 
the larger uterine horns and asymmetrical placing of the light diffuser fibre.
3.3.8.3.3 Pharmacokinetics of ALA
Wyss et al (Wyss et al. 1176-83), used rats and rabbits as animal models to study the 
pharmacokinetics of the intrauterine instillation of ALA. Peak concentrations of PPIX 
(the active metabolite of ALA) in the endometrium were observed at 3 hours. ALA 
concentrations in the endometrium were much higher than the myometrium. 
Increasing the concentrations from 100 mg/ml or buffering the ALA solution to a pH 
of 5.5 did not alter the findings. PDT caused destruction of the endometrial glandular 
epithelium with minimal stromal scarring which was maintained at 7 days. Studies 
using monkeys showed peak concentrations at 4-5 hours with similar PDT results. 
Intravenous administration of ALA at doses of 250 g/kg did not have any adverse 
effects other than for increased serum aspartate aminotransferase levels which were 
transient.
One of the steps that render PPIX inactive is iron dependant. Connell et al 
(unpublished data) investigated the addition of CP94 (an iron chelator) to the 
pharmacokinetics of ALA. They were able to demonstrate that the peak 
concentrations of ALA were higher in the rabbit uterine horn where CP94 was added. 
This translated to a better PDT effect which was maintained at 10 days. Patchy 
regeneration of the endometrium was however seen at 28 days.
3.3.8.3.4 Clinical studies
Gannon et al performed the first clinical studies with ALA PDT of the endometrium. 
He did 2 series of experiments with different doses of ALA. (Gannon) In the first 
series, twenty five women were administered 2 capsules of ALA (250 mg/capsule)
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inserted through the cervix into the uterine cavity with the aid of an endotracheal tube 
as an introducer. Light was delivered by a copper vapour laser (wavelength 630 nm) 
through a light diffuser fibre which was passed centrally into a custom made soft latex 
balloon distended by Intralipid solution. The drug-light interval was 3-4 hours. All 
women had oestrogen priming of the endometrium. Unfortunately there was no effect 
of the treatment on menstrual blood loss with two thirds of women proceeding to 
surgery.
In a further study comprising of 4 women the dosage of ALA was doubled to 1000 
mg given in divided doses 12 hours apart. With each dose an iron chelator (60 mg 
Desferrioxamine) was also inserted in to the uterine cavity. Light delivery was 
fractionated in three of the women. Results in this group were much better with an 
80% reduction in menstrual blood loss with no woman requiring surgery.
3.4 Interstitial laser photocoagulation (ILP)
ILP is a technique of producing gentle thermal coagulation of a lesion in the centre of 
solid organs using low power laser energy delivered via flexible fibres inserted 
through needles. The power delivered to the centre of the lesion is approximately 3-5 
watts. ILP does not have any cumulative toxicity and hence the treatment can be 
repeated.
3.4.1 History of interstitial laser photocoagulation
Hyperthermia, induced by microwave or radiofrequency applicators, had been 
investigated for the treatment of tumour tissue for many years. Temperatures in the 
treated tissue were of the order of 41-44 ° C. Difficulty in the control of the delivery 
of energy resulted in the destruction of normal surrounding tissue. These 
shortcomings limited the use of this treatment modality.
In 1983, Bown sought to overcome this problem by delivering laser light directly into 
the centre of the tumour tissue. He used low powers (typically 3 watts) to cause 
gentle coagulation of the tumour tissue with minimum effect on the surrounding 
normal tissue (Bown 700-09).
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3.4.2 Terminology of ILP
There is wide variation in the terminology used to describe ILP for uterine fibroids. 
Terms that have been used are myolysis, interstitial hyperthermia, interstitial thermal 
ablation and Laser Induced ThermoTherapy (LITT). Myolysis was the term given to 
the high power thermal destruction of fibroids as described previously (see section 
2.3.2.3). The problem with using “Hyperthermia” is that this conventionally indicated 
fairly uniform temperature rises to 41-45 °C for up to several hours, so that cells die 
during the remaining cell cycle over several days. However using laser powers of 1.5 
to 3 W over 5 to 15 minutes with bare optical fibres would result in immediate tissue 
necrosis around the optical fibre tip. We therefore prefer the term interstitial laser 
photocoagulation to differentiate it from the previous therapy.
3.4.3 Non gynaecological applications of interstitial laser photocoagulation
Since Bown’s initial work, ILP has been applied to the treatment of tumours in several 
organs including the liver, breast, prostate, bone and uterus.
3.4.3.1 ILP for the treatment of hepatic m etastases
The prognosis for patients with secondary liver tumours is poor with few patients 
surviving more than one year after diagnosis. Treatment options in this group of 
patients are limited. Surgical resection, radiation therapy, hepatic artery ligation or 
embolisation may have a high morbidity without significantly affecting survival.
Consequently less invasive techniques were developed. These included cryotherapy 
and intra hepatic injection of absolute alcohol. Cryotherapy has the disadvantage of 
needing a large probe which limits precision in treatment and requires a larger portal 
of entry into the abdominal cavity. Intra hepatic injection of absolute alcohol is fairly 
effective for soft hepatomas but not for hard metastases. This however causes a 
diffuse necrosis of the liver thereby damaging normal functioning liver tissue.
Mathewson et al used Nd:YAG laser to perform ILP on normal rat liver and found 
that it produced well defined highly reproducible necrotic lesions of up to 16 mm in 
diameter (Matthewson et al. 550-57). Healing occurred with the formation of a small 
fibrotic lesion at day 60. This prompted the investigation of ILP for patients with 
hepatic secondaries. ILP is attractive as precise thermal damage of the tumour can be 
carried out under conscious sedation using small diameter needles inserted under
radiological guidance. Healing can then take place after resorption of the necrosed 
tissue with minimal scarring. The best results are obtained with isolated metastases 
that are less than 3.5 cm (mainly from previously resected colorectal primaries) in 
patients unfit for surgery (Amin et al. 339-47).
3.4.3.2 ILP for the treatment of breast disease
ILP for the treatment of fibroadenomas and small breast cancers as an alternative to 
surgical excision has been investigated as the procedure can be done in the outpatient 
department under a local anaesthetic without leaving a scar or causing a cosmetic 
deformity. Real time ultrasound or MRI imaging enables accurate placement of the 
fibres. Basu et al (Basu, Ravi, and Kant 148-52) reported a significant reduction both 
clinically and by ultrasound in twenty seven women who underwent ILP for 
fibroadenomas. The cosmetic effect was excellent with no women having keloids or 
abscess formation. The best results were obtained in the smaller fibroadenomas.
Harries et al (Harries et al. 1617-19) showed that ILP with a pre charred fibre tip 
caused a predicable 14 mm diameter of necrosis in forty four women with small 
breast cancers. However much more research is required before ILP can be used in 
the routine treatment of small breast cancers as an alternative to lumpectomy. It is 
important to be sure that all the cancer has been destroyed before the necrosed tissue 
can be safely left in situ (Harries et al. 1617-19) (Mumtaz et al. 651-58).
3.4.3.3 ILP for the treatment of prostatic hyperplasia
ILP for the treatment of prostatic hyperplasia can cause prostatic shrinkage from 
intraprostatic coagulative necrosis without causing damage to the urethra or tissue 
sloughing. Complications such as intraoperative haemorrhage, incontinence and 
impotence are therefore minimised. In a series with twenty five patients, a significant 
improvement in patient symptom scores, maximum urinary flow rates and reduction 
in residual post void urine volumes have been demonstrated (de la Rosette et al. 433- 
38). More recently, a 3 year follow up of forty two patients has shown that the 
shrinkage is maintained with no patient requiring repeat treatment. Furthermore when 
compared to other therapies, patients undergoing ILP have one of the highest patient 
satisfaction scores. There were no problems with erectile function in 71% of patients 
(Arai et al. 1206-11). There is no convincing evidence however to date that suggests 
that ILP is superior to trans urethral resection of the prostate.
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3.4.3.4 ILP for the treatment of osteoid osteom a
ILP is an attractive treatment for osteoid osteomas as in addition to the minimally 
invasive nature of the procedure, it does not cause any restriction of post operative 
activity. Witt et al showed that there was an 88% reduction in mean pain scores and a 
100% patient satisfaction rate with the procedure in twenty three patients with osteoid 
osteomas undergoing ILP (Witt et al. 1125-28).
3.4.4 ILP for the treatment of uterine fibroids
As outlined previously (see section 2.1.1), there is a growing need for uterine 
conserving surgical treatments in women with uterine fibroids. This is a combination 
of a need for fertility preservation and a growing number of women who wish to 
preserve the uterus for reasons other than fertility. The other minimally invasive 
techniques (see section 2.3) may result in either ischaemia or damage to normal 
myometrium which may not be ideal in women seeking to become pregnant.
ILP is an exciting treatment in this respect as it would cause coagulative necrosis 
within the centre of the fibroid without damage to the normal myometrium. Precision 
of treatment would therefore limit weakening of the uterine muscle layer and reduce 
the risk of uterine scar dehiscence in a subsequent pregnancy.
3.4.4.1 Experimental work on ILP for uterine fibroids
ILP of uterine fibroids has been performed using in vitro and in vivo techniques to 
determine the extent of the thermal necrotic lesion. One or two bare tipped pre 
charred fibres from a 25 watts semi conductor laser (805 nm wavelength) were used 
to treat forty fibroids after surgical removal. The fibres were inserted into the centre 
of the fibroid and treatment was delivered with 2- 10 watts for 100 -  1000 seconds. 
Specimens were subsequently sectioned perpendicular to the fibre track and 
evaluated. Macroscopically there was little evidence of coagulation. With diaphorase 
stain techniques ellipsoid zones of devitalised tissue up to 15 mm per fibre were seen.
At the time of a planned myomectomy or hysterectomy, twenty fibroids were 
similarly treated by ILP. The treatment delivered was 3-4 watts for 250 -300 seconds 
using the semi conductor diode laser (805 nm wavelength). The fibroids were 
processed as for the in vitro studies. Again a single fibre produced an ellipsoidal
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lesion of coagulative necrosis of 10-14 mm diameter. If 2 fibres were used the area 
increased to a diameter of 20 mm (Gordon AD et al. 859-66).
3.4.4.2 Current clinical work on ILP for uterine fibroids
The first ILP for uterine fibroids was performed by Dr Roxana Chapman (Chapman 
171-78) at the private patients’ wing at University College London Hospital in 1991. 
In 1998, she reported the use of ILP on 300 symptomatic patients with 950 fibroids. 
Two hundred and ninety three women were treated under laparoscopic guidance. Pre 
treatment with GnRha ranged from 6 weeks to 6 months. The fibroids were measured 
using the side of the needle microstat which was subsequently quantified using a 
ruler. The Potassium-Titanyl-Phosphate/Nedymium:Yttrium-Aluminium-Gamet 
(KTP/YAG) laser was used. The KTP laser was used to bore a hole from the serosal 
surface of the uterus to the centre of the fibroid. Once the quartz fibre tip was in the 
centre of the fibroid the YAG laser was used to deliver 8 watts of power in continuous 
mode for 5 minutes. Depending on the size of the myoma, the fibre was withdrawn 
by 2 cms and the sequence repeated until a column of coagulated myoma had been 
achieved. Six hundred and ninety four fibroids (73%) which varied between 3 and 6 
cms were found to disappear in 6 months. A modification of this technique using the 
KTP laser alone at a distance of 1 cm from the false capsule was reported with the 
same results and a reduction in treatment times to 1 minute.
Dr Chapman also described ILP under CT guidance using a diode laser (805 nm 
wavelength) with a 4-way fibre splitter (Chapman 171-78). 4 W of power was 
applied for duration of 400 seconds. The fibres were withdrawn by 2 cms on 2 
occasions and the treatment repeated. Disappearance of fundal fibroids with the 
uterus regaining its normal size was reported.
While this data is encouraging in terms of feasibility many issues need clarification. 
ILP was performed outside a research setting. The majority of the treatments 
described were using a KTP laser with single fibre treatments. This resulted in long 
treatment times. It was not possible to follow up the majority of women treated as 
most of them were from abroad and returned home after treatment. Complications 
were not objectively documented.
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3.5 Conclusions
3.5.1 PDT of the endometrium
PDT appears to have all the requirements to become the ideal minimal access 
technique for the treatment of women with DUB. A lot of intensive work has been 
carried out in rat, rabbit and primate models. However the results are not encouraging 
and this is due to the fact that if even a small area of endometrium is not destroyed, 
complete regeneration is possible resulting in treatment failure. The problem is that 
ALA even when enhanced by the addition of an iron chelating agent does not cause 
sufficient depth of damage. Furthermore ensuring that the whole of the uterus is 
evenly and globally illuminated is difficult even with the aid of custom made light 
devices. These factors require further investigation if PDT of the endometrium is 
going to be a viable treatment in the 21st century.
3.5.2 ILP of uterine fibroids
From the literature reviewed ILP is a technique that has been investigated in many 
branches of medicine with encouraging results. It has a great potential in the 
treatment of women with uterine fibroids as it may be performed with minimal access 
surgery as a day case procedure. From the published work of Dr Chapman it is 
proven that it is a safe and feasible technique. However since most of the women in 
these series did come from abroad, assessment of the efficacy and long term follow up 
is missing. Furthermore, we do not know if the procedure is associated with post 
operative adhesions -  a factor that makes both myomectomy and myolysis 
undesirable.
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[4] Aims of the thesis
From the preceding 3 chapters it can be realised that Interstitial laser photocoagulation 
of uterine fibroids and photodynamic treatment of the endometrium in women with 
dysfunctional uterine bleeding are exciting minimally invasive alternatives to 
currently available techniques of treatment.
4.1 Interstitial laser photocoagulation of uterine fibroids
Research in ILP of uterine fibroids has shown that it is a safe and feasible technique 
with about one thousand procedures having been carried out without significant short 
term complications. The problems are that this was carried out by a single surgeon 
with no follow up of the women treated. As most of the women were from abroad 
they were lost to follow up and it is not known what degree of shrinkage occurred and 
whether there were any long term side effects of the treatment.
4.1.1 The aims of this thesis with regards interstitial laser photocoagulation
1) Whether the safety and feasibility of ILP of uterine fibroids by a minimal 
access technique can be reproduced by other surgeons.
2) The short term effect of ILP on the uterine fibroid as imaged either by 
ultrasonography or magnetic resonance imaging.
3) The longer term effect of ILP on the uterine fibroid as imaged either by 
ultrasonography or magnetic resonance imaging.
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4) If possible to ascertain whether ILP would cause significant post operative 
adhesions.
5) To ascertain if refinements can be made to the technique that would make the 
technique easier and minimise complications.
4.2 Photodynamic therapy of the endometrium in women with 
dysfunctional uterine bleeding
Dysfunctional uterine bleeding is the commonest indication for hysterectomy. As 
discussed in the preceding chapters alternatives to surgery have and are being 
developed in order to conserve the uterus. The problems with the first generation 
methods are that they are operator dependant and thereby have a long learning curve 
with the potential to have surgical complications such as haemorrhage, uterine 
perforation and fluid overload. There is still no ideal second generation method with 
concerns still about complications from the thermal effect produced in the uterus. 
Most of the second generation methods rely on complex monitoring systems to 
prevent this complication.
PDT is an exciting alternative as it has the potential to cause damage mainly to the 
endometrium in relation to the myometrium reducing the risk of perforation, would 
not require fluid distension of the uterus thereby reducing the risk of fluid overload, 
has minimal risk of haemorrhage and does not require any specialised skill to perform 
therefore having a very steep learning curve and would not be operator dependant. 
The problems however with this modality of treatment are the risk of systemic 
photosensitisation, inadequate treatment of the endometrium with areas being missed 
and inconvenience to the patient if the drug light interval is too long. The ideal PDT 
method would therefore be a topical intra uterine instillation of a drug minimising 
systemic side effects, a short drug light interval for the photosensitiser so that 
treatment can be offered as a day patient and total and global destruction of the 
endometrium. The photosensitiser that has been popularly used has been 5 amino 
laevulinic acid as it can be used topically, has its maximum light absorbtion in the red 
part of the spectrum allowing for good light penetration, has a drug light interval of 3 
hours and is a potent photosensitiser. There was an increase in its efficacy using iron 
chelators but the results are still not satisfying. This could be due to 2 reasons. 1) 
ALA is not the ideal photosensitiser and 2) Light illumination of the uterine cavity is
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not uniform so that even though the photosensitiser is evenly distributed to a sufficient 
depth it cannot be activated. It is most likely that it is a combination of these two 
factors that are responsible for the suboptimal effect.
4.2.1 The aims of this thesis with regards investigation of an alternative 
photosensitiser to Aminolaevulinic acid for photodynamic therapy in an 
animal model
1) To investigate diphosphonated phthalocyanine (ALS2Pc) as an alternative 
photosensitiser to ALA.
2) To determine the distribution of AlS2Pc in the uterus after topical
application in an animal model (female New Zealand white rabbit).
3) To determine the optimal drug light interval for PDT damage to rabbit
endometrium.
4) To determine the extent of PDT damage to rabbit endometrium.
5) To determine the extent of rabbit myometrial damage from PDT treatment of 
the endometrium.
6) To determine the extent of rabbit endometrial regeneration following PDT
treatment
4.2.2 The aims of this thesis with regards the investigation of light delivery to 
the human uterus
1) To determine if intrauterine balloons made with titanium chips embedded in 
its walls are more effective in light delivery than the standard balloons used.
2) Whether different sizes of balloons are required depending on the size of the 
uterus being illuminated.
3) To determine if intrauterine balloon devices are the best way of delivering 
light to the uterine cavity using extirpated uteri.
4) To determine if intrauterine pathology like polyps, septae or previous 
endometrial treatment affects light delivery to the uterus.
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SECTION 2 -  EXPERIMENTAL WORK
Chapter 5 Distribution of Aluminium Disulphonated Phthalocyanine in the rabbit
uterus after topical instillation
Chapter 6 Morphological changes in the normal rabbit uterus following PDT with
Aluminium Disulphonated Phthalocyanine
Chapter 7 Intrauterine light delivery for photodynamic therapy of the
endometrium
Chapter 8 Interstitial laser photocoagulation of uterine fibroids
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[5] Distribution of
Aluminium 
Disulphonated 
Phthalocyanine in 
the rabbit uterus 
after topical 
instillation
5.1 Introduction
Photodynamic therapy of the endometrium is an exciting alternative to the currently 
available second generation endometrial ablative techniques. Clinical results to date 
however have not been encouraging. This is due to the capacity of the endometrium 
to regenerate following treatment. If endometrial regeneration is to be prevented, 
PDT damage of the whole thickness of the endometrium must occur. Furthermore 
PDT must also damage the endometrium of the tubal ostia and the cervical isthmus as 
regeneration commonly occurs from these sites as described in chapter 1.
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For PDT to be effective, the photosensitiser must localise to the deep glands. In order 
to avoid complications of haemorrhage, post treatment adhesions and uterine 
perforation the drug must have some selectivity for the mucosa over the connective 
tissue. After administration of the drug, the time interval at which the concentration is 
highest in the uterine mucosa must be known so that light may be delivered to the 
uterus with optimal results. It is important therefore that the pharmacokinetics of a 
drug be studied before PDT treatment is commenced. This may then be exploited for 
optimal results.
Most of the work with PDT of the endometrium has been done using 5 amino 
laevulinic acid (ALA) as the photosensitiser. In 1993, Michelle Judd investigated the 
systemic administration of another photosensitiser, aluminium disulphonated 
pthalocyanine, in the rabbit uterus. The pharmacokinetics and the PDT damage in the 
rabbit model were comparable with the results obtained with ALA. However this 
work has not been carried further because of the risk of cutaneous photosensitivity. 
This may be reduced or even eliminated by the topical administration of the drug. 
This chapter investigates the pharmacokinetics of AlS2Pc in the rabbit uterus after 
topical instillation. The rationale for the choice of a rabbit animal model and 
advantages of AlS2Pc over ALA will also be discussed.
5.2 Choice of an animal model
The uterus, cervix and the fallopian tubes in women develop from the 
paramesonephric or Mullerian ducts which extend from the genital ridge to the 
urogential sinus. The lower ends of the ducts fuse in the midline and subsequently 
become canalised and form the cavity and lining of the uterus and the cervix. 
Mesenchymal proliferation occurs around the fused portions to form the muscular 
layer of the uterine wall. The animal model that closely resembles the human uterus 
is that of the higher primates. It is unethical to use primates as an animal model.
Another alterative is the rat. The rat uterus is approximately l-1.5cms in length and is 
extremely thin walled and would not be able to withstand the instrumentation required 
for experiments in photodynamic therapy. This makes it an unsuitable model.
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Figure 16 showing a schematic diagram o f  the urogential system  o f  the fem ale rabbit
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Figure 17 showing a transverse section o f  the rabbit uterus. The superficial glands, deep glands, 
stroma and myometrium where fluorescence intensity measurements were taken are shown
(m agnification xlO)
The model chosen for this experiment was the rabbit uterus despite its structure being 
quite unlike that found in women. The rabbit uterus consists o f two long uterine 
horns and two cervices with a total length o f approximately 10 cms (see). Both the
99
endometrium and the myometrium are different to the human uterus. The 
endometrium is arranged in complex villi like processes and the myometrium is very 
thin with a width of about 1-3 mm which is one tenth the thickness of human 
myometrium. However there are certain characteristics of the rabbit uterus that make 
it an attractive animal model.
1) Rabbits are reflex ovulators and hence the endometrium is always in the 
proliferative phase. As described in section 2.2, all endometrial destructive 
techniques are planned in the early proliferative phase of the endometrial cycle. This 
is convenient as timing of experiments is not necessary.
2) The sequence of endometrial regeneration in the rabbit uterus following curettage 
and cryosurgery has been extensively studied as detailed in Table 12. This is quite 
like the regeneration of human endometrium after menstrual shedding as described in 
Chapter 1. This knowledge is important to assess the efficacy of PDT as endometrial 
regeneration is the principal cause of treatment failure.
Curettage Cryosurgery
Maximum extent of damage 70% of surface endometrium 
denuded
95% of surface endometrium 
denuded
3 hours post treatment Regenerating cells No regeneration
6 hours post treatment Same as 3 hours No regeneration
12 hours post treatment 40-50% denuded areas covered 
by regenerating endometrium
Early regenerating cells from 
glandular and epithelial 
remnants
24 hours post treatment Up to 60% denuded areas 
covered by regenerating 
endometrium
40-50% denuded areas covered 
by regenerating endometrium
48 hours post treatment Surface completely lined by 
endometrial cells
Same as 24 hours
72 hours post treatment Endometrial regeneration 
completed
Same as 24 hours
2 1 - 3 0  days Same as 72 hours Endometrial regeneration 
completed
Table 12 Regeneration of rabbit endometrium following curettage and cryosurgery
3) Endometrial regeneration occurs from the same place as in the human uterus (from 
the glands in the depths of the destroyed glands and the glands that were not
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destroyed). Hence improvements in the technique of PDT in this animal model are 
theoretically applicable to the human uterus.
4) As the rabbit uterus is a duplex structure, it can act as its own control thereby 
greatly reducing the number of animals required.
5) Previous animal experiments on PDT with other photosensitisers and with the 
photosensitiser used in these series of experiments have been conducted using the 
rabbit model. To a certain extent it is therefore possible to compare results obtained 
by other researchers in this field. In our study this is especially pertinent as it would 
be interesting to see if the topical application of AlS2Pc would have the same 
pharmacokinetics as systemic administration.
6) The rabbit is a small animal and the small animal laboratory could be used with 
researchers being easily trained in the handling and treatment of these animals 
according to home office guidelines. A further advantage of the choice of a small 
animal is the reduction in cost.
5.3 Choice of photosensitiser
As discussed in Chapter 3, clinical trials of PDT of the endometrium for women with 
dysfunctional uterine bleeding are disappointing. The photosensitiser used in almost 
all these cases was ALA (5-amino laevulinic acid). The advantages of using ALA are 
that it is easy to synthesize, has a convenient absorption peak of the photoactive 
derivative PPIX which is in the red spectrum at 635 nm where there is good 
penetration of tissues. There is also a high yield of reactive radicles. PPIX is easily 
detected in vivo and vitro and fluorescence corresponds to photoactivity. Side effects 
with systemic use include hypotension, hepatotoxicity and photosensitivity. These are 
minimised when used topically in the uterine cavity. The problem however may be 
that the concentration of PPIX in the endometrium may not be sufficient to cause the 
best PDT effect.
There has been a growing interest in looking for an alternative photosensitiser. The 
phthalocyanines have been investigated in this respect. The advantages are that they 
have similar biological properties to the porphyrins with an absorbtion peak further in 
the red part of the spectrum at 675 nm and hence theoretically tissue penetration is 
better with little unwanted absorbtion by natural biomolecules. It induces lower skin
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photosensitivity to sunlight than ALA when used systemically. It has been used in 
animal models and has been found to be non toxic.
Pure phthalocyanines are not water soluble however it can be easily made soluble by 
sulphonation of the metallic compound by treatment with fuming sulphuric acid. 
Complexing the phthalocyanines with transition metals like copper or iron gives dyes 
with short triplet lifetimes whereas closed diamagnetic ions such as Zinc, Aluminium 
and gadolinium give phthalocyanine complexes with both high triplet yields and long 
life times. Sulphonation of metal phthalocyanines increases the phototoxic effect 
however it also results in the formation of inactive aggregates with reduced 
photochemical activity.
The biological effect of sulphonated metallophthalocyanine dyes has been studied by 
fluorescent microscopy of V-79 Chinese Hamster cells. Highly photocytotoxic 
disuphonated derivatives gave uniform fluorescence in the cell cytoplasm whereas tri 
and tetra sulphonated derivatives showed very little dye uptake (Paquette et al. 215- 
20).
Judd et al studied the distribution of AlS2Pc in the rabbit uterus after intravenous 
administration. The concentrations of A1S2PC were indicated by measurement of 
fluorescence intensity using a cooled charged coupled device (CCD). The location of 
the fluorescence was confirmed by haematoxylin and eosin staining of the same tissue 
sections. She reported a peak tissue concentration at 1 hour which fell to plateau 
between 6 and 48 hours following administration. There was a four fold increased 
uptake by the endometrium when compared with the myometrium and serosa which 
was almost at the level of background fluorescence. In the endometrium the glandular 
uptake was higher than in the surrounding stroma at all time points other that at 24 
hours.
This selectivity was comparable with that of PPIX levels. The problems with clinical 
applications are that women would not tolerate the side effects of photosensitivity for 
the treatment of a benign condition. Topical administration of AlS2Pc would be an 
ideal alternative. However we do not know whether the tissue concentration and 
distribution would be the same as that after systemic administration.
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5.4 Aim of this study
We therefore aim to study the distribution and localisation of AlS2Pc in the rabbit 
uterus after topical application.
5.5 Methods
5.5.1 Photosensitiser
Aluminium Disulphonated Phthalocyanine (A1S2Pc) powder (Prof D Philips, Imperial 
College London) was dissolved in physiological strength, phosphate-buffered saline 
(PBS) and administered in a volume of 0.5 ml, the stock solution concentration was 1 
mg ml'1.
5.5.2 Animals
Normal, female, New Zealand White rabbits (3-4 Kg) supplied by Charles River UK 
Ltd. (Margate, Kent) were used through out.
5.5.3 Preoperative care
The animal was kept for a minimum of two weeks to allow for acclimatization to the 
new surroundings. Training of the handling and management of small animals was 
done at University College London and a personal license obtained from the home 
office in accordance with the Animals (Scientific Procedures) Act 1986.
5.5.4 Operative care
Anaesthetic Regime
The animals were under a general anaesthetic for the entire surgical procedure. 
Anaesthesia was induced using Hypnorm (Fentanyl and Fluanisone, Janssen 
Pharmaceutical s Ltd, Oxford, UK) intramuscularly for induction. When the animal 
was drowsy about 15 minutes later Diazepam (Phoenix Pharmaceuticals Ltd 
Loucester UK) was given intravenously. Anaesthetic was maintained by using 
Hypnorm O.lml/Kg every 45 minutes after induction.
Baytril (Enrofloxacin) which is a floroquinolone group of antibiotic was administered 
at a dose of 0.2ml/kg s.c immediately pre operatively. Vertegesic was given 
subcutaneously for post operative pain relief. Table 13 shows the dosages of 
Hypnorm, Diazepam and Vertegesic that were administered according to the body
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weight of the animal. Before beginning the laparotomy the depth of anaesthesia was 
tested with skin pressure using a toothed forceps. In all the experiments that were 
performed the above anaesthetic regime was found to be adequate without recourse to 
further drugs.
Weight Hypnorm (ml) Diazepam (ml) Vetergesic(ml)
1.7 0.51 0.68 0.17
For every extra 0.1 Kg Increase by 0.03 ml Increase by 0.04ml Increase by 0.01ml
Table 13 Table showing anaesthetic and pain relief regime used according to the body weight of the
rabbit
Surgical technique
After the general anaesthetic the fur was shaved using an electric razor to expose the 
lower 5cms of the abdomen. The shaved area was then cleaned with 70% alcohol and 
then with aqueous Chlorhexidine solution. A 2 cms long midline incision was made 
approximately 2 cms above the symphysis pubis. The peritoneum was lifted by two 
atraumatic graspers before being incised to prevent damage to underlying organs. The 
uterus was hooked out with the aid of a finger from behind the bladder and 
surrounded by moist towels. 0.5 ml of the AlS2Pc solution was injected into the 
lumen via the anti-mesenteric border of the proximal end of the uterine hom and a silk 
ligature was used to isolate the uterine hom and prevent the dye from entering the 
vagina by peristaltic action of the uterine homs. The abdomen was closed in layers 
with vicryl. The skin was closed with a continuous subcutaneous suture using 2-0 
vicryl so that there were no knots that the animal could gnaw at post operatively.
Intraoperative monitoring
The set up at surgery and the monitoring of the rabbit is shown in Figure 18. The 
rabbit was attached to a pulse oximeter and the oxygenation was maintained 
throughout the procedure at 99 -  100% saturation.
5.5.5 Post operative care
The rabbits were transferred to warm boxes and placed prone on warm towels and 
covered with towels till they woke up. The animals were checked daily for wound
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healing and were given free access to food and water. Any change in state o f the 
animals post instillation o f the dye was noted.
Figure 18 Picture showing the rabbit positioned for laparotomy with the Boyles apparatus and pulse 
oximetry showing monitoring used during surgery
5.5.6 Tissue processing
Animals were killed with intravenous pentobarbitone at 0.5, 1, 3, 6, 18, 24 and 48 
hours (1 animal with 2 uterine horns at each time point) after topical instillation o f 
AlS2Pc. The lower abdominal incision was re opened. The peritoneal cavity was 
inspected for any effect from intraperitoneal spill o f the AlS2Pc. The entire uterus 
was then inspected for any chemical effect from the intraluminal A1S2PC. These 
findings were recorded. The uterus was then removed. Multiple transverse sections 
were taken from each uterine hom and specimens were “snap frozen” by placing it in 
isopentane (BDH Ltd, UK) which had been cooled in liquid nitrogen for a few 
minutes. The frozen specimens were removed with forceps and placed in screw- 
topped bijoux. The tissue samples were stored in liquid nitrogen containers until they 
were sectioned. The tissue samples were then mounted in OCT medium (Tissue Tek 
II embedding compound BDH) and were cut using a Cryostat E microtome (Reichert 
Ltd) to a thickness o f 10 pm. H alf o f the sections from each block were mounted on
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clean glass slides, which had been cooled by placing in the microtome, and stored in a 
refrigerator at -70 °C. The other half of the sections was stained with Haematoxylin 
and Eosin (H&E) for examination under light microscopy.
5.5.7 Fluorescence microscopy
Studies have shown that fluorescence seen in tissue after the uptake of A1S2 Pc 
correlates well with the quantity of photosensitiser. This fluorescence can be detected 
through computer imaging of false colour coding or grey imaging. Quantification of 
the fluorescence is possible with computer software that calculates the number of 
counts per pixel in an area in a box superimposed on the area where the fluorescence 
is being measured.
The 10 pm frozen sections were allowed to thaw at room temperature. The slides 
were then placed face down on the specimen stage of an inverted microscope. The 
specimens were then focused under phase contrast illumination with the room 
darkened (see Figure 19). The excitation light was provided by an 8mW helium neon 
laser emitting at 632.8 nm which was chosen because of its spectral purity, low cost 
and more importantly the relatively low tissue auto fluorescence produced using this 
wavelength in contrast to shorter wavelength excitation. The fluorescence from 
AlS2Pc was detected using a long pass filter which transmitted in the range of 665 -  
700 nm which covered its fluorescence bands. All photometry was carried using 
magnification of X10 N.A. 0.3.
106
Snecimen
ctive
I i Iter
Prism
computer
Phase contrast and Fluorescence 
microscope (inverted)
Figure 19 showing the fluorescence imaging system and the cooled charged coupled device. The 
second diagram illustrates how the image is obtained. DM = Dichroic mirror and IF= interference filter
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The fluorescence signal was processed by a personal computer in to falsely colour 
coded or grey scale fluorescence images of the section (Wright instruments, model 1, 
resolution 600 x 400 pixels). The software also enabled quantitative measurement of 
fluorescent levels over selected areas of interest on the displayed fluorescence image. 
Representative areas of endometrium and myometrium were selected for fluorescence 
measurements which were then corrected for auto fluorescence levels of each 
respective tissue layer as measured on specimens from control unsensitised animals. 
These corrected fluorescence measurements had been shown to correlate with the total 
quantity of chemically extracted AlS2Pc from tissue specimens of animals given 
AlS2Pc (Loh et al. 47-54).
For each tissue cryosection three readings were taken. For each time point six 
sections (three from each uterus) were examined. Eighteen fluorescent intensity 
readings were obtained for a time point.
Following fluorescence microscopy the specimens were fixed in formalin and stained 
with haematoxylin and eosin for comparative light microscopy. The fluorescence 
image and its comparative light micrograph were photographed. The images were 
written to compact disc for storage purposes. Permanent copies of the fluorescence 
images were made by photographing them directly off the monitor using a single lens 
reflex camera (Olympus OM-2).
5.6 Results
5.6.1 Effect of topical instillation of AIS2Pc on the whole animal
None of the animals showed any photosensitivity or other systemic reactions to the 
intrauterine topical instillation of AlS2Pc.
5.6.2 Effect of topical instillation of AIS2Pc on the peritoneal cavity and 
macroscopic appearance of the rabbit uterus
At all time points there was no evidence of a chemical effect of AlS2Pc on the serosal 
surface of the uterus or in the peritoneal cavity from peritoneal spillage of the 
photosensitiser.
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5.6.3 Fluorescence microscopy
An image depicting the fluorescent intensity seen and subsequent haematoxylin and 
eosin staining of the same slide is shown in Figure 20 and Figure 21. These figures 
pictorially demonstrate the difference in fluorescent intensities at 30 minutes and 3 
hours. At 30 minutes, significant fluorescence is seen in the myometrium that almost 
extends to the serosa. At 3 hours the fluorescence is seen mainly in the endometrium.
The software enabled quantitative measurement of fluorescent levels over 
representative areas of endometrial glands, submucosal and myometrium. Eighteen 
readings were obtained for each time point (as described in 5.5.7). These could be 
represented graphically with the mean and error bars for the standard error of the 
mean. These images also demonstrate that there is a good histopathological 
correlation between the fluorescent images and the H&E stained slides and allows for 
accurate localisation in the tissue layers of AlS2Pc.
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Figure 20 Fluorescence image o f  normal rabbit uterus 30 minutes after topical administration o f  0.5 ml 
(1 mg/ml) AlS2Pc with the same section subsequently stained with Haematoxylin and Eosin (H&E). 
The fluorescence image shows very high fluorescence in the lumen and the endometrium with 
significant fluorescence in the underlying layers. The upper colour bar indicates fluorescence intensity.
(magnification xlO)
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Figure 21 Fluorescence image o f  normal rabbit uterus 3 hours after topical administration o f  0.5 ml 
(1 m g/ml) AlS2Pc with the same section subsequently stained with Haematoxylin and Eosin (H&E). 
The fluorescence image shows fluorescence in the endometrium without significant fluorescence in the 
underlying layers. The upper colour bar indicates fluorescence intensity, (magnification xlO)
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5.6.4 Changes in concentration of AIS2Pc with time after topical instillation
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Figure 22 A graph showing the comparison o f the fluorescence intensity (arbitrary units) of the 
superficial glands and myometrium as a function of time (hours) when the uterine hom had been 
treated with a topical instillation o f 1 mg/ml in a 0.5 ml volume o f A1S2Pc. Each point represents the 
mean (with the standard error of the mean) from a minimum of two separate uterine horns.
The concentration of A1S2PC in rabbit endometrium is highest at 30 minutes. This 
concentration halves by 1 hour and is maintained at 3 hours. The concentration halves 
again at 6 hours. Measurements at 18, 24 and 48 hours indicate that the concentration 
rises and is maintained at levels seen at 1 and 3 hours. This is graphically represented 
in Figure 4.
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5.6.5 Tissue distribution of AIS2Pc in the rabbit uterus after topical
application
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Figure 23 A comparisons o f  the fluorescence intensity (arbitrary units) layers o f  the uterine horn as a 
function o f  time (hours) when the uterine horn had been treated with a topical instillation o f  1 mg/ml in 
a 0.5 ml volum e o f  A1S2Pc. Each point represents the mean (with the standard error o f  the mean) from
a minimum o f  two separate uterine horns.
The concentration o f AlS2Pc in the other layers o f the rabbit uterus mirror the pattern 
seen in the endometrial layer and this is shown in Figure 23.
Figure 24 shows that the concentration o f AlS2Pc reduces the greater the distance the 
layer is from the tubal lumen. An attempt to differentiate superficial glands from 
deeper glands in the stroma was made when quantifying fluorescence. The 
concentration o f the AlS2Pc in the superficial glands was on average 2.5 times greater 
than in the deeper glands. The fall o ff in the concentration of the AlS2Pc in the 
different layers at each time point is similar.
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Figure 24 Graph showing the comparison o f  the fluorescence intensity (arbitrary units) o f  the different 
layers in the uterus as a function o f  time (hours) when the uterine horn had been treated with a topical 
instillation o f  1 mg/ml in a 0.5 ml volume o f  A1S2Pc. Each point represents the mean (with the standard 
deviation o f  the mean) from a minimum o f  two separate uterine horns.
5.6.6 Selectivity of AIS2Pc in the endometrium
Time Endometrium Myometrium Ratio E/M
0.5 hour 8206 1312 6
1 hour 4856 250 19
3 hour 4644 172 27
6 hour 1860 58 32
18 hour 5189 117 44
24 hour 3826 134 29
48 hour 3010 72 42
Table 14 Table showing the difference between normalised fluorescence intensity (arbitrary units) o f  
the myometrium and the endometrium at each time point when the uterine horns had been treated with 
a topical instillation o f  1 mg/ml in a 0.5 ml volume o f  AlS2Pc from a minimum o f  two separate uterine
horns
The greatest difference in concentrations of AlS2Pc between the endometrium and the 
myometrium is seen at 18 and 48 hours after topical application.
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In the early time points, the highest difference is seen at 6 hours however the 
fluorescence intensity in the endometrium is one of the lowest of all time points. At 3 
hours, the difference in concentrations is not as high but the fluorescence intensity in 
the endometrium is much higher.
5.7 Discussion
The pharmacokinetics of a drug used for photodynamic therapy of the endometrium is 
important as 1) there should be a high concentration of the photosensitiser in the 
target tissue and 2) there should be a low concentration of the photosensitiser in 
normal surrounding tissues and 3) the drug light interval should be calculated at the 
time point when there is optimal concentration of the photosensitiser in the 
endometrium. 4) There should be minimal side effects of the drug with the optimal 
clinical efficacy to the woman. The accurate localisation of the photosensitiser at 
tissue level is important as PDT had now been shown to be dependant on a highly 
reactive oxygen species with a very short half life and therefore a very short distance 
of tissue effect from the site of localisation. Therefore if the photosensitiser is not 
localised in all the areas that require treatment then the PDT effect will not be 
optimal. In other organs this would still lead to a clinical improvement but treatment 
success is an all or none phenomenon in the uterus because of its capability of 
regeneration as discussed in Chapter 1.
The limiting factor for systemic administration of AlS2Pc is photosensitisation. This 
can range from mild to even severe photosensitivity reactions. It is difficult to offer a 
clinical treatment today with side effects that significantly curtail activity. It is mainly 
for this reason that it was decided to see if the topical application of A1S2PC would 
show similar pharmacokinetics to the systemic administration as described by Judd et 
al (Judd).
Technique used
The technique of quantifying fluorescence levels in the different layers of tissue and 
correlating this to the concentration of the photosensitiser present which has been 
used for this experiment has been extensively studied and validated. As shown in 
Figure 20 and Figure 21, high quality colour images are produced by the charge 
coupled device imaging system. In our experience repeated measurements by two
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observers and by the same observer on different days produced little variation in the 
intensities measured.
5.7.1 Local effects of topical application of AIS2Pc
One of the concerns with topical intrauterine application of the drug is the chemical 
effect on normal tissues of the drug which may be caused by spill which would 
include the intraperitoneal spill if the fallopian tube closure pressure is exceeded. 
What will also need working out is how the drug can be administered into the uterus 
in the human subject.
In this study, topical administration of the A1S2PC was done directly into the uterine 
lumen and there was very little contact with the vaginal epithelium. There was 
minimal spill in the peritoneal cavity as seen by faint blue staining especially in the 
animals that were killed in the early time points. There was no evidence of any 
chemical action of the photosensitiser on the peritoneal cavity or on the vaginal or 
endometrial lining of the uterus. If AlS2Pc was to be administered in the human, the 
administration would have to be transcervically. No pressure would be required to 
administer the drug and as such the uterine tubal closure pressure would not be 
exceeded. Hence there will be minimal peritoneal spill and it is reassuring that even if 
it does occur this study has shown that AlS2Pc is non irritant at least in the animal 
model.
5.7.2 Tissue distribution of AIS2Pc
In this experiment, the concentration of the AlS2Pc after topical application was 
highest in the endometrial glands when compared to the other layers of the rabbit 
uterus in all the time points that were used. This was encouraging as this is the target 
area for PDT. There was a sharp fall in concentration of the AlS2Pc the deeper the 
layer is from the uterine lumen. This is of some concern as it also affects the glands 
that are deeply situated in the stroma from which regeneration of the endometrium can 
occur.
The concentrations of AlS2Pc were lowest in the myometrium. As discussed in 
chapter 2, most endometrial destruction techniques used to reduce MBL relies on a 
thermal effect. These invariably destroy some of the superficial myometrium as well. 
Healing occurs by intra uterine adhesions or synechiae referred to as Ashermanns
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syndrome. This may be associated with cyclical midline pelvic pain from loculi of 
blood entrapped in the adhesions and is a major setback of the procedure. The 
investigation of a woman with Ashermanns syndrome who develops abnormal uterine 
bleeding is difficult both by ultrasonography and hysteroscopy. This study has shown 
that in a rabbit model, there is minimal concentration of AlS2Pc in the myometrium 
and hence there would be minimal myometrial damage from subsequent PDT. This 
should not therefore have any of the adverse effects of the thermal techniques of 
endometrial destruction.
At all time points there was almost no fluorescence detected in the deepest parts of the 
myometrial layer. This is reassuring as the risk of uterine perforation is low but still 
present in all the thermal techniques but with this procedure will be almost non 
existent.
5.7.3 Changes in concentration of AIS2Pc with time following topical 
application
The temporal relationship of ALS2Pc is almost the same in all the layers of the rabbit 
uterus. This is highest at 30 minutes and then falls to its lowest at 6 hours and then 
rises again at 18 hours and then falls gradually over the next 36 hours. At the 30 
minute time point there was a lot of residual drug still in the uterus which was washed 
with normal saline before snap freezing. We did expect to find a high intensity in the 
lumen. Interestingly drug was seen in all the layers with a lot of fluorescence in the 
myometrial layer. With increase in time the concentration in the endometrium fell 
and the difference in the concentration between the endometrium and the myometrium 
increased. The unexpected finding was the zenith at the 6 hour time point. Again the 
concentrations seem to increase at 18 hours and then fall again.
This relative selectivity of the drug to the endometrium has been described with the 
systemic use of AlS2Pc in the rabbit uterus as well as AlS2Pc in the rat bladder. It 
has also been described with the use of other photosensitisers like ALA. 
Suggestions as to why these happen include the increased vascularity and proliferation 
rates of the glandular endometrium. On a cellular level it is thought that it is because 
of the high density of reticulo endothelial components found in these cells.
There is some difficulty in explaining why there is a drop in concentration at the 6 
hour time point. This may have something to do with dimerisation, ie aggregation of
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the phthalocyanine dyes which subsequently reduces the fluorescence efficiency. It is 
known that only the monomers are fluorescent.
At 6 hours perhaps the phthalocyanine has become partially aggregated in the cells 
reducing the fluorescence. This also happens in tissue culture at longer incubation 
times. However at 24 hours the phthalocyanine will be clearing from the uterus (or 
the aggregates that have monomerised) which reduce the amount o f aggregation and 
hence improve the fluorescence efficiency. Alternatively the phthalocyanine might 
have recirculated back into the uterus thus increasing the signal. In this case however 
one would expect to see some blood vessel damage and less selectivity.
5.7.4 Systemic administration of AIS2Pc
5.7.4.1 Concentration of AlS2Pc in the endometrium
Surface epithelium 
Glands 
Stroma 
Myometrium
3h 6h 24h
Fluorenscence intensity (au)
48h
Figure 25 Fluorescence kinetics o f  the microscopic distribution o f  AlS2Pc in the normal uterine wall. 
Each point represents the mean o f  separate measurements corrected for auto fluorescence, (reproduced
by permission from M Judd)
In Judd’s work (Judd) following intravenous AlS2Pc the endometrium had two 
fluorescence peaks at 1 and 24 hours. At 48 hours the endometrium and its glands 
had twice and four times respectively the background levels o f fluorescence and these
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values fell slowly. One week after administration there was approximately twice the 
fluorescence in the glands when compared to the background levels. The 
fluorescence intensity as a function of time in hours is depicted in Figure 25.
5.7.4.2 Tissue distribution after systemic administration of AIS2Pc
After systemic administration of AlS2Pc, the highest concentration was found in the 
endometrium (in the epithelium and the glands).
Time Endometrium Myometrium Ratio E/M
1 hour 42 7 6
3 hour 37 3 12
6 hour 30 7 4
24 hour 28 7 4
48 hour 27 6 5
168 hour 17 1 17
Table 15 Table showing the difference between normalised fluorescence intensity (counts per pixel) of 
the myometrium and the endometrium at each time point when an intravenous dose of 1 mg/kg AlS2Pc 
was administered, (reproduced with permission from M Judd)
This was higher by a factor of 4-17 than the concentration that was found in the 
myometrium as shown by Table 14. The highest difference in concentration was 
found at 168 hours and 3 hours after intravenous injection.
5.7.5 Comparison of local with systemic administration of AIS2Pc on the 
pharmacokinetics in the rabbit uterus
The pharmacokinetics of a drug after topical application does not necessarily mirror 
that after systemic administration. Studies using AlS2Pc topically in the rat bladder 
have been disappointing when compared to systemic administration. Pope et al 
showed that systemic administration of AlS2Pc was reliable showing a good uptake in 
the urothelium, four fold selectivity over the muscle layer and rapid clearance from 
the muscle layer whereas topical intravesical application gave unreliable results.
The methodology employed by Judd for investigation of the pharmacokinetics in the 
rabbit uterus after systemic administration of AlS2Pc was similar to ours. Direct 
comparisons of the fluorescence intensities of the tissues between the two experiments
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cannot be made as absolute concentrations of the drug cannot be measured using this 
method. Furthermore the fluorescence intensities depend on the background 
fluorescence which was different in the two experiments. However, the trends and 
selectivity of drug distribution may be compared.
The concentrations o f AlS2Pc in the glands after topical and systemic administration 
are shown in Figure 26.
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Figure 26 A comparison o f  the fluorescence intensity (arbitrary units) o f  the uterine horn as a function 
o f  time (hours) when the uterine horn had been treated with a topical instillation o f  1 mg/ml in a 0.5 ml 
volume o f  A1S2Pc and when it has been systemically administered at a concentration o f  1 mg/kg
To generate this graph the fluorescent data o f the fluorescence intensities o f both the 
superficial and deep endometrial glands have been considered together. This was 
thought to be clinically applicable as this is the target area for PDT. It is interesting to 
note that the concentration o f AlS2Pc was lowest in both experiments 6 hours after 
administration. In both, high concentrations were seen at 1 and 3 hours after 
administration. After systemic administration selectivity of AlS2Pc for the
endometrium was high 3 hours after administration whereas with topical application, 
selectivity continued to increase till 18 hours after administration as shown in Figure 
27. The degree of selectivity was higher after topical application. The different
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characteristics studied after the two methods of administration are summarised in 
Table 15.
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Figure 27 A graph showing the comparison o f  the fluorescence intensity (arbitrary units) o f  the 
superficial glands and myometrium as a function o f  time (hours) when the uterine hom has been treated 
with a topical instillation o f  1 mg/ml in a 0.5 ml volume o f  A1S2Pc and when it has been treated 
systemically with a concentration o f  1 mg/kg.
Systemic administration Topical administration
Route o f  administration Marginal vein o f  the ear Direct instillation into uterus
Concentration o f  AlS2Pc 1 mg / Kg 1 mg / ml (0.5 ml)
Peak fluorescence intensity 2 peaks at 1 and 24 hours 0.5 and 18 hours
Peak selectivity in 
endometrium: myometrium
3 hours and 168 hours 18 hours and 48 hours
Degree o f  selectivity 4-17 times higher in 
endometrium
6-44 times higher in endometrium
Table 16 A table comparing the distribution and tissue selectivity o f  AlS2Pc in the rabbit uterus after
topical and systemic administration.
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5. 7. 5.1 Limitations of this study
Only one rabbit was used at each time point described in this experiment. The 
advantages were that minimal number of animals were used. The cost of the 
experiment was also significantly reduced. However, results can be distorted by 
biological variations in the animals. The selectivity however is comparison between 
layers of the same animal and hence will not be affected by biological variation.
5.8 Conclusion
This experiment has used a validated technique to show the quantitative imaging of 
AlS2Pc after topical application in the rabbit uterus. The results are encouraging 
when compared to similar experiments using intravenous AlS2Pc. In fact, the 
selectivity between the endometrium and myometrium is better with the topical 
method. To have the maximum effect of PDT, light of an appropriate wavelength 
must be administered at a time when the concentration of the drug in the target tissue 
is at a maximum. From this experiment this would be 30 minutes and 18 hours after 
administration. However, drug was still found in the lumen at 30 minutes and 
required washing out with saline. In practice this would reduce the light reaching the 
glandular components of the endometrium. The 18 hour drug light interval is not 
acceptable for day care treatment which is the aim of this treatment. Drug 
concentrations remain high at 1 and 3 hours after administration with increasing 
selectivity. On the basis of these results, we decided to administer light at 1, 3 and 6 
hours after topical intrauterine administration of AlS2Pc.
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[6] Morphological 
changes in the 
normal rabbit uterus 
following PDT with
Aluminium
Disulphonated
Phthalocyanine
6.1 Introduction
The pharmacokinetics of AlS2Pc in the rabbit uterus after topical instillation of 0.5ml 
of 1 mg/ml solution has been investigated in chapter 5. The experiments show that 
there is high fluorescence and therefore concentration of AlS2Pc in the glandular 
component of the rabbit endometrium with some selectivity over the surrounding 
stroma and the underlying myometrium. The highest fluorescence intensity in the 
endometrium was seen 30 minutes after instillation of AlS2Pc. This concentration fell 
at the 1 and 3 hour time points and reached its lowest point 6 hours after instillation
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before rising again. There was increasing selectivity however for the glandular 
component over the stroma and the myometrium with increasing time. Furthermore at 
30 minutes there was a significant amount of the drug still present in the rabbit uterine 
lumen which would interfere with subsequent PDT treatment. It was decided 
therefore to choose drug light intervals of 1, 3 and 6 hours in performing PDT of the 
rabbit endometrium after topical instillation of A1S2 Pc
The light dose used when illuminating the target area influences the PDT effect. 
Problems with this would include a thermal effect with damage to underlying 
structures if the power is too high. Hence the rate of energy delivery to the target 
tissue must be known. However in the uterus, thermal damage to the stroma or the 
myometrium would not have serious consequences when compared to other organs. 
As described in chapter 2, nearly all the second generation endometrial ablative 
techniques employ a thermal effect to destroy not only the endometrium but a 
significant amount of superficial myometrium as well. Disadvantages of significant 
myometrial damage would be obliteration of the endometrial cavity with problems of 
haematometra and difficulties in evaluation of the uterine cavity in the event of 
subsequent abnormal uterine bleeding as discussed in chapter 5. It is important 
therefore to use an optimal light intensity with a maximal PDT effect with minimal 
thermal damage to the stroma and the underlying myometrium.
The biggest problem with PDT of the human endometrium is that of endometrial 
regeneration following destruction. As discussed in chapter 1, this is due to 
insufficient depth of destruction and difficulty in destroying endometrium in 
inaccessible sites like the comua and the isthmus. Studies in the rabbit uterus (see 
table) have shown that regenerating endometrial cells are present as early as 3 hours 
after uterine curettage and regeneration completed by 72 hours. Cryosurgery to rabbit 
endometrium delays the appearance of regenerating cells to 12 hours post treatment 
with complete regeneration occurring at 21 to 30 days. It is therefore important when 
studying the PDT effect of AlS2Pc on the rabbit endometrium to examine the 
endometrium at 21 -  30 days post treatment to evaluate treatment.
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6.2 Aim of this study
Three experiments were therefore designed to answer the following questions
1) To compare the short term and intermediate term effect of PDT using topical 
AlS2Pc on the rabbit endometrium using drug light intervals of 1, 3 and 6 hours.
2) To compare the PDT effect of topical AlS2Pc when the light intensity is increased 
from 50 to 100 Joules/ cm2 .
3) To evaluate the long term effect of topical AlS2Pc PDT on rabbit endometrium.
6.3 Experiment 1
a) To compare the short and intermediate term PDT effect of topical 
AIS2Pc on rabbit endometrium using drug light intervals of 1, 3 and 6 
hours
b) To compare the PDT effect of topical AIS2Pc on rabbit endometrium 
when the light intensity is increased from 50 to 100 Joules/  cm
c) To compare the effect of topical AIS2Pc with that in previous work 
using systemic AIS2Pc
6.3.1 Methods
6.3.1.1 Photosensitiser
Aluminium Disulphonated Phthalocyanine (AIS2 PC) powder (Prof D Philips, Imperial 
College London) was dissolved in physiological strength, phosphate-buffered saline 
(PBS) and administered in a volume of 0.5 ml, the stock solution concentration was 1 
mg ml'1.
6.3.1.2 Animals
Normal, female, New Zealand White rabbits (3-4 Kg) supplied by Charles River UK 
Ltd. (Margate, Kent) were used through out. The pre operative, intraoperative, 
postoperative care and handling of the animals were the same as described in the 
methods section of chapter 5.
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6.3.1.3 Surgical technique
The preparation o f the skin of the anterior abdominal wall and operative technique 
and procedure of injecting 0.5 ml of the AlS2Pc into each rabbit uterine horn and 
isolating it with a silk ligature was done as described in chapter 5. Abdominal closure 
was similar with the skin closed using continuous subcutaneous suture using 2-0 
vicryl so that there were no knots that the animal could gnaw at post operatively. The 
animals were recovered from anaesthetic and were kept sedated. A second 
laparotomy was performed at time intervals of 1, 3 and 6 hours after the instillation of 
the drug in the uterine horns. The peritoneal closure suture was undone, and the 
uterus hooked out from behind the bladder and surrounded with moist towels.
Figure 28 Photograph showing the rabbit uterus exteriorised from the anterior abdominal wall and 
surrounded by moist towels. The light diffuser fibre has been inserted through a 0.5 cm incision in the 
anti mesenteric border o f  the left uterine horn and is activated by light o f  670nm wavelength produced
by a diode laser at a power o f  100 mwatts/cm2.
A 0.5 cm incision was made on the anti mesenteric border of the uterine horn 1cm 
distal to the cervical end. This incision enabled the introduction of a cylindrical fibre 
with a diameter of 1.6 mm and a 4 cm light diffuser tip. The fibre was placed 
centrally in the lumen of the uterine horn as shown in Figure 28. A diode laser (see 
Figure 29) was used to deliver light at a wave length o f 670 nm with the power 
adjusted to deliver 100 mwatts/cm of uterine horn. In the right tube, the light was
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delivered for 500 seconds and in the left tube for 1000 seconds making the energy 50 
and 100 Joules/ cm2 respectively.
Figure 29 Figure showing the set up o f  the diode laser and the light delivery system used for PDT o f
the rabbit uterus
At the end of the procedure the animals were returned to their cages with no special 
precautions. The animals were killed 72 hours after PDT. A laparotomy was 
performed and a detailed examination of the pelvic and abdominal cavity was made 
for the presence of adhesions or damages to neighbouring organs especially the 
bladder and the intestine. If external uterine damage was present from PDT this was 
noted. In the first animal, the uterine horn was laid open to assess macroscopic 
damage to the endometrium but this did not yield much information and interfered 
with subsequent histological sections and was not repeated. A minimum of three 
transverse sections were taken from the proximal, middle and distal thirds o f the 
uterine horns and placed in 4% formol saline solution. Serial 10 pm sections were 
taken and stained using Harris’ haematoxylin and eosin stain. Tissue processing was 
undertaken at our centre at University College Hospital London.
Nine tissue sections were examined for PDT damage for each uterine horn. Both 
depth of the damage as well as the proportion of each section that was affected by the 
PDT damage was noted. In order to compare results with different drug light 
intervals and different light intensities a grading system was developed.
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6.3.1.4 Grading of PDT damage to rabbit endometrium after topical
application of AIS2Pc
The extent and depth of damage to the endometrium and the myometrium from PDT 
was assessed. A grading system was developed to enable easy interpretation and 
comparison of results. With increasing depth of damage, the endometrium was scored 
from 0 to 3. Details of the grading of damage and the pictorial representation of this 
are given below.
Grade 0 was given if there was no evidence of any damage. The endometrium could 
not be differentiated from the histology of the endometrium from the control rabbit 
(see Figure 30).
Grade 1 was given if there was some evidence of glandular damage but a significant 
glandular component was still present (see Figure 31).
Grade 2 was given if most of the glands were destroyed but some remnant glandular 
structures were seen in the deeper parts of the stroma (see Figure 32 ).
Grade 3 was given if all the glandular components were destroyed and no remnant 
glands were found on reviewing the section (see Figure 33).
The extent of the damage was also noted. This was represented as a percentage of the 
section that showed the grade of damage when compared to the entire circumference 
of the section being examined.
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Figure 30 -  Grade 0 damage -  the glandular architecture o f  the rabbit endometrium is the same as that 
o f  normal histology. There are no signs o f  PDT damage.
Figure 31 -  Grade 1 damage -  Many o f  the glands are destroyed by PDT. However a significant 
proportion o f  the deeper glands have not been affected.
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Figure 32 -  Grade 2 damage -  Most o f  the glands in the endometrium have been damaged but there are 
a few scattered glands that have avoided PDT damage.
Figure 33 -  Grade 3 damage -  There is com plete PDT destruction o f  the endometrium with no
surviving glands.
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6 .3 .1 .5  Grading o f P D T  dam age to rabbit myometrium after topical application
o f A IS2 P c
Figure 34 -  Grade 0 -  untreated myometrium
Figure 35 -  Grade 1 -  Haemorrhage and cellular infiltration of the myometrium
The myometrium hardly shows any histological damage with PDT and hence was 
given only two grades o f  damage as described above.
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Grade 0 was given if there were no histological changes seen in the myometrium. 
The section could not be differentiated from the control (see Figure 34).
Grade 1 was given if there were areas of haemorrhage and cellular infiltration of the 
myometrium (see Figure 35).
6.3.2 Short term and intermediate term effects of PDT with topical AIS2 Pc
Seven animals were used in this part of the experiment. Short term effects were 
studied at 3 days. PDT was performed with drug light intervals of 1 hour (1 animal; 2 
uterine horns), 3 hours (2 animals, 4 uterine horns) and 6 hours (1 animal). The 
intermediate effects were studies in 3 animals (1 at each drug light interval) at 13 
days.
6.3.2.1 Whole animal effects following PDT using topical AIS2Pc
There were no major complications in any of the animals following PDT treatment. 
Their behaviour was normal and they were active until sacrifice at the required time 
intervals. One animal had gaping of the middle part of the wound that required a 
single mattress suture.
6.3.2.2 Macroscopic damage caused by PDT using topical AIS2 Pc
At laparotomy, three days after PDT, there were no adhesions in the peritoneal cavity. 
Removal of the uterus, cervix and vagina was technically easy as there was no 
peritoneal reaction. Inspection of the small intestine, large intestine and bladder did 
not reveal any congestion, haemorrhages or damage. The serosal surface of the 
uterine horns was intact with no evidence of any PDT effect. This is shown in Figure 
36. The mucosal surface of the treated uterine hom did show some evidence that PDT 
damage had occurred. There was widespread vascular congestion and some degree of 
mucosal oedema. However the transverse rugae were maintained and the tissue itself 
was viable. This was compared to the control uterus where AlS2Pc was instilled but 
no light illumination was conducted. The comparison of both specimens illustrating 
this is shown in Figure 37.
132
Rieht uterine horn
Vagina
Left uterine horn
Cervix
Figure 36 M acroscopic appearance o f  uterus and vagina 3 days after PDT using 0.5 ml o f  1 mg/ml o f  
AIS2 Pc with a light dose o f  100 Joules/ cm 2 at a drug-light interval o f  3 hours (both uterine horns 
have been treated). N o serosal reaction was seen follow ing PDT
Figure 37 Rabbit uterine horn cut open to show macroscopic appearance o f  uterine mucosa. Normal 
mucosal pattern on the left (control) and appearance after PDT using 0.5 ml o f  1 mg/ml o f  AIS2 Pc 
with a light dose o f  100 Joules/ cm 2 at a drug-light interval o f  3 hours
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6.3.2.3 Microscopic features caused by topical PDT using AIS2 Pc at 3 days
6.3.2.3.1 Histological features seen in the control animal
Figure 38 Transverse section o f  the rabbit uterus on day 3 follow ing topical application o f  0.5 ml o f  
1 mg/ml o f  A lS2Pc. There was no light illumination follow ing drug application. (M agnification xlO )
Two animals (four uterine horns) were used as controls for PDT. In one, 0.5 ml o f 
AlS2Pc at a concentration o f 1 mg/ml was inserted into each uterine horn. No light 
illumination was done. In the other, no drug was administered, only light illumination 
with 100 J was done. The animals were killed at 3 days. Transverse sections o f the 
distal, middle and proximal sections o f both uterine horns did not show any evidence 
o f glandular, stromal or myometrial damage. A representative histological specimen 
is shown in Figure 38.
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Grade o f  PDT damage at 3 days using a drug light interval o f  1 hour
The microscopic features o f the transverse section o f the rabbit uterus treated by PDT 
after a drug light interval o f 1 hour is shown in Figure 39. A significant amount o f the 
glandular element o f the endometrium had been damaged. However there were a few 
glandular components remaining. The myometrium did not show any damage. Most 
o f the sections examined showed an endometrial damage score o f 2 and a myometrial 
damage score o f 0. The architecture o f the endometrium however had been 
maintained.
Figure 39 Transverse section o f  the rabbit uterus on day 3 follow ing PDT using 0.5 ml o f  1 mg/ml o f  
AlS2Pc with a drug light interval o f  1 hour and a light intensity o f  50 Joules/ cm 2 . (M agnification
xlO)
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6.3.2.3.2 Grade o f  PDT damage at 3 days using a drug light interval o f  3 hours
The microscopic features o f the transverse section o f the rabbit uterus treated by PDT 
after a drug light interval o f 3 hours is shown in Figure 40. Here there is a complete 
absence o f all glandular elements in all the sections that were examined. Under high 
power examination empty lacunae were seen in some o f the areas where there had 
been glands. No glandular epithelium was seen to line these spaces. The 
myometrium did not show any damage. Most o f the sections examined showed an 
endometrial damage score o f 3 and a myometrial damage score o f 0. The architecture 
o f the endometrium however was maintained.
Figure 40 Transverse section o f  the rabbit uterus on day 3 follow ing PDT using 0.5 ml o f  1 mg/ml o f  
A lS2Pc with a drug light interval o f  3 hours and a light dose o f  100 Joules/ cm 2 (magnification xlO).
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6.3.2.3.3 Grade o f  PDT damage at 3 days using a drug light interval o f  6 hours
The microscopic features o f the transverse section o f the rabbit uterus treated by PDT 
after a drug light interval o f 6 hours is shown in Figure 39. This representative 
section showed that the PDT damage to the glandular component was patchy. 
Examinations o f all the sections showed that there were areas o f the endometrium that 
had remained unaltered or showed minimal glandular damage. These areas were 
scored as 0-1. Again there was no damage to the myometrium in all the sections and 
these were scored as 0. The architecture was maintained in all the sections.
Figure 41 Transverse section o f  the rabbit uterus on day 3 following PDT using 0.5 ml o f  1 mg/ml o f  
A lS2Pc with a drug light interval o f  6 hours and a light dose o f  100 Joules/ cm 2 (magnification x lO ) .
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6.3.2.3.4 Extent of PDT damage at 3 days using a drug light interval of 1 hour
Light
dose Site
PDT Damage
Endometrium Myometrium
Grade Extent (%) Grade Extent (%) Grade Extent(%)
50 J LD 3 100 0 100
LD 3 100 0 100
LD 3 100 0 100
LM 1 100 0 100
LM 1 100 0 100
LM 1 100 0 100
LP 0 100 0 100
100 J RD 0 100 0 100
RD 0 100 0 100
RD 0 100 0 100
RM 2 80 0 20 0 100
RM 2 80 0 20 0 100
RM 2 80 0 20 0 100
RP 3 50 0 50 0 100
RP 3 50 1 50 0 100
RP 3 50 1 50 0 100
Table 17 Table showing the proportions of the rabbit uterine horn showing the various grades of 
uterine damage due to PDT. Sections were examined 3 days after PDT treatment using topical 
instillation o f 0.5 ml of 1 mg/ml of AlS2Pc, a drug light interval of 1 hour and a light dose o f 50 and 100 
Joules/ cm2. Three sections were examined from the right distal (RD), right middle (RM) and the right 
proximal (RP) parts o f the uterus. One rabbit with two uterine horns were used at this time point.
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6.3.2.3.5 Extent of PDT damage at 3 days using a drug light interval of 3 hours
PDT Damage
Light
dose
Endometrium Myometrium
Grade Extent (%) Grade Extent (%) Grade Extent (%)
50 J RD 3 40 2 60 0 100
RD 3 40 2 60 0 100
RD 3 40 2 60 0 100
RM 3 95 2 5 0 100
RM 3 95 2 5 0 100
RM 3 95 2 5 0 100
RP 1 40 1 60 0 100
RP 0 95 1 5 0 100
RP 0 100 0 100
100 J LD 3 100 0 100
LD 3 100 0 100
LD 3 100 0 100
LM 3 100 1 100
LM 3 100 1 100
LM 3 100 1 100
LP 3 100 1 100
LP 3 100 1 100
LP 3 100 1 100
Table 18 Table showing the proportions of the rabbit uterine horn showing the various grades of 
uterine damage due to PDT. Sections were examined 3 days after PDT treatment using topical 
instillation of 0.5 ml of 1 mg/ml of AlS2Pc, a drug light interval o f 3hours and a light dose of 50 and 
100 Joules/ cm2. Three sections were examined from the right distal (RD), right middle (RM), right 
proximal (RP), left distal (LD), left middle (LM) and left proximal parts of the uterus. These represent 
the averages of the uterine horns from 2 animals.
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6.3.2.3.6 Extent of PDT damage at 3 days using a drug light interval o f 6 hours
Light
energy Site
PDT Damage
Endometrium Myometrium
Grade Extent (%) Grade Extent (%) Grade Extent (%)
50 J LD 3 50 1 50 0 100
LD 3 50 1 50 0 100
LD 3 50 1 50 0 100
LM 0 90 1 10 0 100
LM 0 90 1 10 0 100
LM 0 90 1 10 0 100
LP 0 70 3 30 0 100
LP 0 80 1 20 0 100
LP 0 80 2 20 0 100
100 J RD 3 95 1 5 0 100
RD 3 60 2 40 0 100
RD 3 60 2 40 0 100
RM 3 90 1 10 0 100
RM 3 90 1 10 0 100
RM 3 90 1 10 0 100
RP 3 50 1 50 0 100
RP 3 50 1 50 0 100
RP 3 50 1 50 0 100
Table 19 Table showing the proportions o f the rabbit uterine horn showing the various grades of  
uterine damage due to PDT. Sections were examined 3 days after PDT treatment using topical 
instillation of 0.5 ml of 1 mg/ml of AlS2Pc, a drug light interval o f 6hours and a light dose of 50 and 
100 Joules/ cm2 . Three sections were examined from the right distal (RD), right middle (RM) and the 
right proximal (RP) parts of the uterus. This data represents both uterine horns from a single animal.
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The results show that the extent o f PDT damage when the drug light interval is 1 hour 
is patchy with only a small proportion o f the uterus showing features o f Grade 3 
damage. This is similar when the drug light interval is 6 hours. The best results were 
obtained with a drug light interval o f 3 hours. In these sections, a high proportion o f 
specimens showed Grade 3 damage.
6.3.2.4 Microscopic features caused by PDT using topical AIS2 Pc at 13 days
6.3.2.4.1 Microscopic features at 13 days after AlS2Pc PDT using a drug light 
interval o f 1 hour
Figure 42 Figure showing endometrial regeneration 13 days after using topical A lS2Pc PDT with a 
drug light interval o f  1 hour and a light dose o f  100 Joules/ cm 2 (M agnification xlO)
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Light
dose Site
PDT Damage
Endometrium Myometrium
Grade Extent (%) Grade Extent (%) Grade Extent (%)
50 J LD 1 100 0 100
LD 1 100 0 100
LD 1 100 0 100
LM 1 40 1 60 0 100
LM 1 50 1 50 0 100
LM 1 50 1 50 0 100
LP 2 40 0 60 0 100
LP 2 40 1 60 0 100
LP 2 40 0 60 0 100
100 J RD 3 85 1 15 0 100
RD 3 85 1 15 0 100
RD 3 85 1 15 0 100
RM 3 85 1 15 0 100
RM 3 85 1 15 0 100
RM 3 85 1 15 0 100
RP 3 100 1 100
RP 3 95 2 5 1 100
RP 3 100 1 100
Table 20 Table showing the proportions of the rabbit uterine horn showing the various grades of 
uterine damage due to PDT. Sections were examined 13 days after PDT treatment using topical 
instillation o f 0.5 ml of 1 mg/ml of AlS2Pc, a drug light interval of 1 hour and a light dose of 50 and 100 
Joules/ cm2. Three sections were examined from the right distal (RD), right middle (RM) and the right 
proximal (RP) parts of the uterus. These data are from both uterine horns in a single animal.
The glandular components were almost normal at 13 days when a drug light interval 
of 1 hour was used and a light dose of 50 Joules/ cm2. The PDT effect was much 
better when the light dose was increased to 100 Joules/ cm2. Here there was a total 
absence of glandular components in 85% of the circumference of the specimen see 
Figure 42. There was no evidence of myometrial fibrosis.
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absence o f glandular components in 85% o f the circumference o f the specimen see 
Figure 42. There was no evidence o f myometrial fibrosis.
6.3.2.4.2 Extent o f PDT damage at 13 days using a drug light interval o f 3 hours
Figure 43 Figure showing endometrial regeneration 13 days after using topical A lS2Pc PDT with a 
drug light interval o f  3 hours and a light dose o f  100 Joules/ cm 2 (M agnification xlO)
'j
At a drug light interval o f 3 hours, at a light dose o f 50 Joules/ cm , 40% o f the 
circumference o f the sections examined showed Grade 3 damage (see Table 18). The 
rest o f the sections showed Grade 2 damage. There was no evidence o f myometrial
t 'y
damage. When the incident light dose was increased to 100 Joules/cm there were no 
glandular elements seen in any o f the sections as illustrated by Figure 43. Grade 1 
myometrial damage was seen at this light dose.
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Light
dose Site
PDT Damage
Endometrium Myometrium
Grade Extent (%) Grade Extent (%) Grade Extent (%)
50 J LD 3 20 2 80 0 100
LD 3 40 2 60 0 100
LD 3 20 2 80 0 100
LM 3 40 2 60 0 100
LM 3 40 2 60 0 100
LM 3 40 2 60 0 100
LP 3 80 2 20 0 100
LP 3 60 2 40 0 100
LP 3 40 2 60 0 100
100 J RD 3 100 0 100
RD 3 100 0 100
RD 3 100 0 100
RM 3 100 0 100
RM 3 100 0 100
RM 3 100 0 100
RP 3 100 0 100
RP 3 100 0 100
RP 3 100 0 100
Table 21 Table showing the proportions of the rabbit uterine horn showing the various grades of 
uterine damage due to PDT. Sections were examined 13 days after PDT treatment using topical 
instillation of 0.5 ml o f 1 mg/ml of AlS2Pc, a drug light interval of 3hours and a light dose o f 50 and 
100 Joules/ cm2. Three sections were examined from the right distal (RD), right middle (RM), right 
proximal (RP), left distal (LD), left middle (LM) and left proximal parts of the uterus. These data are
from both uterine horns in a single animal.
6.3.2.4.3 Extent of PDT damage at 13 days using a drug light interval of 6 hours
The histological features that were seen at 13 days after PDT when a drug light 
interval of 6 hours was used were similar to that seen at 3 days. There were areas of
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Grade 3 damage which however were patchy. The other areas did not show any 
evidence o f damage and were scored as Grade 0 damage. This is well illustrated in 
Figure 44 which shows that the mucosal lining on the left side o f the section was 
devoid o f glandular elements whereas the mucosal lining abutting this area is filled 
with glandular components see Figure 44.
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Figure 44 Figure showing endometrial regeneration 13 days after using topical A lS2Pc PDT with a 
drug light interval o f  6 hours and a light dose o f  100 Joules/ cm 2 (M agnification x4)
This PDT effect could have been predicted from the fluorescence kinetics o f AlS2Pc 
as described in chapter 5.
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Light
energy Site ,
PDT Damage
Endometrium Myometrium
Grade Extent (%) Grade Extent (%) Grade Extent (%)
50 J LD 3 70 1 30 0 100
LD 3 70 1 30 0 100
LD 3 70 1 30 0 100
LM 3 50 1 50 0 100
LM 3 80 2 20 0 100
LM 3 80 2 20 0 100
LP 3 95 1 5 0 100
100 J RD 3 85 1 15 0 100
RD 3 85 1 15 0 100
RD 3 85 1 15 0 100
RM 3 80 1 20 0 100
RM 3 50 1 50 0 100
RM 3 50 1 50 0 100
RP 3 70 1 30 0 100
RP 3 60 1 40 0 100
RP 3 60 1 40 0 100
Table 22 Table showing the proportions of the rabbit uterine horn showing the various grades of 
uterine damage due to PDT. Sections were examined 13 days after PDT treatment using topical 
instillation of 0.5 ml of 1 mg/ml of AlS2Pc, a drug light interval o f 6hours and a light dose of 50 and 
100 Joules/ cm2. Three sections were examined from the right distal (RD), right middle (RM) and the 
right proximal (RP) parts o f the uterus. These data are from both uterine horns in a single animal.
6.3.2.4.4 Effect of light dose used on the PDT damage to rabbit endometrium
From Figure 45 it can be seen that a light dose of 100 Joules/ cm2 gave a better PDT 
effect at all the drug light intervals used. An optimal PDT effect was seen at a drug 
light interval at 3 hours where the entire circumference of the uterine horn was 
affected by full thickness PDT damage.
146
___________________
_____
100 J100 J
6 hour 6 hour3 hour 3 hour1 hour 1 hour
Figure 45 Percentage o f  uterine horn with grade 3 damage at 3 days with AIS2 Pc PDT with light 
intensities o f  50 J/ cm2 and 100 J/ cm2 at different drug light intervals
Figure 46 Figure comparing the PDT damage to rabbit endometrium at 3 days using light intensities o f  
50 J/cm2 (left) and 100 J/cm2 (right). Topical application o f  0.5 ml o f  1 mg / ml o f  AIS2 Pc and a 
drug light interval of 1 hour were used. (Magnification x4)
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Figure 47 Figure comparing the PDT damage to rabbit endometrium at 3 days using light intensities of  
50 Joules/cm2 (left) and 100 Joules/cm2 (right). Topical application of 0.5 ml of 1 mg / ml of AIS2 
Pc and a drug light interval of 3 hours were used. (Magnification x4)
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Figure 48 Figure comparing the PDT damage to rabbit endometrium at 3 days using light intensities of 
50 Joules/ cm2 (left) and 100 Joules/ cm2 (right). Topical application of 0.5 ml of lmg / ml of A1S2 
Pc and a drug light interval of 6 hours were used. (Magnification x4)
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These changes are further demonstrated in Figure 48 where there are a few scattered 
glands in the endometrium when 50 Joules/cm2 were used compared to the complete 
destruction of all glands when 100 Joules/ cm2 of light energy is used. In one section 
there was a 5% circumferential area of grade 1 myometrial damage which was not 
seen in any of the other sections.
6.3.3 Discussion
6.3.3.1 PDT damage to normal rabbit endometrium using topical AIS2PC -  
optimal parameters
This experiment shows that with topical application of A1S2PC there is significant 
PDT damage to the glandular component of the endometrium. The drug light interval 
that showed the best PDT effect was 3 hours. The minimal PDT damage was seen at 
6 hours and patchy PDT damage was seen at 1 hour drug light intervals. This was 
predicted from the pharmacokinetics of A1S2PC after topical application using the 
fluorescence microscopy method as described in Chapter 5. Increasing the light dose 
from 50 Joules/ cm2 to 100 Joules/ cm2 increased the PDT damage at all drug light 
intervals. As a small thermal effect would not be of much consequence in the uterus, 
100 Joules/ cm2 would be preferred for PDT treatment. It appears therefore that for an 
optimal PDT effect in the rabbit uterus after topical application of AlS2Pc, the 
parameters that should be used are a drug light interval of 3 hours and a light dose of 
100 Joules/ cm2.
6.3.3.2 PDT damage of normal rabbit endometrium with systemic 
administration of AIS2Pc
Michelle Judd investigated PDT using systemic ALS2Pc. 1 mg/kg of AlS2Pc was 
administered intravenously via the central or marginal vein of the ear. From the 
results of the fluorescence studies, she chose drug light intervals of 1 hour and 24 
hours. The light source used was a copper vapour pumped dye laser (wavelength = 
675 nm) which was set to deliver 50 J (100 mW for 500 seconds). The light dose was 
fractionated into four doses. The light was delivered by a 2cm long cylindrically 
diffusing fibre with a 2 mm diameter. Two separate sites in each uterus were treated. 
The animals were killed at time intervals varying from 3 to 13 days. The results 
showed that PDT damage with a drug light interval of 24 hours was disappointing.
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There was no damage to the glandular structures, stroma or the underlying 
myometrium. This was contrary to what was suggested from the fluorescence studies. 
The best results were seen with a drug light interval of 1 hour. Here there was full 
thickness damage of the uterine wall with areas of myometrial necrosis. In this 
experiment, Judd compared the effect of AlS2Pc with ALA. The difference was that 
ALA showed a much better selectivity to the endometrial glands with minimal 
damage to the surrounding stroma or the underlying myometrium.
6.3.3.3 Comparison of systemic with topical administration of AIS2Pc for PDT 
-  short and intermediate effect on normal rabbit endometrium
Before comparing the results of Judd’s work with systemic administration of AlS2Pc 
with ours, it is important to take into consideration that there were differences in the 
methodology used in the two experiments. The main differences between the two 
have been outlined in Table 23.
The PDT effect using topical AlS2Pc is more like that of systemic ALA than that of 
systemic AlS2Pc. There was a high degree of selectivity towards the endometrial 
glands when compared to the PDT damage of the endometrial stroma and the 
myometrium. The maximum insult of the myometrium that was observed 
histologically was areas of haemorrhage and cellular infiltration in one uterine hom.
This may be explained by the fact that with systemic administration there is a higher 
concentration of the AlS2Pc in the myometrium and the stroma that after topical 
application.
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Parameter Michelle Judd’s thesis Present study
Light delivery
Laser Copper vapour pumped dye Diode
Wavelength 675 nm 670 nm
Fibre diameter 2 mm 1.6mm
Fibre tip length 2 cm 4 cm
Site of insertion Transcervically Transtubal
Number of lesions / horn 2 1
Power (mwatts/cm2) 100 100
Treatment time (seconds) 500 for each of 2 sites 1000 & 2000
Energy/area (J / cm2 ) 50 50 & 100 in each horn
Photosensitiser (AlS2Pc)
Route of administration Intravenously Topically
Dose lm g / kg lmg / ml
Volume Depending on body weight 0.5 ml per horn
Drug light intervals
Single lesion 1 and 24 hours 1,3 & 6 hours
Time of kill in days Time of kill in days
No of NZWR / time point 3 5 7 9 3 5 7 9
1 hour 1 0 2 1 1
3 hour Time scale not chosen 2
6 hour Time scale not chosen 1
24 hour 0 1 1 0 Time scale not chosen
Table 23 Table comparing the methodology in the experiments with topical and systemic 
administration of AlS2Pc for PDT of the normal rabbit uterus. Parameters compared include light 
delivery, photosensitiser administration, drug light intervals and time of tissue sampling.
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6.4 Experiment 2 - To study the long term effect of PDT of the rabbit 
endometrium after topical application of AIS2Pc
6.4.1 Methods of long term effects of PDT with topical AIS2 Pc
PDT regeneration in the rabbit uterus after cryosurgery occurs after 25 days. 
Cryosurgery is aimed at producing the same endometrial damage as PDT. The long 
term effects of PDT are therefore best studied by reviewing the histological effects at 
around 28 days.
For this experiment three rabbits (six uterine homs) were used. It was decided to use 
the optimal PDT parameters after topical application of AlS2Pc, namely a drug light 
interval of 3 hours and a light dose of 100 Joules/ cm2 for illumination.
A solution of 0.5ml of lmg/ml of AIS2 Pc was instilled in to both uterine homs as 
described in 6.3.1.3. The uterine cavity was exposed to light at a dose of 100 Joules/ 
cm2 at a drug light interval of 3 hours. Single treatments were done in all 
experiments. The animals were recovered as described in the section 5.5.5. The 
animals were killed at twenty nine days following PDT. Observations, tissue 
sampling and assessment of tissue damage were done as described in section 6.3.1.4 
and 6.3.1.5.
6.4.2 Results of long Term effects of topical PDT with AIS2 Pc
6.4.2.1 Whole animal effects at 29 days following topical PDT with AlS2Pc
There were no intraoperative or postoperative complications seen in the three rabbits 
until 29 days. There was no change in their behaviour or eating habits following the 
treatment. There were no wound complications
6.4.2.2 Macroscopic rabbit uterine changes at 29 days following topical PDT 
with AlS2Pc
There was no serosal reaction or damage to any surrounding organs when laparotomy 
was carried out 29 days later. There were no adhesions seen. This is illustrated in 
Figure 49.
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6.4.2.3 Microscopic rabbit uterine changes at 29 days following topical PDT 
with AIS2Pc
In rabbits 1 and 2, 25% of all the sections that were examined showed that there were 
no glandular elements persisting. However in the rest o f the sections there were a 
significant number o f glandular elements with intact stroma. No myometrial fibrosis 
was seen in any o f the sections. In rabbit 3 however there was significant damage 
with no glandular elements in 96% of the circumference o f the specimen. This effect 
was consistent in both uterine homs. In these uterine specimens the endometrium was 
flattened with loss o f villi however there was no myometrial fibrosis. These changes 
are illustrated in Figure 50. The grade and extent o f endometrial damage are 
illustrated in Figure 51.
Right uterine hom
Left uterine hom
Intestine
Anterior abdominal wall
Figure 49 Figure showing the rabbit uterus 29 days after PDT exteriorised from the abdominal cavity. 
PDT was done using 0.5ml of 1 mg/ml of AlS2Pc, a drug light interval o f 3 hours and a light dose of 
100 Joules/cm2. Both uterine horns do not show any serosal reaction and there are no adhesions or
damage to the bladder
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Figure 50 Transverse section of rabbit uterine horn showing PDT damage at 29 days using 0.5 
ml of 1 mg/ml of AIS2 Pc topically with a light dose of 100 Joules/cm2 at a drug light interval of
3 hours
□  Percentage Grade 2/3 damage 
■  Percentage Grade 0/1 damage
Rabbit 1 Rabbit 2 Rabbit 3
Figure 51 Percentage of uterine horn with grades 0/1 and 2/3 damage at 29 days with AIS2 Pc PDT at 
a 3 hour drug light interval with light intensities of 100 J
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6.4.3 Discussion
The PDT damage in rabbit 3 showed that with topical AlS2Pc, endometrial damage 
can occur to a sufficient depth and extent that prevents endometrial regeneration. 
Interestingly there was no other damage seen on histology suggesting a selectivity of 
AlS2Pc in the endometrial glands when applied topically. This supports the results of 
tissue distribution of the drug in the rabbit uterus when evaluated using fluorescence 
kinetics as described in Chapter 5. PDT damage in the other four uteri was however 
patchy. When PDT effects were seen, the damage was significant suggesting that the 
depth was sufficient to prevent regeneration even from the neighbouring 
endometrium. In other areas there was complete regeneration. The reasons for this 
may be that the entire uterus was not treated or that light did not reach the areas where 
glandular elements were seen to persist. This is an important consideration as when 
we express light dose we talk about the incident light. What is important is the light 
dose that strikes the molecule of AlS2Pc which can then get excited to produce the 
free oxygen radicals and the PDT effect. This re iterates the importance of an 
efficient intra uterine light delivery system. Experiments designed to evaluate newer 
intrauterine balloon devices for the delivery of light are described in chapter 7. It is 
important to realise that a uniform light delivery is not as important as every area of 
the endometrium receiving light above the threshold required for effective PDT.
6.4.3.1 Comparison of systemic with topicai administration of AlS2Pc for PDT 
-  long term effect on normal rabbit endometrium
Table 24 shows the main differences in the macroscopic and microscopic features 29 
days following PDT with systemic vs topical AlS2Pc. The methodology used in the 
experiments conducted by Judd for systemic AlS2Pc PDT has already been described 
in Table 23. There was a significant difference in the macroscopic appearance 
following systemic AlS2Pc compared with that of topical AlS2Pc. Out of the 4 
animals that were treated at this time point, one had an absent uterus which meant that 
the treatment caused sufficient necrosis and autolysis occurred of the necrosed organ. 
In two of the animals there were significant adhesions seen with only one animal 
having no serosal reaction. The uterus itself was pale, stenosed and significantly 
thinned out in two of the animals. In our study, there were no macroscopic changes 
seen in any of the animals treated.
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Systemic AlS2Pc Topical AlS2Pc
No of uteri 8 6
Absent uteri 1/8 0/&
Macroscopy 5/7 thinned and distorted All normal appearance
Villi Loss of all villi in 5/7 Loss of villi less marked
Absent glands 1/7
Epithelium Re epithelialisation 7/7 Re epithelialisation 6/6
Myometrium Myometrial fibrosis in 7/7 Myometrium intact
Table 24 Table comparing the macroscopic and microscopic features of rabbit endometrium 29 days 
after PDT treatment with systemic AlS2Pc and topical AlS2Pc
The microscopic assessment of PDT damage to the endometrium was different. Judd 
comments on the overall impression of the uterus after PDT at 30 days. In our study 
an attempt was made to make this assessment more objective with the development of 
a grading system and expressing the proportion of the uterine hom affected as a 
percentage of the whole section. Nevertheless, she reports loss of villi and few glands 
in 2/3 rabbits with the third rabbit having normal villi and glands. Our results 
compare favourably with this. 1/3 rabbits had almost no glands in both uteri. The 
other 2 rabbits showed no glands in 25% of the sections examined.
It appears therefore that even though the macroscopic effects of systemic PDT suggest 
a more powerful PDT action than topical application, microscopically the results 
appear to be similar. This may be explained by the fact that pthalocyanines exert their 
main phototoxic effect by destruction of a tissue’s vascularity rather than by direct 
cell killing mechanisms. Systemic application would therefore cause massive areas of 
necrosis due to vascular shutdown. This appears to be more selective with topical 
application. The hypoxia that may be produced by s vascular effect is maximal within 
1 hour of administration but does not seem to affect the PDT damage.
6.5 Conclusion
The experiments described in this chapter have demonstrated a range of tissue effects 
produced by PDT using topical AlS2Pc in the rabbit uterus. The aim is to produce a 
full thickness necrosis of all endometrial glands. An added advantage would be 
minimal myometrial damage so that healing with fibrosis and intrauterine adhesions
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would not result. It is clear that the optimal drug light interval was 3 hours and that 
increasing the light dose carried the advantage of causing a more global effect on 
endometrial damage without significant myometrial damage. The long term results 
following PDT were encouraging with one animal showing no attempts at endometrial 
regeneration at 29 days. These results compared favourably with the results obtained 
by Judd who used systemic AlS2Pc. Her results show a more dramatic macroscopic 
response with autolysis of a uterus and adhesion formation. The microscopic features 
however were similar suggesting more selectivity with topical AlS2Pc. It would 
appear therefore that PDT with topical AlS2Pc for the treatment of women with DUB 
would be preferable to systemic AlS2Pc as it appears to have the same PDT effect on 
endometrial glands without causing damage to surrounding structures. Furthermore 
systemic photosensitisation may be avoided with topical application.
These experiments also show the importance of understanding the pharmacokinetics 
of AlS2Pc so that the optical parameters may be manipulated to give an optimal PDT 
effect. Further studies would therefore be required to study the pharmacokinetics of 
AlS2Pc in the human uterus. This would improve our understanding of this drug and 
will enable us to maximise its potential for PDT for the treatment of DUB.
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[7] Intrauterine light
delivery for 
photodynamic 
therapy of the 
endometrium
7.1 Introduction
The effective delivery of light for photodynamic therapy of the endometrium is 
challenging. This is because of the wide individual variations in the size and shape of 
the uterine cavity. Similar problems have been encountered where PDT has been 
applied to other hollow organs like the oesophagus and the bladder.
Effective light delivery depends on the following factors. 1) The use of light of an 
appropriate wavelength at which maximum absorbtion by the photosensitiser used 
occurs. 2) A uniform distribution of light in the cavity so that all areas of the uterus 
are illuminated 3) the intensity of light at all sites must be higher than a threshold 
intensity required for photodynamic therapy.
Photodynamic therapy of the endometrium is being developed as an out patient 
technique. In order that this is feasible 4) the development of any light delivery 
device must be of a sufficiently low diameter so that it can be passed through the
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cervix with minimal cervical dilatation and hence discomfort. 5) treatment time must 
not be too long as this would preclude outpatient management. The effect of 
photodynamic therapy is that oxidative cell death occurs and for this a good tissue 
perfusion which supplies oxygen to the endometrium must be maintained during 
treatment. It is important therefore that 6) excessive distension of the uterus is 
avoided during treatment as this would compress myometrial and endometrial blood 
vessels and reduce the efficacy of the treatment.
An appropriate light source
As discussed in Chapter 3, Lasers are ideally suited for light delivery to the uterine 
cavity for the following reasons.
1) An exact wavelength can be generated depending on the photosensitiser’s 
absorption spectrum
2) They can be efficiently coupled to fibre optics thereby reducing the diameter 
of the device used making it easier to pass through the cervix
3) Higher powers may be used reducing the treatment time. The power 
however must not be high enough to produce a thermal effect.
Diode lasers are becoming increasingly available for clinical use and in addition to 
being portable are relatively inexpensive compared to conventional laser sources.
Light delivery devices
There are commercially available optical light fibres that have shaped and modified 
ends to create different beam profiles for treatment. The most commonly used fibres 
for PDT use are the microlens fibres, the cylindrical and spherical shaped fibres. 
Dwyer et al compared these existing photodynamic therapy delivery devices which 
have been summarised in the Figure 52. From this it can be seen that cylindrical and 
cleaved fibres have good efficiency but poor uniform irradiation whereas clear 
balloons with scattering medium have good uniformity of irradiation but poor 
efficiency. All the devices listed have the short coming of not being able to delivery 
light uniformly and efficiently over complex shapes like a uterine cavity. 
Furthermore as mentioned earlier devices that forces the tissue to assume a different 
shape may cause vascular compromise and reduce the PDT effect from lack of 
oxygen.
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Delivery device Uniform irradiation (>70%) Good
efficiency
>60%Simple surfaces 
of target
Complex 
surfaces of target
Cleaved tipped fibres No No Yes
Microlens fibres Yes No No
Spherical tipped fibres No No Yes
Cylindrically radiating fibres Yes No Yes
Clear balloons with scattering medium Yes Yes No
Figure 52 Comparison of existing photodynamic light delivery device systems (from Dwyer et al)
Fehr et al demonstrated that the insertion of three diffusing fibres in the uterus 
delivered an optical dose above the photodynamic threshold level even in the most 
remote areas of the uterus.
More recently however, Dwyer’s group reported the use of a soft silicone rubber 
based balloon which was different from the current commercially made balloons in 
that it had small chips of Titanium embedded in its wall. Advantages that were 
quoted are that the softness of the rubber enabled these balloons to be expanded easily 
to fit complex surfaces like the uterus without distorting or compressing the 
vasculature. The Titanium chips that were embedded in the wall caused optical 
scattering compared with the other commercially available balloons.
7.2 Aim of the study
1) To compare the intrauterine light distribution of the commercially available 
intra uterine light delivering balloon (Medlight SA) with balloons made as 
described by Dwyer.
2) To compare the intrauterine light distribution of these balloon devices with 
non balloon devices that can be used for intra uterine light delivery.
3) To ascertain the effect of intrauterine pathology on light distribution by these 
light delivery devices.
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7.3 Experiment 1 - Comparison o f the Medlight balloon with the UCL 
small balloon, UCL large balloon and the trifurcator device
7.3.1 Methods
7.3.1.1 Devices
7.3.1.1.1 Construction o f the UCL small and UCL large balloons using Dwyers 
technique
The balloon catheters consisted o f two parts. A soft shaped silicone balloon and a 
flexible nylon tube used for manipulation and inflation o f the balloon and to carry the 
optical fibre.
Construction o f  a  m odel o f  the uterine cavity
A model o f the uterine cavity was modelled by hand and smoothened with an 
abrasive. A cast was then made in plaster o f Paris. Molten dental paraffin wax was 
then poured into the mould. When it was cooling a metal rod was inserted in to the 
cervical end o f the uterine cast as shown in Figure 53.
Figure 53 Photograph showing the plaster of paris mould used for the pouring o f the molten paraffin 
wax and the uterine cavity cast with the metal rod cervical end.
The resulting cast o f the uterine cavity was not uniform. It was then decided to obtain 
a ready made uterine model (Limbs and Things Ltd, Bristol UK). This was bisected. 
The molten wax could then easily be poured into the cavity o f the uterus. Both halves 
were then kept in place by the use o f O bands Figure 54. The model was then kept in
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the refrigerator to cool with a metal rod at the cervical end that helped with the 
subsequent coating o f the cast with the silicone mixture.
Figure 54 Photograph showing the ready made uterine model which has been bisected. The dental 
wax which is poured into the uterine cavity when molten is also showed. The uterus is kept together
with the O bands.
P repara tion  of the silicone m ixture
Ingredients
Figure 55 showing ingredients for the making of the silicone mixture 
12 ml o f translucent medical grade silicone adhesive
1.5 grams Titanium dioxide (Ti02) powder with 1-3 (Jm diameter particle sizes 
35 ml o f ethyl ether anhydrous
162
The ingredients were mixed together in a 100 ml glass screw topped container. The 
components were stirred by hand, mixed thoroughly with an ultrasonic 
dismembranator and then stirred with a magnetic Teflon mixing bar on a stir plate for 
8 hours to disperse the TiC>2 particles.
C oating of the u terine cavity model with the silicone m ixture
\
Figure 56 showing the first and third coated uterine models
In a non sparking fume hood a coat o f the mixture was applied to the wax form by
dipping the model in to the solution allowing the excess to drop off and then place in a 
rack to cure as show in Figure 56.Each coating was approximately 100|Jm thick and 3 
coatings were used to make the balloon.
Use o f the lost wax technique to make the balloon
After curing overnight, the wax models were placed in boiling water to melt the wax 
and the balloon membrane was then flushed many times to remove the entire wax 
residue. The balloons were then allowed to dry.
A ttachm ent of the tube to the balloon
A nylon tube with an outer diameter o f 2 mm and an inner diameter o f 1mm was 
fitted with a female Luer lock which attached to a ‘Y ’ shaped port. This channel was 
used to introduce the light fibre and saline distension medium if  required. A two way 
stop cock was used at the syringe interface to the Y adaptor to allow for the catheter to 
be purged o f air. The distal end o f the nylon tube was sealed with a plug o f acrylic
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epoxy to prevent the optical fibre positioned inside the tube from perforating the 
balloon.
The end o f the nylon tube was rubbed with fine sand paper and attached to the dried 
balloon. The same silicone mixture was applied to paste the balloon to the 
smoothened end o f the tube.
The final product
Two balloons were made with this technique. A smaller balloon based on a model 
with a uterine cavity length o f 6cms and a larger one that was based on a uterine 
cavity length o f lOcms. For the purposes o f identification the small balloon had a 
green nylon tube attached to it and the larger balloon a red nylon tube.
Figure 57 the inflated small UCL balloon with the green nylon tube attached to it
►
Figure 58 the inflated large UCL balloon with the red nylon tube attached to it
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7.3.1.1.2 The Medlight S.A. uterus balloon light diffuser model UB
The Medlight SA is a uterus balloon light diffuser which has been developed in 
collaboration with the Swiss University Hospital o f Zurich (Dr P Wyss). This is a 
commercially available balloon that has been used for PDT of the endometrium in 
women with menorrhagia.
Figure 59 The Medlight S.A. uterus balloon light diffuser model UB
The balloon is smeared with a gel and then inserted into the introducing tube. The 
balloon is then inserted into the uterine cavity by means o f the introducing tube. The 
introducing tube is then pulled out leaving the deflated balloon in place. The balloon 
is then inflated with normal saline using a syringe.
Figure 60 Simulation showing the insertion o f  the M edlight balloon into the uterine cavity
The optical fibre diffuser is then introduced into the balloon catheter and fixed with 
the use o f a SMA connector. The optical characteristics o f this balloon are quoted as 
a transmission o f > 70% and a balloon irradiation surface o f 12.4 cm2 .
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7.3.1.1.3 The Gynelase system (Trifurcator)
Out o f the current second generation endometrial thermal ablation technologies, the 
Gynelase system utilises lasers as the heat source.
Figure 61 the Trifurcator
This system is manufactured by STORZ (Tuttlingen, Germany) and is composed o f a 
compact tabletop 20W, 830 nm diode laser and a disposable handset. The system can 
emit laser beams through each o f the three channels simultaneously (see Figure 61) 
and can be manipulated individually on each side by the operator in response to the 
shape o f the uterine cavity. It did not require distension o f the uterine cavity for 
activation o f the device. We contacted the company who confirmed that a 645 nm 
laser may be used and permission was obtained for the system to be modified for light 
delivery for this experiment.
Figure 62 simulation showing the EL1TT procedure handset insertion
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In practice the operator advances the distal end o f the handpiece to the fundus and 
adjusts the side diffusers forming a butterfly wing contour that conforms to the shape 
o f the uterine cavity as shown in
Figure 62. The laser is then activated.
7.3.1.2 Comparison o f light devices
7.3.1.2.1 Uterine specimens
Women at University College London Hospitals and Harold wood hospital in 
Romford Essex who were undergoing hysterectomy for DUB not responding to 
medical treatment were approached. Permission was obtained to use the uterine 
specimens for the testing o f the light devices. It was discussed with the department o f 
pathology with regards the length o f time allowed for the specimens to be without 
formalin. An upper limit o f 8 hours was set to avoid severe tissue autolysis and 
difficult histopathological evaluation. Provision was made to keep the tissues moist 
with normal saline. As a consequence o f this it was decided that experiments would 
be done on site in specimens from women recruited at Haroldwood Hospital. The 
laser power used for the experiments were below that required to produce any thermal 
damage, so no biological changes were expected in the tissue. Once these 
measurements were completed the uterus was bisected and measured, immersed in 
formol saline and sent for histological assessment, as was routine practice. This 
study was approved by the ethics committee o f the University College London 
Hospitals and Barking Havering and Redbridge Hospitals and all patients gave 
written, informed consent prior to their participation.
7.3.1.2.2 Light measurements 
Preparation o f the light detecting fibres
A 400 micron core optical fibre with an spherical, isotropically diffusing tip (Rare 
earth medical, USA) was measured and a small piece o f tape attached as a “flag” so 
that, when the fibre was passed down a 18 gauge intravenous cannula (Vygon 
laboratories France) as far as the flag, the tip o f the fibre was flush with the tip o f the 
cannula. The proximal end o f the detector fibre was butted against a photodiode 
which was connected to a trans impedance amplifier. The analogue input was
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digitised and read into a computer using AcquiVision (West Sussex, England) 
software. A series o f results were obtained for each experiment.
Figure 63 Pictures showing the locations o f  the spherical isotropically diffusing fibres in the uterus 
and the hysteroscopic guided placement o f  the cannulae. The fibres are flagged and passed through the
cannulae.
Insertion o f the intravenous cannulae into the uterus
The uterine specimen was suspended and secured. Five 18 gauge intravenous 
cannulae were inserted in to the endometrial cavity through the serosal surface o f  the 
uterus. A 6 mm flexible hysteroscope was passed in to the uterus with air as the 
distending medium. The tips o f  the cannula were inserted till they were flush with the 
endometrial surface. The cannulae were inserted at the following positions. 1) In the 
middle o f the anterior wall o f the uterus 2) in the middle o f the posterior wall o f  the 
uterus 3) the right and 4) left uterine cornua and the 5) cervix as shown in Figure 63. 
If the cannulae did not fit snugly in the uterine wall -  a braided silk suture was used to 
secure it in position. This ensured that there was no movement o f the cannula 
between measurements.
7.3.1.2.3 Insertion o f the light devices
The light devices were inserted after dilatation o f  the cervix to 6 Hegars. The UCL 
large balloon device was always tested last as it was then easier to pass and did not 
interfere with leakage o f gas.
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7.3.1.2.4 Illumination o f light delivery devices 
Light fibre
The light delivery device was inserted through the cervix. A 2 cm long spherically 
diffusing fibre was inserted so that it was in the centre o f the balloon. The proximal 
end o f the light fibre was connected to the laser. With the balloon devices, distension 
o f the balloon was achieved by a gravity feed o f water at a head o f  1 metre. The 
Gynelase device did not need any uterine distension.
Laser system
The light source used was a Diode Laser (Diomed Ltd, Cambridge, UK) which 
emitted at a wave length o f 630nm. With the room dimmed, the laser was activated to 
deliver 100 mW. This is illustrated in Figure 64 Recordings were made o f  the light 
levels detected by each o f the fibreoptic sensors to build up a picture o f the light 
distribution within the uterus.
A diagrammatic representation o f the set up used for the illumination o f the test 
devices and the recording o f the light intensity within the uterine cavity is shown in 
Figure 65.
Figure 64 showing the intrauterine balloon illuminated with the laser light at 635 nm. The light at the 
endometrial surface at 5 fixed points were measured with each o f  the devices.
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Figure 65 Diagrammatic representation of the set up used for testing intrauterine light illumination of
the different devices.
7.3.2 Results
Eight uteri were used in experiment one. Hysterectomy was performed in these 
perimenopausal women for dysfunctional uterine bleeding (DUB) that was not 
responding to medical therapy. None of them had a previous endometrial ablative 
procedure done. Dimensions of the seven uteri were of average size and one uterus 
was mildly enlarged with a cavity length of 10 cms. The uterine specimens were 
collected from theatre immediately after removal and all experiments were completed 
within two hours. After the experiment was over the uterine specimens were bisected 
before placing it in saline. None of the specimens had any intrauterine pathology. 
Accurate histopathological evaluation of the uterine specimens was possible in all 
cases as significant autolysis had not occurred. Histology confirmed DUB in all 
cases. There was reporting of adenomyosis in two cases which was mild.
7.3.2.1 Comparison of the uniformity of intra uterine light distribution
The light distribution in the uterine positions with each device is shown in Figure 66. 
There is poor illumination of the cornual regions with all the balloon devices. The
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UCL small balloon however was better than the commercially used Medlight balloon 
in that 14% o f the light was in the cornual region compared with only 8%.
Medlight
■ Right cornual
■ Anterior 
35% □ Left cornual
□ Posterior
□ Right cornual 
■ Anterior
□ Left cornual
□ Posterior
UCL large
10%
38% /
11%
a Right cornual 
■ Anterior 
P Left cornual 
□ Posterior
Trifurcator
■ Right cornual
■ Anterior
□ Left cornual
□ Posterior
Figure 66 showing the mean light distribution in the anterior, posterior, right and left cornual positions 
o f  the uterus with the Medlight balloon, UCL small balloon, UCL large balloon and the trifurcator
device.
The UCL large balloon did not show a difference from the Medlight balloon. The 
trifurcator however showed the most uniform distribution o f light. However the 
anterior wall o f the uterus only received 17% of the light. This may be explained by 
the shape o f the device. The side arms project well into the cornual ends whereas the 
middle arm is shorter and in an anteverted uterus more illumination will occur in the 
posterior wall which is more in line with the axis o f the cervical canal.
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7.3.2.2 Comparison of the intrauterine light intensity o f the uterine d ev ices
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Figure 67 showing box plots o f  the light intensities o f  the Medlight balloon, UCL small balloon, UCL 
large balloon and the trifurcator at each o f  the uterine positions. The length o f  each box shows the 
range within which the central 50% o f the values fall, with the box edges (called hinges) at the first and 
third quartiles. The centre horizontal line marks the median o f  the sample.
A box plot has been used to demonstrate the light intensity at each uterine position see 
Figure 67. To describe the information contained in a box plot, a few terms must be
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defined. H spread is the absolute value o f the difference between the values o f the 
two hinges. Fences define outside and far outside values and are defined as follows: 
Lower inner fence = lower hinge - (1.5 x (H spread)); Upper inner fence = upper 
hinge + (1.5 x. (FI spread)); Lower outer fence = lower hinge - (3 x (H spread)) and 
Upper outer fence = upper hinge + ( 3 x ( H  spread)). The whiskers show the range of 
observed values that fall within the inner fences. Values between the inner and outer 
fences are plotted with asterisks. Values beyond the outer fences, called far outside 
values, are plotted with empty circles.
The light illumination in the left cornual region is lower that all other positions. The 
median light intensity in the anterior and posterior uterine positions was highest with 
the Medlight balloon. The median light intensities in the right and left cornual 
positions were highest in the trifurcator.
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Figure 68 showing the average intrauterine light intensity o f  the Medlight balloon, UCL small balloon,
UCL large balloon and the trifurcator device.
The light illumination at all positions for each device is compared in Figure 68. The 
UCL large balloon showed the lowest light intensity at all positions. There was little 
difference between the minimum light intensity of each device.
Summary of all positions
Device tested
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7.3.3 Discussion
There are two characteristics of an intra uterine delivery device that is essential for 
PDT of the endometrium to be effective. This includes uniformity of the light 
distribution and more importantly every area of the endometrium must have a 
minimum light intensity for activation of the photosensitiser.
Uniformity of light illumination
From the results of the experiment 1, it was surprising that trifurcator gave the most 
uniform illumination of the uterine cavity. The advantages quoted for balloon devices 
are that the light is distributed evenly on the surface of the balloon causing a more 
uniform illumination. This is true of other balloon devices tested in other hollow 
organs like the bladder and the oesophagus. It is the peculiar shape of the uterine 
cornua that prevents the balloon filling that area. Even the balloon using Dwyers 
recipe, which should be easily distensible and can take the shape of whatever organ it 
is in, was unable to overcome this.
Minimum light intensity
Unlike other organs, a relatively high light intensity would not harm the uterus as 
purely thermal effects are in use for endometrial ablation. It is therefore the minimal 
light intensity that is important. The UCL large balloon had the lowest light intensity 
with there being no significant difference between the other devices. Impregnating 
the balloon wall with Titanium chips did not appear to have an effect on the minimum 
light intensity.
Effect of a bigger balloon on intrauterine light illumination
The results of the UCL large balloon were disappointing. This was due to the fact that 
in most of the experiments the balloon could not be distended to the full capacity. In 
the one uterus with a cavity length of 10 cms, the UCL large balloon matched the 
minimum light intensity and uniformity of light distribution of the other balloons
The trifurcator for intrauterine light illumination
From the data it appears that the trifurcator was the best option for intra uterine light 
delivery. However the arms of the trifurcator were coated to prevent thermal damage 
as it is designed for heat delivery. It is possible that the coating interfered with light 
illumination.
174
To address the issues discussed above, we wanted to investigate the effect of 1) 
adding light fibres into a balloon device and 2) creating light fibres delivered through 
non coated tubes on the uniformity and intensity of intra uterine light illumination.
7.4 Experiment 2
a) The effect of adding another light diffuser into a balloon device on 
the intrauterine light delivery of the balloon devices.
b) Comparison of the balloon devices with a custom made bifurcator 
device for intrauterine light delivery.
7.4.1 M ethods
7.4.1.1 Devices
Construction of a bifurcator device for intrauterine light delivery
Two nylon tubes with an outer diameter of 2 mm and an inner diameter of 1mm were 
attached together side by side. The distal ends of the tube were remodelled using heat 
to take the shape of the fundus of the uterus as shown in Figure 69. The proximal end 
of the tubes was fitted with a female Luer lock which attached to a ‘Y’ shaped port. 
This channel was used to introduce the light diffuser fibre and saline distension 
medium if required. The tubes had metal rods which kept it straight. This was 
inserted in to the uterus up to the fundus. The metal rods were removed. The light 
fibre was first inserted into the right tube The light intensity measurements taken. The 
measurements were then taken with the fibre inserted into the left tube. A two way 
stop cock was used at the syringe interface to the Y adaptor to allow for the catheter to 
be purged of air.
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Figure 69 showing the design o f  the bifurcator device. The light fibre was inserted into each tube at 
different times for the purposes o f  the experiment. If a 2 way beam splitter was used then the two
fibres could be inserted at the same time.
Construction o f a balloon with an additional light diffuser fibre
Figure 70 the bifurcator in the UCL small balloon
A balloon was made as described for the UCL small balloon using Dwyers technique 
see 7.3.1.1. Instead o f using the nylon tube as described, a bifurcator was inserted 
into the balloon as shown in Figure 70. The Y shaped port was used to distend the 
balloon with saline after it was inserted in to the uterus. The distal end o f the nylon 
tube was sealed with a plug o f acrylic epoxy to prevent the optical fibre positioned 
inside the tube from perforating the balloon. The device is illustrated in Figure 65.
176
Comparison of the light delivery devices
The Medlight balloon, UCL small and UCL large balloons were compared with the 
bifurcator device in the UCL small balloon and the bifurcator device without a 
balloon using the methodology as described in section 7.3.1.2.
7.4.2 Results
Seven uteri were used in experiment 2. Hysterectomy was performed in these pre 
menopausal women for dysfunctional uterine bleeding (DUB) that was not responding 
to medical therapy. None of them had a previous endometrial ablative procedure 
done. Dimensions of the seven uteri ranged from a cavity length of 6cms to 9 cms. 
The uterine specimens were collected from theatre immediately after removal and all 
experiments were completed within two hours. After the experiment was over the 
uterine specimens were bisected before placing it in saline. None of the specimens 
had any intrauterine pathology. Accurate histopathological evaluation of the uterine 
specimens was possible in all cases as significant autolysis had not occurred. 
Histology confirmed DUB in all cases.
7.4.2.1 Comparison of the uniformity of intra uterine light distribution
The uniformity of the light distribution within the uterus using each of the devices 
used is illustrated in Figure 71. The balloon devices with a single light diffuser in 
them had similar light distributions in that the majority of the light was delivered to 
the anterior and posterior walls of the uterus. The areas that were poorly illuminated 
were the cornual regions of the uterus. When the bifurcator was inserted in to a 
balloon, there was good illumination of the left cornual region with poor illumination 
of the right cornual region of the uterus and the anterior wall of the uterus. The 
bifurcator showed almost perfect uniform illumination of all areas of the uterus.
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Figure 71 showing the mean light distribution in the anterior, posterior, right and left cornual positions 
of the uterus with the Medlight balloon, UCL small balloon, UCL large balloon, bifurcator in UCL 
small balloon and bifurcator device without a balloon.
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7.4.2.2 Comparison of the intrauterine light intensity of the uterine devices
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Figure 72 showing box plots of the light intensities of Medlight balloon, UCL small balloon, UCL large 
balloon, bifurcator in UCL small balloon and bifurcator device without a balloon at each of the uterine 
positions. The length of each box shows the range within which the central 50% of the values fall, with 
the box edges (called hinges) at the first and third quartiles. The centre horizontal line marks the
median of the sample.
The light intensity at each uterine position with each device is shown in Figure 72. 
There was no difference between the three balloon devices with a single light
179
diffusing fibre. The bifurcator in a balloon device showed a higher light intensity in 
all the positions but the highest light intensity was seen with the bifurcator device 
without a balloon.
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Figure 73 showing the average intrauterine light intensity of the Medlight balloon, UCL small balloon, 
UCL large balloon, bifurcator in UCL small balloon and bifurcator device without a balloon.
The overall intrauterine light intensity seen with each device is shown in Figure 73. 
The minimum light intensity for the Medlight, the UCL small and the UCL large are 
similar. The minimum intensity is higher with the bifurcator in the balloon device and 
the bifurcator device.
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7.4.2.3 Comparison of the intrauterine light intensity of the uterine devices at 
the level of the cervix
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Figure 74 showing the light intensity at the level o f  the cervix with each o f  the devices tested
The illumination o f the uterine cavity at the level of the internal os is shown in Figure 
74. The UCL small, Medlight and the bifurcator in the UCL small balloon give 
minimal illumination at the level o f the cervix. The UCL large balloon and the 
bifurcator device have a larger range o f intensity values. All the devices have outliers 
and other than for the bifurcator these are in the “far outside values” range as 
described in section 7.3.2.1.
7.4.3 Discussion
As discussed earlier the two characteristics o f an intra uterine delivery device that is 
essential for PDT of the endometrium to be effective are the uniformity o f light 
distribution and the minimum light intensity for activation o f the photosensitiser.
Uniformity o f light illumination
The addition o f another light diffuser fibre in to the balloons which had titanium chips 
impregnated in to the wall did not have any effect on the uniformity o f intrauterine 
light distribution. There was preferential illumination o f the posterior wall and the 
left cornual region o f the uterus. This may be explained by the positioning o f the two
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ends of the bifurcator in the balloon when inserted into the uterus. The bifurcator 
however gave excellent results with almost all areas of the uterine cavity being 
illuminated uniformly. The results of the bifurcator were better than that of the 
trifurcator from experiment 1. As discussed before, the trifurcator has been designed 
to deliver heat and not light and shadowing would result in interference of light being 
uniformly distributed. The ends of the bifurcator were shaped almost like that of an 
intrauterine contraceptive device which has been designed to be retained in the uterus 
by its shape. This design allowed for illumination of the cornual regions of the uterus 
which are essential if PDT is to be successful.
Minimum light intensity
The minimum light intensity of the Medlight balloon, UCL small and large balloons 
were similar. This confirmed the results that were obtained in experiment 1. The 
minimum light intensity was increased by adding another light diffuser in to the 
balloon as seen in the bifurcator in balloon device. The best improvement in the 
minimum light intensity however was seen with the bifurcator device. This could be 
attributed to its design whereby the light fibres actually go into the cornual regions of 
the uterus where the light intensity is usually the lowest.
Illumination at the level of the cervix
An ideal light delivery device would produce minimal illumination at the level of the 
cervix. This is important to avoid PDT destruction and subsequent cervical stenosis. 
One of the complications of all endometrial ablative techniques is cyclical midline 
pain from haematometron caused by cervical stenosis. All the devices do not show 
significant cervical illumination. However all devices show outliers and even “far 
outside value”. This indicates that on a particular day, sufficient illumination of the 
cervix did occur. If sufficient concentration of photosensitiser was also present in the 
cervical canal then PDT damage would have occurred.
7.5 Experiment 3 - To investigate the effect of intrauterine pathology on 
light distribution in the uterus.
7.5.1 Methods
Three women who were undergoing hysterectomy for abnormal MBL and had 
intrauterine pathology were identified.
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The pathology identified were
1. Intrauterine scarring from a previous transcervical resection of the endometrium.
2. A 5 cm Type 2 submucosal fibroid situated in the fundus of the uterus
3. A small intrauterine septum
The devices tested were the Medlight balloon, UCL small balloon, UCL large balloon, 
trifurcator, bifurcator in UCL small balloon and the bifurcator without a balloon 
device. The methods and the set up for the comparison of the light delivery by these 
devices were the same as that described in Experiment 2.
7.5.2 Results
7.5.2.1 Comparison of intrauterine light delivery of the Medlight balloon, UCL 
small, UCL large, bifurcator in UCL small balloon, trifurcator and 
bifurcator device without a balloon in a uterus with a previous 
transcervical endometrial resection.
The worst results were from the trifurcator. This was because as the uterine cavity 
was smaller it was difficult to manipulate the trifurcator and extend it fully. A similar 
problem occurred with the UCL large balloon. There was no difference with the 
Medlight balloon, UCL small and bifurcator in UCL small balloon with regards the 
minimum light intensity. The UCL small balloon and the bifurcator in UCL small 
balloon gave a high illumination of the cervix which was undesirable. The best 
results came from the bifurcator without a balloon device which gave a better 
uniformity and intensity of illumination with a low cervical illumination.
183
Li
gh
t 
in
te
ns
ity
 
(a
rb
itr
ar
y 
un
its
)
4500
o
_Q
X_
n .
x_
x
o
X
♦  Anterior 
■  Right cornual 
Left cornual 
O Posterior 
X Cervix
Medlight UCL small UCL large Bif in balloon Trifurcator Bifurcator
Device tested
Fi
gure 75 showing the light distribution with each o f  the devices (vertical line) in a uterus with a previous
transcervical resection o f  the endometrium
7.5.2.2 Comparison of intrauterine light delivery of the Medlight balloon, UCL 
small, UCL large, bifurcator in UCL small balloon and bifurcator 
without a balloon device in a uterus with a 5cm submucous fundal 
fibroid
Figure 76 showing the 5cm type 2 submucosal fundal fibroid. Note narrowing o f  the cornua
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The bifurcator without a balloon device gave the best uniformity o f illumination with 
sparing o f the cervix. However the light intensities recorded for all the devices were 
low.
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Figure 77 showing the light distribution with each o f  the devices (vertical line) in a uterus with a 5cm
Type 2 submucosal fundal fibroid.
7.5.2.3 Comparison of intrauterine light delivery of the Medlight balloon, UCL 
small, UCL large, bifurcator in UCL small balloon and bifurcator 
without a balloon device in a uterus with septum.
Figure 78 and Figure 79 demonstrates the limitation o f the balloon devices. All the 
balloon devices gave a very poor illumination o f the right cornual region. The 
bifurcator was able to reach the cornua and thereby produce sufficient illumination.
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Figure 78 showing the light distribution with each o f  the devices (vertical line) in a uterus with an
intrauterine septum
Figure 79 showing how the bifurcator overcom es the midline uterine septum to deliver light to the 
uterine cornua. The balloon devices were not able to reach the fundus o f  the uterus.
7.6 Discussion
The presence o f any change in the structure o f the endometrial cavity either by a 
congenital septum or fibroids affects the overall light intensity irrespective o f the 
device used. The balloon devices are affected more by these structural changes than 
the bifurcator device. One o f the difficulties facing gynaecologists today is the 
treatment o f woman with heavy periods who have had an endometrial ablative
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technique that has failed. A second ablative technique may only be considered with 
the first generation resections or ablations and required a considerable amount of 
operator skill. The bifurcator however was able to produce sufficient illumination of 
all parts of the uterine cavity. This is promising in that with a light delivery device 
like the bifurcator PDT may become another modality of treatment in these situations.
7.7 Conclusions
This series of experiments have revealed many interesting facts about intrauterine 
delivery devices. The results of PDT to date have used balloon devices. These 
studies have either used custom made balloons or the Medlight balloons. Dwyers 
suggestion of impregnating titanium in the wall of the silicon balloon to improve the 
uniformity and the intensity of light delivery demanded further investigation. 
Furthermore the ability of these balloons to adapt to the shape of the uterine cavity 
when distended made them a desirable alternative to the Medlight balloon. In this 
series of experiments however, we could not demonstrate any improvement of these 
balloons on the Medlight balloon. Altering the size of the balloon, even in the larger 
uterus, did not make a difference. In the smaller uterus, the bigger balloon failed to 
distend and results were disappointing.
The addition of a second light diffuser fibre did improve the intensity of the light 
delivered with a reduction in the uniformity of light distribution. We did not find this 
device more difficult to insert into the uterus when compared to the other devices.
The use of non balloon devices like the bifurcator and the trifurcator gave the best 
uniform illumination of the uterine cavity. This was because the side arms of both 
devices were designed like an intra uterine contraceptive device and fitted into the 
cornual ends of the uterus. The trifurcator was not designed for light delivery and 
considerable shadowing reduced its efficacy. The bifurcator was therefore 
constructed with nylon tubing and produced a higher intensity of light that all other 
devices. We found the insertion of the bifurcator easier than that of the balloon 
devices.
Photodynamic therapy of the endometrium may be improved by increasing the 
uniformity of light delivery and ensuring that all areas of the endometrium receive a 
light intensity above that of a minimum threshold. These series of experiments 
suggest that a non balloon device like the bifurcator would produce better results than
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that of balloon devices that are currently in use for PDT. An additional advantage for 
clinical use is that uterine distension is not required with the bifurcator. This reduces 
uterine cramps and discomfort for the woman and makes it more attractive for 
outpatient use.
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[8] Interstitial laser 
photocoagulation of 
uterine fibroids
Interstitial laser photocoagulation (ILP) of uterine fibroids is a feasible and safe 
procedure. As discussed in Chapter 3 most of the results reported are by a single 
surgeon using the KTP; YAG laser without detailed follow up of the women treated. 
It is important to therefore standardise the methodology using newer portable less 
expensive diode lasers and to quantify the effect of this treatment on fibroid 
shrinkage.
Twelve women with l£  fibroids underwent ILP for the treatment of uterine fibroids in 
our centre during the period 1999 to 2000. This group of women were followed up by 
serial MRI scans during the period of the thesis to objectively evaluate the effect of 
ILP on uterine fibroids. Nine more women with l^f fibroids underwent ILP for uterine 
fibroids during the period of the thesis and were similarly followed up. Results of 
both cohorts of women will be included in the data analysis.
The purpose of this study is to perform a detailed assessment of the effect of ILP on 
women with uterine fibroids and to critically evaluate its potential clinical role.
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8.1 Methods
8.1.1 Patient recruitment
Patients for the study were recruited from the outpatient clinics at the University 
College London Hospitals (UCLH). Most of the women treated had menorrhagia as 
the primary symptom. Other symptoms included dysmenorrhoea, infertility and 
pressure effects. All patients had declined conventional surgical treatment of open 
myomectomy or hysterectomy and were referred to us for consideration of Interstitial 
Laser Photocoagulation (ILP). Eligibility for entering the trial was a clinical 
evaluation that showed that the uterus was smaller than a 16-week pregnant uterus and 
a screening MRI or US that showed that no single fibroid had a diameter greater than 
10 cms. An outpatient hysteroscopy was then performed to see if there were any 
other fibroids that could be treated by transcervical resection. Patients were 
counselled regarding the risks, benefits, alternatives and fertility issues associated 
with ILP. The risks of a laparoscopic procedure and the risks of bleeding from the 
treatment site necessitating open myomectomy or hysterectomy to arrest the 
haemorrhage was discussed in detail. This study was approved by the ethics 
committee of the University College London Hospitals and all patients gave written, 
informed consent prior to their participation
8.1.2 Technique used for ILP
The in vitro study by Gordon et al (see section 3.4.4.1) showed that a single fibre 
produced an ellipsoidal lesion of coagulative necrosis of 10-14 mm diameter. If 2 
fibres were used the area increased to a diameter of 20 mm. Before surgery the 
fibroids were localized and the volume estimated by MRI. The volume of each was 
estimated by assuming it to be roughly spherical (for radius r, volume = 4/37ir3). The 
calculation for the treatment required for each fibroid was based on aiming to get all 
parts of the fibroid within 2 cms of a needle tip.
Prior to laser treatment, the optical fibres (400 pm glass core) were prepared by 
stripping about 10mm of plastic cladding off the tip and cleaving the core to leave 
about 3mm of clean glass protruding from the cladding. Each fibre was then measured 
and a small piece of tape attached as a “flag” so that, when the fibre was passed down 
a 16 G needle (Tuohey, 110 mm long with 1 cm gradations, Portex, England) as far as
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the flag, the tip of the fibre protruded by 2-3 mm from the tip of the needle. The fibres 
were sterilised by putting them through an automatic endoscope cleaning cycle using 
Tristal 700 (active ingredient chlorine dioxide, Tristel Ltd, Snailwell UK).
A general anaesthetic was used in all cases. The patient was cleaned and draped as 
for a standard laparoscopy with a Spackmann cannula being used as the intra uterine 
manipulator. With the woman in the dorsal position a Veress needle was inserted in 
the umbilicus. A carbon dioxide pneumoperitoneum was then created up to a pressure 
of 20 mm Hg. A 10 mm trocar was inserted in the umbilicus and a 10 mm 
laparoscope was used. The uterus was checked and the fibroids confirmed. A second 
port was inserted in the right flank at least 8 cms from the midline taking care to avoid 
the inferior epigastric vessels. The patient was then tilted head downwards in to a 
Trendelenberg position. An atraumatic grasper was used to gently remove all bowel 
from the pouch of Douglas and retract it using gentle traction. A suction irrigator was 
primed and ready for use
Two to four 16G Tuohey needles were inserted into the substance of the fibroid under 
laparoscopic guidance so that their tips were 2 cms apart, aiming to get all parts of the 
fibroid within 2 cms of a needle tip. The optical fibre tips were pre-charred by dipping 
them in a drop of the patient’s blood and energising with laser light for a few seconds 
as this has been shown previously to give more predictable tissue heating (Amin et 
al). On one day, an attempt was made to simplify this procedure by simply heating 
the fibre tip in a bare flame, although this was unsuccessful, as described below. The 
fibres were then inserted through the Tuohey needles and were connected to a 
semiconductor diode laser with a 4-way beam splitter (Diomed 25, Diomed Ltd, 
Cambridge, UK). The power used was 3.5 W per fibre for a planned duration of 300 
seconds. For larger lesions, the fibres were repositioned after light delivery by pulling 
them back by 1-2 cms and the dose repeated. During light delivery, the bowel was 
retracted from the area of treatment and constant laparoscopic surveillance was 
maintained for bum through (signs that the laser effect might have reached the 
opposite side of the uterus) or bum back (signs of coagulation of the tissue around the 
sites where the needles entered the uterine wall). After treatment was completed, the 
fibres and the Tuohey needles were removed, and any active bleeding from the serosal 
entry points was treated with bipolar cautery. All patients were kept in hospital 
overnight after treatment for observation.
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Figure 80 Semiconductor 805 nm Diode Laser Diomed 25W , Diomed Ltd Cambridge UK)
Figure 81 -  A 4-way beam splitter allows 4 freshly cleaved optical fibres (400pm ) to be used
simultaneously for ILP treatment
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Figure 82 Picture showing 10 mm laparoscope in umbilical port and grasper in the right flank (used for 
retracting bowel from the pouch o f  Douglas) and the Tuohey needles with the fibres inserted through 
them. Four fibres were used with a beam splitter. The flags on the fibres are also shown.
Figure 83 Picture showing the Tuohey needles inserted into the fibroid being treated. The 1cm 
graduations are visible. The aim is to keep a distance o f  2 cm s between each needle point.
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8.1.3 Follow up -  MRI imaging of fibroids
All patients had repeat measurements o f the size o f the treated fibroids during follow 
up. MRI measurements and patient assessment were planned at 6 weeks 6 and 12 
months after treatment in the first series. In the second series follow up was 3, 6 and 
\y  J9 months following treatment. Any patient who was unhappy with the clinical 
response was offered conventional surgery.
8.1.4 MRI imaging of fibroids before and after treatment with ILP
Figure 84 MRI showing subserous posterior wall fibroid with 2 diameters being measured
8.2 Results
8.2.1 Patient details
Twenty one women with 3^ symptomatic uterine fibroids were treated with ILP. 
Thirteen women had single fibroids, five women had two fibroids and three women 
had three fibroids. The age group ranged from 26 to 51 years with a mean age o f 39.2 
years. 14 women were Caucasian while 7 women were black (African descent). Nine 
o f the women treated were nulliparous.
8.2.2 Presenting symptoms
The main complaint in 13 women was an increased MBL. In this group five women 
also had dysmenorrhoea with two women complaining of pressure effects. The main 
complaint in the remaining eight women was pressure effects. In this group two
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women were also concerned about fertility with one woman wanting treatment prior 
to referral for in vitro fertilisation. One woman complained of a severe dull pelvic 
ache mainly in the right iliac fossa.
8.2.3 Effect of ILP on uterine fibroid volume 
21 women with 32 fibroids were treated with laparoscopic ILP.
Fibroid No Initial volume 
(cm3)
Volume at 6 
weeks (cm3)
Volume at 6 
months (cm3)
Volume at 12 
months (cm3)
Reduction
%
18 353 423 326 97 72
19 10 11 9 17 -77
20 9 10 10 10 -10
21 30 42 22 6 79
22 33 52 33 30 10
23 37 50 20 12 69
24 12 3 3 2 68
25 28 40 50 11 61
26 54 59 34 Not done 62 at 6 months
27 107 145 67 45 58
28 152 161 105 171 -13
29 5 12 3 Not done * Long term
30 44 45 44 Not done T o n g  term
31 258 140 196 226 12
32 29 40 24 9 79
33 167 191 176 160 4
Table 25 Table showing the volume changes in fibroids (in cm3 measured by MRI) following 
treatment by laparoscopic ILP -  Series 1.
Treatment produced shrinkage in 17 of the women and in 24 fibroids. Therefore 81% 
of women treated had shrinkage of their fibroids. The volume changes of all fibroids 
are represented in Table 25 and Table 26. In this series the time points were 6 weeks, 
6months and 12 months. 3 patients did not have MRI scans at 12 months. In 2
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patients however (*Long term) the patients wpfe had MRI scans at 18 months and is
X  A
discussed in 8.2.13.
Fibroid 
. No.
Initial volume 
(cm3)
Volume at 3 
months (cm3)
Volume at 6 
months (cm3)
Volume at 
12 months 
(cm3)
Reduction at 12 
months
%
1 244 124 119 109 75
2 68 21 19 Not done 72 at 6 months
3 8 1 0 Not done 100 at 6 months
4 198 176 164 169 15
6 116 139 135 148 -28
7
23 19 26 17 26
8 19 4 4 1 95
9 67 69 73 107 -60
10 166 72 68 58 65
11 94 70 72 Not done 23 at 6 months
12 50 39 38 Not done 24 at 6 months
13 29 28 7 Not done 76
14 47 38 30 30 36
15 4 2 1 1 75
16 25 11 Not done Not done 56 at 3 months
17 12 5 Not done Not done 58 at 3 months
Table 26 Table showing the volume changes in fibroids (in cm3 measured by MRI) following 
treatment by laparoscopic ILP -  Series 2. In this series, the time points were 3, 6 and 12 months. 3 
patients were not followed up to 12 months. The patient with fibroid numbers 2 and 3 was referred for 
IVF treatment at 6 months. The patient with fibroids 16 and 17 underwent laparoscopic surgery for 
dense pelvic adhesions. The patient with fibroids 11 and 12 migrated to Australia.
8.2.3.1 Fibroids that shrank with iaparoscopic ILP
At 6 weeks, 14 out of the 15 fibroids (93%) from series 1 (see Table 25) showed an 
expansion in fibroid volume. The mean expansion in volume was 23%. At the 3 
month follow up 7 out of the 24 fibroids measured from series 1 and 2 (see Table 25 
and Table 26) had still shown expansion (29%) with a mean fibroid volume reduction
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of 19%. By 6 months 90% of all the fibroids that were eventually going to shrink at 
12 months with treatment had done so with a mean volume reduction o f 25% and at 
one year there was a mean shrinkage of 50%.
A B C
Figure 85 MRI o f  patient with fibroid no. 25. MRI showing (A) Before ILP 28cm3 (B) 6 weeks after 
ILP 40cm3 and (C) 1 year after ILP 11 cm3. In this patient there was a 40% reduction in fibroid
volume.
8.2.3.2 Fibroids that did not shrink with laparoscopic ILP
Laparoscopic ILP failed in six patients with eight fibroids (Both series). Two patients 
had two fibroids treated. Failure was seen in one out o f the three fibroids treated in 
two women. The other two fibroids shrank after treatment.
Fibroid
No.
Initial volume
(cm 3)
Volume at 3 
months (cm 3)
Volume at 6 
months (cm 3)
Volume at 12 
months (cm 3)
Reduction
%
6 116 139 135 148 -28
9 67 69 73 107 -60
16 25 11 Not done Not done -18
17 12 5 Not done Not done -89
20 9 15 15 10 -11
28 152 138 138 171 -13
30 44 45 57 Not done -30
Table 27 Table showing the volume changes o f  fibroids (in cm3 measured by MRI) follow ing  
treatment by laparoscopic ILP -  where laparoscopic ILP did not work. Negative values indicate a
growth in the fibroid.
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8.2.4 Effect of the pre treatment volume on effect of laparoscopic ILP
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Figure 86 Graph showing the volume changes o f  fibroids (pre treatment volume less that 60 cm 3) up
to 12 months after laparoscopic ILP
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Figure 87 Graph showing the volume changes o f  fibroids (pre treatment volume greater than that 60
cm3) up to 12 months after laparoscopic ILP
In those with fibroids where the pre treatment volume was greater than 60 cm3 the 
mean shrinkage was 38% (range 4-73%). In the laparoscopic ILP failure group, the 
pre treatment volume of 5 fibroids was less than 60 cm3 and 3 were greater than 60 
cm3.
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8.2.5 Effect of pre charring the fibres prior to laparoscopic ILP
In the first series, on a single day treatment, three women were treated without pre 
charring the fibres. Three fibroids were treated in one woman, and two single 
treatments were performed on the other two women. The three failures of 
laparoscopic ILP in this series came from this group of 16 fibroids. However 
shrinkage was seen in one of the single treatments and in one of the three fibroids 
treated. In the second series, all fibres were pre charred prior to treatment and two out 
of 17 fibroids treated did not respond to ILP.
8.2.6 Effect of the increasing the energy used on fibroid volume reduction 
after laparoscopic ILP
In our planning of treatment for the second series we aimed at delivering a minimum 
* y
dose of 125 cp*3 for 1 cubic cm of fibroid tissue. Consequently, in the second series 
the amount of energy per unit volume of fibroid treated was 194 J/cm3 when 
compared to 105 J/cm3 in the first series. This was done not by increasing the power 
but by using the technique of pull backs as described in section 8.1.2. The average 
shrinkage obtained by doubling the pull backs (and therefore treatment sites) 
increased from 29% to 44%. This is illustrated in Table 28. However, analysis of the 
data showed that there is no linear correlation between dose density and shrinkage.
Series 1 Series 2
Mean Dose/cm3 105 194
No of points treated 3 6
Mean Shrinkage 29 44
Table 28 Table showing the effect of doubling the energy / cm3 o f fibroid treated 
on the shrinkage obtained by laparoscopic ILP
8.2.7 Effect of laparoscopic ILP on patients symptoms
Nine out of the 13 women with an increased MBL as the main complaint reported an 
improvement in MBL. Four women reported no improvement. Six out of the eight 
women with pressure effects reported a substantial improvement in symptoms. In one 
woman they became worse and 1 woman (with pelvic ache as a secondary complaint) 
left the study as she was scheduled for surgery because of findings at laparoscopy.
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8.2.8 Other procedures required
Other procedures were required in six women. Two women required transcervical 
resection of uterine fibroids for type 1 submucous fibroids, two women required 
laparoscopic adhesiolysis to gain access to the fibroids for treatment, one woman had 
endometriosis which was treated at the same time and one woman had an 
appendicular mass and bilateral hydrosalpinges and was scheduled for laparoscopic 
adhesiolyis, appendicectomy and bilateral salpingostomy at a later date.
8.2.9 Complications of ILP
Two patients required bipolar diathermy to the entrance of one of the needle tracts due 
to bleeding. In two patients the laser light was seen to come through to the other side 
of the uterus and this required stopping treatment, repositioning the needles before 
completing the treatment. In one patient the tip of the quartz fibre was charred and 
broke off. In attempting to retrieve this 1mm charred tip -  it disintegrated. 
Peritoneal irrigation and suction was done. The loss of the fibre tip was explained to 
the woman.
8.2.10 Pain after laparoscopic ILP
14 out of the 16 women were discharged home the following morning. Two women 
were discharged home the second day after surgery -  one because of severe shoulder 
tip pain requiring opiate analgesia and the other for observation after loss of a fibre tip 
at surgery. This woman was seen weekly in the outpatient clinic for 3 weeks mainly 
for discussion; follow up at 12 months did not reveal any adverse effects.
8.2.11 Infection following laparoscopic ILP
None of the women treated in either of these series had complications relating to 
sepsis.
8.2.12 Adhesions following laparoscopic ILP
Only 3 out of the 21 women who underwent ILP had subsequent surgery in the 
duration of the study. Information regarding adhesion formation following ILP is 
limited to these 3 cases.
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One woman was scheduled for an interval TCRF as she had a large intramural fibroid 
with subserosal and intramural extension in addition to two other large intramural 
fibroids. Due to persisting menorrhagia she opted for a hysterectomy. At laparotomy 
no adhesions were seen at the sites of ILP.
The second woman wanted a hysterectomy for pressure effects. She was a referral 
from a consultant from another hospital. She did not satisfy the entry criteria for the 
study as clinically she had a 28 weeks gestation size uterus. As she was adamant that 
she did not want a hysterectomy or myomectomy, she was commenced on GnRh 
analogues for 6 months. The fibroids shrank to a gestation size of 16 weeks. She 
was then entered in to the study. She had two large fibroids. ILP was performed on 
the first fibroid only. The second fibroid was not accessible as it was situated below 
the first and was deep in the pouch of Douglas. Following ILP, the treated fibroid 
began to grow even after 6 months. It had increased in size by 28% at 12 months. 
The untreated fibroid was also monitored by MRI and was found to have increased by 
133%. During this time she had discontinued the GnRh analogues.
The third woman underwent ILP for pressure effects and a deep pelvic ache in the 
right iliac fossa which was non cyclical. At laparoscopy prior to commencement of 
ILP, she was found to have dense pelvic adhesions which involved the appendix and 
both fallopian tubes. Adhesiolysis was required to visualise the uterus and adnexae. 
ILP was done to 2 fibroids. One fibroid shrank by 72% and the other fibroid was not 
measurable at 6 months. At her post operative visit discussion she opted for 
adhesiolysis, appendicectomy and bilateral salpingostomy. This was undertaken 
together with the surgeons. A laparotomy was done and even though there were 
dense adhesions around the appendix there were only filmy adhesions at the ILP sites 
which were easily separated. At open myomectomy for the remaining second fibroid 
there was no difficulty in finding a plane of cleavage.
8.2.13 Long term follow up of laparoscopic ILP
In the duration of this study, four women with single fibroids had MRI follow up of 
the treated fibroids for greater than 12 months. Two women had an MRI at 17 -  18 
months and two women at 22 months. Figure 88 shows the volume changes of these 
fibroids.
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Figure 88 Graphical representation o f  volume changes o f  laparoscopic ILP 
treated fibroids followed up to greater than 12 months
8.3 Discussion
Interstitial Laser Photocoagulation has been shown to be a safe, well tolerated 
procedure that can produce marked shrinkage o f fibroids. The few complications 
encountered were minor, easily dealt with and did not have any sequelae. Although 
all patients were kept in hospital overnight according to the study protocol, it is now 
considered that the procedure can be undertaken as a day case.
8.3.1 Effect of ILP on symptoms
This study was designed primarily to document the response o f individual fibroids to 
ILP. In most cases, the clinical responses were only assessed subjectively. 
Furthermore this group of women were highly committed to avoiding any form of 
conventional surgery and this could result in bias in favour o f laparoscopic ILP.
Effect o f ILP on menstrual blood loss
Nevertheless, nine o f the 13 patients presenting with menorrhagia as the principal 
symptom reported an improvement. Two of these women also complained o f 
pressure effects and had both a transcervical resection o f a coexisting type 1 
submucous fibroid and laparoscopic ILP for the intramural and subserous fibroids. 
Relief o f both the MBL and the pressure effects were reported. It was interesting to
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note that one of the women with a single fibroid in this group did not have any 
shrinkage of the treated fibroid.
In the four women with an increased MBL that had treatment failures, two women 
had three fibroids treated and two women had single fibroid treatments.
One of the women with three fibroids had a large type 2 fibroid occupying the entire 
uterine cavity and extending deep in to the myometrium. She was referred to our 
centre from Wales as she was desperate to conserve her uterus even though she had 
completed her family. This type of fibroid was not suitable for transcervical resection 
and as the MBL was severe enough to cause marked iron deficiency anaemia this 
patient had been advised to have a hysterectomy. It was decided to treat all three 
fibroids with ILP and if significant shrinkage occurred to plan an interval resection of 
the submucous fibroid. Shrinkage of 95% (pre-treatment volume = 19 cm3) and 26% 
(pre-treatment volume = 23 cm3) of the other two fibroids occurred but the 
submucous fibroid enlarged by 60 % (pre-treatment volume = 57 cm3). There was a 
net increase in uterine volume of 10 cm3 and her menorrhagia persisted with her 
eventually consenting to a hysterectomy.
The other woman with three fibroids (pre-treatment volumes of 353, 10 and 9 cm3) 
showed shrinkage of 8 % in the largest fibroid while curiously the two small fibroids 
grew by 70% and 11%. This was classified as a treatment failure even though there 
was a net reduction in uterine volume post treatment by 5%. The MBL was not 
severe enough to cause anaemia and this patient wishes to have another treatment with 
laparoscopic ILP. The remaining two women in the treatment failure group had 
single fibroids (volumes 105 and 95 cm3) one of which grew by 13 % and the other 
shrank by 4% but still do not wish to have conventional surgery.
Effect of ILP on pressure symptoms
Seven out of the eight women with pressure symptoms as the principal complaint 
reported significant improvement following treatment. This group of women had 
moderate sized fibroids. One of the women who wished to have ILP prior to assisted 
reproduction for male factor infertility had a 65% reduction of a 166 cm3 fibroid at 6 
months. Unfortunately she did not go ahead with in vitro fertilisation due to problems 
in the relationship.
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The treatment failure in this group was the woman who had two large fibroids that 
required shrinkage in order to be entered into this trial. This was because the fundus 
of the fibroid uterus was at a point mid way between the umbilicus and the 
xiphistemum. It was not amenable to laparoscopic surgery. It was interesting to note 
that the fibroid that was not treated (pre-treatment volume = 153 cm3) grew by 133%, 
once GnRH analogues was discontinued post operatively, whereas the treated fibroid 
(pre-treatment volume =115 cm3) grew by 28%. This is the only instance where we 
had a “control” and may suggest that ILP did curtail the growth of the treated fibroid.
Effect of ILP on fertility
Only one woman in series 2 underwent laparoscopic ILP to improve her chances of 
fertility. This was a 381 cm3 intramural fibroid without submucous extension which 
showed 51% reduction in volume at 12 months post treatment. We have reported a 
previous series of women that underwent ILP where monitoring of the fibroids where 
by ultrasound scanning. In this series three patients presented with infertility. Two 
were not helped, but the third became pregnant 2 years after ILP at the age of 40, 
shortly after her last follow-up scan. She delivered a healthy infant vaginally at term.
There is evidence that uterine fibroids have some effect on fertility. Initial studies 
showed that there was a lower pregnancy rate in women that presented with uterine 
fibroids and two observational studies showed an association between myomas and 
infertility. Studies of women undergoing assisted conception have shown - 
significantly decreased pregnancy and implantation rates in women with uterine 
fibroids. Initially this was shown to be due to the alteration of the uterine cavity 
because of the uterine fibroids. However there is evidence that fibroids that are 
intramural can also affect implantation rates. The difficulty is to prove that treatment 
of these fibroids would increase fertility. To date there is no randomised controlled 
trials to prove that treatment of fibroids improve fertility. As discussed in Chapter 1, 
the other uterine conserving surgical options are associated with post operative 
adhesions which may worsen the chances of fertility and be associated with weakness 
of the uterine wall from scarring following surgery with the risk of uterine rupture in 
subsequent pregnancy. ILP on the other hand is ideally suited for this clinical setting. 
It is minimally invasive, treatment being localised to the centre of the fibroid with 
much less damage to the normal myometrium than the other methods described in 
chapter 1. The limitations of ILP would be that some of the treated fibroid would
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remain and it is not sure whether volume reduction alone rather than removal would 
improve fertility.
8.3.2 Factors affecting fibroid shrinkage with laparoscopic ILP 
Significance of initial increase in fibroid size
As the study progressed, it became clear that the patients with the best long term 
response were the ones with the greatest increase in fibroid size in the first few weeks 
after ILP as seen in series 1. This early response is most likely due to oedema and 
inflammatory changes. Even at 6 months, three out of the 25 fibroids that showed 
shrinkage at 12 months were still larger than the pre treatment size and this is 
important in counselling women who contemplate having laparoscopic ILP in the 
future. The observation that early swelling was indicative of a good long term result 
has also been made when ILP is used to treat fibroadenomas of the breast (Lai LM et 
al. 89-94).
In the four women that MRI was repeated at 18 and 21 months post treatment, further 
reduction of the treated fibroids were noted. This is encouraging as it indicates that if 
ILP does work the effect is long lasting and may continue to produce shrinkage of the 
treated fibroids,
Pre Treatment volume of the fibroid
Our study failed to show a correlation between the pre treatment volume of the fibroid 
treated and the shrinkage obtained by ILP. The biggest fibroid treated in our group 
was 353 cm3 and this showed a 58% reduction in volume at 12 months. We were 
unable therefore on the basis of shrinkage to determine a cut off for fibroids suitable 
for ILP.
Pre charring fibres prior to ILP
This was a pilot study and it has helped to clarify some of the technical issues 
associated with the treatment. The importance of adequately pre-charring the laser 
fibres has been underlined. Laboratory experiments in our centre (unpublished data) 
showed that light at the wavelength used in this study (805nm, in the near infra red 
part of the electromagnetic spectrum) is not strongly absorbed or scattered in excised 
fibroids. If there is no modification to the fibre tip, the laser beam can just bum a hole 
through the fibroid without coagulating a significant volume. However, if the tip is
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adequately charred, the light is absorbed by the charring and converted into heat, so 
the tip acts as a point source of heat, which distributes the energy evenly in all 
directions. This has been documented more rigorously in liver tissue.(Amin et al. 
113-20) In vivo, when more blood is present, one would expect more absorption of 
infra red light as it passes through fibroids, but our clinical results suggest that with 
poor pre-charring, useful coagulation is not achieved. There may be a better way to 
pre-char the fibre tips than by using a small quantity of the patient’s blood, but we 
found that this works well and that the simple alternative of charring the tips in a 
naked flame is not good enough. Charring may occur spontaneously during light 
delivery and this is almost certainly what happened in the case of the largest fibroid in 
the inadequately pre-charred group, which did show considerable shrinkage. Other 
authors have not used pre-charred laser fibres, but treatments were at higher powers 
(5-8W) than in our study, which makes it likely that spontaneous charring occurred 
soon after the laser was switched on.
Optimum dosage for ILP
It is clear from tables 1-3 that there was no close correlation between the laser energy 
delivered and the fibroid shrinkage achieved. Each needle and fibre was inserted 
independently rather than using any sort of grid arrangement, so inevitably, 
positioning was imprecise. However increasing the number of pullbacks caused an 
increase in shrinkage as seen in series 2. This may be further improved in the future 
by matching the needle positions more exactly to the size and shape of each fibroid. 
The effect of ILP seems to vary not only between patient to patient but also between 
fibroids in the same patient. Hence the clinical efficacy is likely to depend just as 
much on biology of the fibroid being treated. In the treatment failures there was an 
increase in size of the fibroids and because of the small numbers and absence of a 
control we are unsure as to the significance of this. In the one patient with two 
fibroids where only one was treated, growth was significantly less in the treated 
fibroid.
8.3.3 Conventional surgery following ILP
It is a major attraction of ILP that if it does not work initially, it can be repeated and it 
does not prevent conventional surgery being carried out at a later date if required. 
This was seen in the three women that required surgery post ILP. No adhesions
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related to ILP were encountered and in the open myomectomy there was no difficulty 
in removing the fibroid as the plane of cleavage was conserved. This is a major factor 
why some surgeons do not use GnRH analogues prior to laparoscopic myomectomy.
8.3.4 Comparison with other studies
Two other groups have reported interstitial laser treatment of uterine fibroids although 
there were differences in technique and less extensive documentation of the results 
than in the present series.
Law et al (Law and Regan 277-82), reported MRI guided ILP of uterine fibroids in 66 
women with symptomatic fibroids who had been offered myomectomy or 
hysterectomy. 47 of these patients had MRI follow up at 3 months and 24 patients 
had an MRI scan at 12 months. The mean pre treatment volume was 618 cm3. The 
mean volume reduction at 3 months was 31% and at 12 months was 41%. MBL was 
reduced in eight patients complaining of increased MBL and there was an 
improvement in quality of life scores in these patients. The mean pre-treatment 
volume of fibroids was larger than our group which was limited by the need to insert a 
laparoscope safely in to the peritoneal cavity. Their group have reported a higher 
shrinkage rate than us, 31% at 3 months compared to 9% in our group and 41% at 12 
months compared to 31% in ours. It is unsure from their paper whether the group of 
women that were followed up at 3 (70% of women entered into study) and 12 months 
(36% of women entered into the study) were the women in which ILP was successful. 
Our results would compare favourably if this were the case (25% mean shrinkage at 3 
months and 50% mean shrinkage at 12 months). In one of our women, the pre 
treatment volume was measured after significant shrinkage with GnRh analogues 
(Fibroid No 6). This was not therefore a true measure of the pre treatment volume. 
Following ILP and stopping GnRh therapy there was significant regrowth of the 
fibroid. If this result is not taken into account the mean shrinkage at 12 months would 
be 46% in our group.
By far the largest series was reported by Chapman (Chapman 171-78;Law and Regan 
277-82;Chapman 171-78), who treated 300 patients with a total of 950 fibroids. Of 
these, 73% were 3-6cm in diameter (measured by ultrasound) and it was stated that a 
single laser treatment made them disappear within 6 months although it is not clear 
what follow up examination was undertaken as most patients lived outside the country
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in which they were treated. With such a large series, it is disappointing that there is 
not more information on the response of individual fibroids although there was a 
marked symptomatic improvement in most patients complaining of menorrhagia and 
dysmenorrhoea.
8.3.5 Laparoscopic ILP vs MRI guided ILP
There were no serious complications reported in any of the series. Our patients and 
those of Chapman were treated with laparoscopic guidance whereas Law et al treated 
theirs percutaneously with real time monitoring in an interventional MR scanner.
Safety issues
The MR scanner has the attraction that thermal changes in the treated lesions can be 
seen in real time, but it is difficult to be sure that this technique will provide adequate 
safeguards in all cases. Our own experience acted as a salutary reminder of the 
importance of direct visualisation of the sites being treated. Without this safeguard, 
the treatment that was seen to extend to the opposite side of a fibroid might have 
damaged adjacent normal tissues, oozing from the uterine puncture sites might have 
led to adhesion formation and the pre-existing adhesions seen in 2 patients might have 
been missed, risking thermal damage to the adherent bowel during delivery of the 
laser energy. Laparoscopy also permitted retraction of bowel from the uterus during 
ILP. In the patient of ours who had a hysterectomy 18 months after ILP because of a 
poor functional result, it was noted that there were no adhesions on the surface of the 
uterus. The one situation where we consider that laparoscopy is not necessary is for 
cervical polyps, where the needles and fibres can be inserted under direct vision with 
a speculum or colposcope. MRI guided ILP has the advantage however of not 
requiring a general anaesthetic and does not have the risk of minimal access surgery.
Procedure failure
Only situations where the dominant fibroid can be safely accessed through an anterior 
abdominal wall approach are suitable for MRI guided ILP. With laparoscopic ILP 
fibroids of both the anterior wall and posterior wall can be treated. However even 
with laparoscopic ILP access is sometimes difficult with very big fibroids and hence 
this approach is limited to a 16 week gestation size fibroid. However as some of the 
fibroid remains after treatment the suitability of ILP as a procedure in bigger fibroids 
is questionable.
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8.4 Conclusions
In conclusion, we have demonstrated that ILP is a safe, effective and a technically 
straightforward procedure that can shrink fibroids and give symptomatic relief. It 
requires relatively little surgical skill and carries less risk of postoperative adhesions 
than other local ablative techniques and less risk of precipitating bleeding that is 
difficult to control than open myomectomy. Patient satisfaction is high and the 
procedure can be performed as a day case. Further evaluation is required in a larger 
number of patients with more objective methods of assessing symptoms but it does 
appear to have considerable promise as a simple therapeutic option for shrinking 
moderate sized fibroids.
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[9] Conclusions
9.1 Introduction
This thesis was concerned with the development o f photodynamic therapy o f the 
endometrium and interstitial laser photocoagulation o f uterine fibroids as alternatives 
to hysterectomy. The purpose o f the research was to
1) Evaluate the PDT effect on rabbit endometrium after the topical application o f 
disulphonated aluminium phthalocyanine.
2) Evaluate the technique o f laparoscopic interstitial laser photocoagulation o f 
uterine fibroids
9.2 Summary of the outcomes of the literature review
The literature review found that hysterectomy is still widely used for the treatment o f 
women with heavy menstrual periods. Although it gives the highest patient 
satisfaction score it is associated with significant morbidity and even mortality. The 
two most common reasons for hysterectomy for heavy periods have been identified as 
dysfunctional uterine bleeding (DUB) and uterine fibroids.
The medical treatments used for women requiring fertility are tranexamic acid and 
mefenamic acid. In women not requiring fertility, long cycle high dose progestagen 
therapy, Danazol, Gestrinone, GnRha therapy and the LNG-IUS may be used. The
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efficacy o f these treatments and their place in the current treatment of DUB has been 
extensively researched in Chapter 1. It was found that long term medical treatment 
only caused a 50% reduction in MBL which was reversed when treatment stopped. 
Furthermore medical treatment was associated with side effects that significantly 
reduced quality o f life and resulted in discontinuation o f  therapy. The LNG-IUS 
which was initially thought to significantly reduce the rate o f hysterectomy has been 
disappointing with a discontinuation rate o f almost 25% with 50% of women 
requiring additional treatment at 5 years o f follow up. There are similarly no effective 
long term medical treatments for uterine fibroids.
Surgical techniques have been developed as an alternative to hysterectomy. First 
generation techniques rely on operative hysteroscopy to resect or ablate the 
endometrial lining up to the stratum basalis and the superficial layer o f the 
myometrium. The efficacy o f these techniques is operator dependant with potential 
complications o f bleeding, infection, uterine perforation and dilutional hyponatraemia 
resulting from fluid shifts with the use o f distension media like 1.5% glycine.
Second generation endometrial ablative techniques were subsequently developed that 
did not require operator skill, reduce the complication rate and could potentially be 
used in an outpatient setting. The number o f techniques that have been developed 
reflect the economic impact of the problem. These techniques and their efficacy rates 
with studies comparing first and second generation methods have been reviewed in 
Chapter 2. This shows that while MBL reduction rates have been quoted at 73-90%, 
there are still complications from the thermal effect which these techniques rely on for 
destruction o f the uterine endometrium. Furthermore, studies consistently show 
equipment failure o f up to 10% with most women still requiring a general anaesthetic. 
Post operative uterine synechiae make subsequent evaluation o f the endometrium 
difficult in the event of a woman developing abnormal uterine bleeding.
Uterine conserving surgical methods for uterine fibroids include myomectomy, 
uterine artery embolisation or clipping and myolysis. Details o f these procedures 
including routes o f surgery, success rates, potential complications and the evidence 
available have been reviewed in Chapter 2. Studies have shown that myomectomy is 
associated with significant recurrence rates o f up to 50% at 5 years with post 
operative adhesions which may involve both bowel and omentum. Myolysis so far 
has been done using high power with significant post operative adhesions. The
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conservative treatment that has shown the best potential is uterine artery embolisation. 
While this causes a reduction in fibroid size o f up to 50% it is associated with 
significant complications including fatal sepsis, post embolisation syndrome, post 
procedural pain that requires narcotic analgesia and a premature menopause in the 
older woman. It is therefore still not used for women requiring fertility.
From the literature review o f the currently available medical and conservative surgical 
alternatives to hysterectomy in women with DUB and uterine fibroids, it is evident 
that further research is required to find the ideal method for the treatment o f these 
conditions which place a high socio economic burden on our national health service.
Photodynamic therapy is an exciting alternative to the current second generation 
techniques for the treatment of DUB. It is a non thermal effect and therefore does not 
have the potential thermal complications o f the existing techniques. PDT causes 
minimal myometrial damage and therefore will not evoke scarring. The reduced 
likelihood o f intra uterine synechiae would be an advantage if subsequent evaluation 
o f the endometrium is required. Little operator skill is required and the technique can 
be readily adapted to the out patient setting.
A literature review of PDT to the endometrium is done in chapter 3. These studies 
involve very small numbers and are mainly in the form o f case reports. The 
photosensitiser used in these studies was 5 amino laevulinic acid (ALA). One o f the 
reasons for choosing ALA is that it is activated by light in the red part o f the spectrum 
where tissue penetration is maximal, has a minimal duration o f skin photosensitivity if 
given systemically and because it has been well studied in other organs with good 
results. Light delivery to the uterine cavity in most o f the studies have been by 
custom made balloons and in some studies the commercially available balloon device 
marketed as Medlight. Results have so far been disappointing. This may be due to 
the fact that the tissue damage produced by ALA is not sufficient and that the light 
delivery devices used did not produce uniform illumination o f the uterine cavity.
Michelle Judd investigated the use o f an alternative photosensitiser -  disulphonated 
aluminium phthalocyanine - for PDT of the endometrium in the rabbit model. She 
compared the PDT effect after intravenous use o f AlS2Pc with that o f ALA. Her 
results showed that the PDT damage with AlS2Pc was much greater when compared 
to ALA. This however also included disappearance o f a rabbit uterus after treatment
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with the formation o f adhesions. Regeneration o f rabbit endometrium was only 
patchy at 28 days. These results were exciting but could not be taken forward in to a 
clinical setting because of the risk o f cutaneous photosensitivity associated with 
systemic administration o f AIS2 PC and it was not approved for clinical use in the 
United Kingdom.
The literature available on interstitial laser photocoagulation o f uterine fibroids is also 
discussed in Chapter 3. Evidence is limited to a single surgeon on a large number o f 
women outside a research setting. Most o f the women treated were private patients 
that came to the United Kingdom for treatment. Follow up after treatment was 
therefore difficult with no imaging used to assess fibroid response to ILP. The 
publication o f these case series however do document that ILP for uterine fibroids is a 
safe and feasible therapy.
9.3 Objectives of the thesis
The objectives o f this thesis therefore were to
1) Compare available light delivery devices for the human uterus with custom 
made devices
2) Investigate the topical application o f AlS2Pc for rabbit endometrial PDT
3) Investigate ILP for the treatment o f uterine fibroids with objective follow up 
by MRI scans and effect on clinical symptoms
9.4 Major findings of the thesis and integration with previous work
9.4.1 Intra uterine light delivery -  Balloon vs non balloon devices
Dwyers group investigated the use o f embedding titanium chips into silicon balloons 
used for light delivery. Experiments showed that light was internally reflected and 
transillumination of the balloons was increased. Using this formula, two different 
sizes of balloons were made to fit uteri with cavity lengths o f 7cms and 10 cms. In 
one o f the smaller balloons, two light fibres were used to see if  this increased intra 
uterine light delivery.
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However, Tadir’s group claimed improvements in intrauterine light delivery by using 
three light fibres without enclosing them in a balloon device. A trifiircator (three laser 
fibres) used for thermal destruction o f the endometrium was modified to deliver light 
without effecting thermal damage. A bifurcator was also made using two clear plastic 
tubes through which two laser fibres could be passed. These devices were compared 
with the commercially available Medlight intra uterine light delivery balloon.
The results showed that the non balloon devices were more effective in producing a 
uniform illumination at all sites o f the uterine cavity. This is an important finding as 
effective PDT relies on every area o f the uterine endometrium receiving a minimum 
threshold dose o f light. Intra uterine light delivery for both the modified trifiircator 
and the bifurcator were better than the currently used Medlight balloon. The addition 
o f titanium chips to the silicon balloons did not appear to improve intra uterine light 
delivery when compared to the Medlight balloon. These experiments also 
demonstrated a marked reduction in light delivery in the presence o f intra uterine 
pathology like a septum, fibroids and adhesions from a previous endometrial 
resection. It would appear therefore that PDT would not be effective in these 
situations.
This is the first time an attempt has been made to compare the different technologies 
o f intra uterine light delivery. Embedding the balloons with titanium chips as 
described by Dwyer did not enhance illumination in the uterus when compared to the 
Medlight balloon. Bifurcators and trifurcators as described by Tadirs group were 
more efficient in producing global intra uterine illumination than the currently used 
Medlight balloon.
9.4.2 PDT of rabbit endometrium after topical application of AIS2Pc -  as 
effective as systemic AIS2Pc?
The pharmacokinetics of AlS2Pc in the rabbit uterus after topical instillation was 
investigated. This information is invaluable for determining the optimal parameters 
for PDT. A validated technique for measuring the fluorescence produced by AlS2Pc 
was used for quantifying the amount o f AlS2Pc in the different layers o f the uterus. 
The highest concentration o f AlS2Pc was found in the endometrium at 30 minutes and 
fell gradually to the 6 hour time point and then rose again. The selectivity o f the
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distribution o f the drug for the endometrium when compared to the stroma and the 
underlying myometrium increased with time.
These results are similar to those described by Michelle Judd (systemic AIS2 PC) who 
also showed two peaks with a reduced concentration at 6 hours. Although drug 
concentrations in our experiment were highest at 30 minutes we did not use this time 
point for PDT as there was still a lot o f drug present in the lumen o f the uterus which 
would have interfered with light reaching the deeper parts o f the endometrium. 
Washing the drug out would not be clinically feasible.
It was decided to investigate PDT of the rabbit endometrium after topical application 
o f AIS2 PC using drug light intervals o f 1, 3 and 6 hours. The PDT effect obtained by 
increasing light doses from 50 to 100 Joules was also investigated. The 3 hour drug 
light delivery interval and a light dose o f 100 Joules gave the best results. There was 
a selective destruction of the rabbit endometrium which was 100 % at 3 days and 13 
days and was o f sufficient depth that regeneration was absent in one out o f the three 
rabbits examined 28 days following PDT.
PDT with topical application o f AlS2Pc did not cause any o f the extra uterine effects 
seen with systemic AlS2Pc. In none o f the animals were there any abdominal 
adhesions or any serosal effects. In all the uterine specimens there were no 
intrauterine adhesions other than for a flattening of the rugae. The PDT damage to the 
endometrium however was comparable to that seen with systemic AlS2Pc indicating a 
high degree o f selectivity with topical administration. This confirmed the 
pharmacokinetics. This degree o f selectivity is similar to studies on the rabbit model 
after PDT with both topical and systemic ALA. This thesis further highlights the 
importance o f  adequate light delivery for effective PDT. Increasing the light 
illumination from 50 to 100 Joules had a dramatic effect on the PDT damage that 
occurred.
As described in Chapter 5, even after cryosurgery to the rabbit endometrium, 
complete regeneration is seen in 21 to 30 days. This is due to the large infolding o f 
the rabbit endometrium and a far greater potential for regeneration than in humans. 
Complete absence of regeneration in one out of three rabbits at 28 days, with only 
areas o f patchy regeneration in the other two are encouraging results when compared 
to similar studies using ALA as the photosensitiser.
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This research shows that PDT of the rabbit endometrium after topical application of 
A1S2PC is as effective as systemic AlS2Pc without the systemic side effects. The 
selectivity demonstrated is similar to that o f ALA. It is therefore an exciting 
alternative to ALA for PDT of the human endometrium.
9.4.3 Interstitial laser photocoagulation of uterine fibroids -  effect on fibroid 
size and women's symptoms.
ILP as a technique for the treatment of uterine fibroids worked in 80% o f women. At 
6 weeks, 14 out o f the 15 fibroids (93%) showed an expansion in fibroid volume. The 
mean expansion in volume was 23%. At the 3 month follow up 7 out o f the 24 
fibroids measured had still shown expansion (29%) with a mean fibroid volume 
reduction o f 19%. By 6 months 90% o f all the fibroids that were eventually going to 
shrink at 12 months with treatment had done so with a mean volume reduction o f 25% 
and at one year there was a mean shrinkage o f 50%.
ILP for uterine fibroids did not work in 20% of the women treated. In this group of 
women there was a mean increase in fibroid volume o f  36%. This was difficult to 
interpret as there was no control group and serial scans were not done prior to ILP to 
know if  these were fibroids that were rapidly growing. The biology o f these tumours 
varies considerably. In 2 women, three fibroids were treated. Curiously, in both 
women, one o f the three fibroids grew with treatment while the other two fibroids 
shrank. In a woman that had two fibroids where only one was treated (the other being 
non accessible in the pouch o f Douglas), the treated fibroid increased in volume by 
28% while the untreated fibroid grew by 133%. Further research is required to 
understand the biology o f these tumours and whether there are in fact sub types o f 
fibroids.
Most women reported symptom improvement with MBL and pressure effects. This 
was not done in an objective manner and may be biased as this group o f women were 
highly motivated and did not want conventional therapy. The symptoms that were 
best served by ILP were pressure effects.
This study confirmed previous work that ILP is a safe and feasible procedure. All 
women were admitted for an overnight stay because o f the protocol. This technique 
however can be developed as a day care procedure. There were no problems with
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post operative pain, sepsis and adhesions in the 3 women who underwent subsequent 
surgery.
Other studies using MRI guided thermal ablation with real time thermography to 
ascertain treatment times have shown similar results. Advantages of this method over 
ours are that a general anaesthetic is not required and complications associated with 
minimal access surgery are avoided. However this method is limited to anterior wall 
fibroids and to centres with access to interventional MRI scanners. In a couple o f 
women treated with laparoscopic ILP, bipolar cautery had to be used to the entry sites 
in the fibroid to stop bleeding. Two women needed adhesiolysis in order to access the 
fibroid before treatment. One woman had a transcervical resection o f a sub mucous 
fibroid and another treatment of pelvic endometriosis which was the cause o f her 
pelvic pain. None o f these procedures would have been possible with MRI guided 
thermal ablation.
The current treatment that is gaining popularity is uterine artery embolisation. This 
technique is an alternative to myomectomy and hysterectomy in women not wishing 
conventional surgery with its attendant morbidity and even mortality. However UAE 
is not without complications as discussed in chapter 2 o f the thesis.
This thesis suggests that comparable fibroid volume reduction may be obtained by 
using ILP. The advantages are that none o f the women treated had any of the side 
effects that are reported consistently with UAE. Theoretically as minimal myometrial 
damage occurs during treatment, ILP may be offered to women who seek fertility. 
Another advantage is that other diseases o f the pelvis like endometriosis and 
adhesions may be treated at the same time.
The complications that were o f some concern were the breaking off of the tip o f the 
fibre after ILP and the bum back effect along the length o f the fibre. This becomes 
possible as after being activated, charring occurs making it more brittle. This 
complication has also been reported with ILP for breast fibroadenomas. Modification 
of the fibre should be done to reduce the likelihood o f this complication.
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9.5 Strengths and limitations of this thesis
9.5.1 PDT of the endometrium
The experimental methods that have been used for the investigation o f topical AlS2Pc 
are standardised and have been validated by previous researchers. The rabbit model 
was chosen as it is a small animal, has two uterine horns (which doubles the result 
yield and can act as its own control when required) is a reflex ovulator with 
copulation (hence timing of experiments were not necessary) and has been extensively 
used by other researchers using other photosensitises for PDT. Valid comparisons 
could then be made. Tissue processing and storage was done with great care with 
training by expert histopathologists. For all measurements, two independent 
observers took readings. The other observer did not use any o f this data for her thesis 
and was therefore unbiased. An average was then taken and if  there was a significant 
difference the slide was re visited and analysed again. All animals were handled with 
the greatest of care in accordance to the rules and regulations o f the home office.
In the pharmacokinetics, two and sometimes only one animals were used at each time 
point. However these experiments compared the concentrations o f the drug at 
different tissue levels that were measured and not absolute concentrations and 
therefore would not have affected the results. The absolute minimum numbers o f 
animals were used in keeping with the ethos o f animal experiments and to reduce cost.
One of the problems o f the systemic administration o f AlS2Pc is photosensitisation. 
It is for this reason that topical application o f AlS2Pc was investigated. Even though 
there were no features of systemic photosensitisation in any o f the animals treated we 
could have objectively determined this by quantifying the concentration o f AlS2Pc in 
rabbit skin specimens. Unfortunately we did not think o f this at the time the study 
was designed.
9.5.2 Interstitial laser photocoagulation of uterine fibroids
The technique for ILP was carefully thought out and the number o f fibres and power 
used were based on previous studies that showed that one fibre produced an elliptical 
zone o f necrosis o f about 1.4 cm. A 4 way beam splitter was used to reduce treatment 
times. Treatment parameters were changed in the second series to see if increasing
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the power and using multiple pull backs affected therapy. Documentation and data 
collection was complete for nearly all the women with only one woman who did not 
attend for follow up as she migrated to Australia. MRI scans, the gold standard for 
the visualisation and measurement o f uterine fibroids, was used to evaluate the effect 
o f ILP on uterine size. This is in keeping with reports o f other conservative 
modalities o f  treatment like UAE and MRI guided thermal ablation. A program was 
created with the consultant radiologist so that the same sections and same 
measurements were taken when women attended for their scans. Two independent 
observers took measurements of the uterine fibroids. There was no knowledge that 
the fibroid that they were measuring was treated or not. This removed observer bias.
The limitations are the use o f the Tuohey needles which were used. These have the 
attraction o f 1 cms graduation which are easily visible laparoscopically and enable 
accurate placement. The disadvantage is the curved ends. This makes it technically 
difficult to withdraw the used fibre into the trocar o f the needle. In one woman this 
charred bit o f glass disintegrated. Extensive peritoneal lavage was done but still lead 
to a lot o f anxiety for the woman.
There was no objective assessment of the symptoms. This was not one of the primary 
aims o f this study but it would have benefited from more objective instruments being 
used rather than a subjective assessment by the woman undergoing treatment
9.6 Future avenues of research
9.6.1 PDT of the endometrium
One o f the draw backs of animal experiments and the results o f this thesis is that the 
same results may not be reproduced in humans. However it is important to 
understand the effect o f the drug on animals before permission may be sought for 
human testing. AlS2Pc may now be considered for clinical trials o f PDT of the 
endometrium in humans. Before this may be done it is important to understand the 
pharmacokinetics o f the drug in the human uterus. This may be achieved by instilling 
the drug in the uterus at different time points prior to hysterectomy for dysfunctional 
uterine bleeding. The relative concentrations of the drug in the different structures of 
the uterus may be evaluated using the technique described in this thesis. It would be 
interesting to see if  the selectivity seen in the rabbit uterus is maintained. The time
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point at which the maximum endometrial concentration of AlS2Pc is found would 
then determine the optimal drug light interval.
Once the optimal drug light interval is obtained, light delivery must be optimised. 
From the results o f this thesis the best device would be a non balloon light diffuser 
fibre. The trifiircator as developed by Tadirs group has been patented in the USA as 
shown in Figure 89.
Figure 89 Diagrammatic representation of the trifiircator ideally situated in the uterine cavity.
PDT may be then performed in women awaiting hysterectomy for DUB. Histological 
evaluation o f the PDT effect would be gained from the hysterectomy specimens. It is 
probable that women gaining relief from PDT would not proceed to hysterectomy.
9.6.2 ILP for uterine fibroids
There are two important considerations for future research in this field. The first is 
the further development of the technique. The second is to determine the exact place 
for ILP of uterine fibroids in current gynaecological practice.
Further developments o f the technique
In our institute, a previous researcher used ultrasound to follow up a group o f women 
treated with ILP. The results obtained in this small group o f women were not 
different from that obtained by MRI. MRI outside a research setting would not be 
feasible and may be replaced by ultrasound. Doppler probes which may be used at 
laparoscopy are being developed. It would be interesting to see if using this 
technology, the blood flow to the uterine fibroids may be coagulated in addition to
221
performing ILP. This may produce a much bigger reduction in the fibroid volume. 
Results would further improve with better dosimetry. The instrumentation may be 
modified further in terms of using needles with straight ends instead o f the Tuohey 
needles that were used in this study. Comparison o f an MRI needle and a Tuohey 
needle are shown in Figure 90.
Figure 90 Photograph of ends of Tuohey needle (above) and MRI needle (below). This illustrates the 
curved end of the Tuohey needle which encourages breakage of the charred tip when the fibre is 
withdrawn following ILP. The advantage of the needle however is the cm graduations which facilitate
accurate needle placement.
We are currently investigating the straight end needles. The advantage that we 
envisage is that by withdrawing the fibre into the sheath before removing it we could 
minimise the risk of breakage.
Exact place of ILP in current gynaecological practice
ILP may be used to cause shrinkage in small to moderate size fibroids in women 
whose main symptoms are pressure effects. There is however growing evidence that 
small fibroids that are intramural affect fertility especially in women requiring 
assisted reproductive techniques. Minimal endometriosis also has similar effects by 
altering the hormonal milieu o f the pelvis. It would be interesting to see if ILP o f 
these fibroids would improve fertility. Advantages o f ILP are that endometriosis that 
is present may be treated at the same time.
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